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Abstract
Mechanism-based chemical kinetic models are increasingly being used to describe biological
signaling. Such models serve to encapsulate current understanding of pathways and to enable
insight into complex biological processes. Despite the growing interest in these models, a number
of challenges frustrate the construction of high-quality models.
First, the chemical reactions that control biochemical processes are only partially known,
and multiple, mechanistically distinct models often fit all of the available data and known
chemistry. We address this by providing methods for designing dynamic stimuli that can
distinguish among models with different reaction mechanisms in stimulus-response experiments.
We evaluated our method on models of antibody-ligand binding, mitogen-activated protein
kinase phosphorylation and de-phosphorylation, and larger models of the epidermal growth
factor receptor (EGFR) pathway. Inspired by these computational results, we tested the idea
that pulses of EGF could help elucidate the relative contribution of different feedback loops
within the EGFR network. These experimental results suggest that models from the literature
do not accurately represent the relative strength of the various feedback loops in this pathway.
In particular, we observed that the endocytosis and feedback loop was less strong than predicted
by models, and that other feedback mechanisms were likely necessary to deactivate ERK after
EGF stimulation.
Second, chemical kinetic models contain many unknown parameters, at least some of which
must be estimated by fitting to time-course data. We examined this question in the context
of a pathway model of EGF and neuronal growth factor (NGF) signaling. Computationally,
we generated a palette of experimental perturbation data that included different doses of EGF
and NGF as well as single and multiple gene knockdowns and overexpressions. While no single
experiment could accurately estimate all of the parameters, we identified a set of five comple-
mentary experiments that could. These results suggest that there is reason to be optimistic
about the prospects for parameter estimation in even large models.
Third, there is no standard formulation for chemical kinetic models of biological signaling.
We propose a general and concise formulation of mass action kinetics based on sparse matrices
and Kronecker products. This formulation allows any mass action model and its partial deriva-
tives to be represented by simple matrix equations, which enabled straightforward application
of several numerical methods. We show that models that use other rate laws such as Michaelis-
Menten can be converted to our formulation. We demonstrate this by converting a model of
Escherichia coli central carbon metabolism to use only mass action kinetics. The dynamics of
the new model are similar to the original model. However, we argue that because our model is
based on fewer approximations it has the potential to be more accurate over a wider range of
conditions.
Taken together, the work presented here demonstrates that experimental design method-
ology can be successfully used to improve the quality of mechanism-based chemical kinetic
models.
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Thesis Supervisor: Forest M. White
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Chapter 1
Introduction
Despite the fact that biological data is becoming increasing quantitative, more often than not
biological knowledge is represented as cartoon drawings or text descriptions. These types of
representations are subjective, open to a range of specific interpretations, and difficult to use
in a systematic way. In contrast, computational models have the potential to encapsulate our
understanding of complex biological processes within a quantitative framework [97, 101]. The
promise of these efforts is being able to predict, a priori, the result of an experiment or a
clinical intervention. To this end, there has been a strong push to build dynamical models,
often based on systems of ordinary differential equations that are capable of recapitulating
the kinetic behavior of signaling and metabolic networks. The hope is that these models will
lead to a deeper understanding of complex biological processes, facilitate new clinical therapies
based on rational design [151, 130], and provide a design substrate for the emerging field of
synthetic biology [54]. However, the success or failure of these models is greatly influenced by
the data that is used to construct, calibrate and validate them. There is currently a lack of
basic methods and best practices for the implementation of models, as well as the design of
experiments used in model calibration and discrimination. The goal of this thesis work is to
address some of these deficiencies.
1.1 Biochemical Mechanisms Are Only Partially Known
Traditionally, the individual reaction mechanisms that underlie these models have been eluci-
dated individually by genetic, biochemical and biophysical techniques. However, newer high-
throughput techniques exist for the large-scale identification of proteins that may be involved in
a pathway. Some of these methods directly probe interactions. For example, yeast two-hybrid
[61], protein chips [90, 128], and affinity purification [44] look to find pairs of proteins that bind
to each other [22]. However, the quality of models based solely on these types of measurements
is suspect. In the case of the direct methods, there is a great deal of disagreement between, and
often within, data sets [176]. Other approaches are more indirect and find putative interactions
by analyzing stimulus response data. Examples of this kind of approach are [65, 4, 161, 147].
In general, these types of approaches suffer from two main shortcomings. First, they rely on
statistical methods that need large numbers of replicate experiments to provide accurate an-
swers. These types of replicates are seldom available in biological experiments. One notable
exception where this kind of analysis has found a foothold is in the analysis of single cell data
as in FACS data [147].
As a result of the limitations of these methods, it is possible if not probable for multiple
mechanistically distinct models to fit all of the available data and known chemistry. One way
in which mechanisms are tested involves stimulating a system with a step change in the input
(adding a high concentration of ligand) and then measuring the change of network outputs
(concentration or activities of the various downstream species). If a set of parameters can
be found such that the candidate models fits to the data it is taken as a validation of the
model. For a linear system this type of experiment provides, at least in a technical sense,
enough information to fully identify the system. However, even simple biochemical systems are
nonlinear, and as such there is no a priori reason to believe that a step response experiment
is sufficient to uncover the relevant dynamics of the system and allow for the selection of a
unique model. A simple example of this is the mechanism of antibody-ligand binding studied
by Lipschultz, Li, and Smith-Gill [111]. This system consisted of only two parts, a monovalent
antibody and its antigen. Even with many time points and accurate measurements it was
impossible to distinguish between these two mechanisms in a standard experiment. However,
through the use of a dynamic stimulus Lipschultz et al. were able to show that the reaction
proceeded according to the two-step mechanism. In this case, the input signal was solved
though intuition; however, for more complicated systems a computational approach is needed.
One formulation of this problem is to find the input signal stimulus that maximizes the
difference of the outputs of the two candidate models [42]. This approach has been applied
successfully to the model selection of a small model (16 equations) of an L-Valine Fermentation
process [28]. The fact that these methods have only been applied to relatively small systems
highlights the major limitation on these types of methods, which is the computational difficulty
of solving the nonlinear dynamic optimization problem. However, in practical experimental
design, the global optimum experiment is not needed. A method finds experiments that are
good-enough and scales to larger systems would be very useful in practice.
In this work, we address the problem of resolving model ambiguity by providing a method
for designing dynamic stimuli that, in stimulus-response experiments, distinguish among pa-
rameterized models with different reaction mechanisms. We develop the approach by presenting
two formulations of a model-based controller that are used to design the dynamic stimulus. In
both formulations, an input signal is designed for each candidate model and parameteriza-
tion so as to drive the model outputs through a target trajectory. The quality of a model is
then assessed by the ability of the corresponding controller, informed by that model, to drive
the experimental system. We evaluated our method on models of antibody-ligand binding,
mitogen-activated protein kinase (MAPK) phosphorylation and de-phosphorylation, and larger
models of the epidermal growth factor receptor (EGFR) pathway. For each of these systems,
the controller informed by the correct model is the most successful at designing a stimulus to
produce the desired behavior. Using these stimuli we were able to distinguish between models
with subtle mechanistic differences or where input and outputs were multiple reactions removed
from the model differences. An advantage of this method of model discrimination is that it
does not require novel reagents, or altered measurement techniques; the only change to the
experiment is the time course of stimulation. Taken together, these results provide a strong
basis for using designed input stimuli as a tool for the development of cell signaling models.
1.2 Applying Experimental Design Methodologies to Epider-
mal Growth Factor Signaling
Motivated by these computational results, we tested the idea that a time varying EGF stimu-
lation could reveal more of the subtle regulation of the EGFR network and help elucidate the
relative effects of the different feedback loops. In this work, we took a combined experimen-
tal and computational approach. First, we built mechanistic models of the pathway. Second,
we used those models to help motivate specific experiments that could be performed in a cell
culture based assay. Finally, we used out models, and other models from the literature to help
interpret and reconcile the results.
The epidermal growth factor receptor (EGFR) system is arguably the best understood
receptor system [164]. It has been extensively studied and modeled by both traditional and
high throughput methods[45], and numerous computational models have been constructed to
describe various aspects of the signaling [21, 43, 18, 149, 31, 27, 95, 152, 59]. This makes EGFR
signaling the perfect substrate for our modeling and computational studies. The emerging
picture of this pathway is that it is governed by a complex network of positive and negative
feedback loops [185, 45, 3, 146, 116, 124]. Modulation of the strengths of these loops has been
implicated in the regulation of pattern formation during development [140, 143], carcinogenesis
[82], and cell motility [117, 91].
EGFR (also know as Erb1 and HER) and its family members (Erb2, Erb3, and Erb4) are
known to mediate cell-cell interactions in organogenesis and adult tissues [33]. Overexpression
of EGFR and Erb2 is a marker of certain types of cancer, including: head, neck, breast [188],
bladder and kidney. Overexpression of Erb2 is correlated with poor clinical outcome in ductal
breast cancers [184]. As a result of its clinical importance, the EGFR receptors themselves, as
well as various down stream proteins, are the targets of therapeutic interventions [76, 158].
Despite clinical interest in the EGFR pathway and over 40 years of intense study, there is
still a lot we do not know about the pathway. For example, two recent studies, [19] and [191],
found a number of proteins that changed phosphorylation state in response to EGF stimulation
that were not previously known to be part of the pathway. Even just at the level of the receptor
there is a large diversity of adaptor proteins that are not understood at a computational level
[90]. In addition, many of the known proteins and interactions are not part of any computational
model [1321.
At the time this work began, the most complete model of EGFR signaling was the model by
Hornberg et al. [86]. This model is a refinement of earlier models of the pathway [95, 152, 59]. It
describes signal transduction all the way from EGF binding to the receptor to phosphorylation of
ERK. The molecular processes include association and dissociation, as well as phosphorylation,
dephosphorylation, synthesis, degradation, and trafficking events, all described with mass-action
kinetics. Recently, two new models have been published that incorporate additional Erb family
members [43, 18], as well as a connection to insulin receptor signaling [21], and neuregulin
signaling [149].
However, current models of EGFR signaling, like many cell signaling models, were developed
to describe the steady state and step response behavior of the network [43, 95, 152, 59, 21, 86].
Less attention is paid to how the systems recover after the initial stimulus. For example, in the
model by Hornberg et al. several proteins may be degraded but cannot be synthesized. As a
result, the dynamics of these models are dominated by short term signaling events especially
the immediate negative feedback loop.
The work presented here will show computationally and experimentally that current models
of EGFR signaling miss important dynamics. Moreover, we will show that simple changes to
the experimental protocols such as time varying stimulation can help to uncover these missing
dynamics. We hope that this will motivate future modeling efforts that will more realistically
capture the diversity of feedback mechanisms.
In particular, we tested the mechanistic assumptions of the Hornberg model [86] that lead
to the dominance of the endocytic pathway. We stimulated the network with pulses of EGF
separated by different lengths of time. The results show that the Hornberg model does not
accurately predict the response of the network to this time varying stimulation. We also show
that some simple changes previously suggested by us [5] do lead to improved predictions, but
ultimately the mechanism previously proposed is not correct. We conclude this work by hy-
pothesizing some alternative mechanisms and suggesting some future experiments that could
help to unravel the details of this complex multi-feedback network.
1.3 Chemical Kinetic Models Contain Many Unknown Param-
eters
Chemical kinetic models contain many unknown parameters, at least some of which are diffi-
cult to measure directly, and instead are estimated by fitting to time-course data. A typical
experiment in model calibration involves stimulating a system with a step change in the input
(adding a high concentration of ligand) and then measuring the change of network outputs
(concentration or activities of the various downstream species). Candidate models are fit to the
data and the best model is selected based on the quality of the fit. Most often the calibration
problem is formulated as a nonlinear least squares optimization problem, where the goal is to
find the set of parameters that minimizes the least squares cost function:
X ) 1 [Ys,c(p , t) Ydata ,c(t)]2 dt (1.1)
2nsnc Tc 02,(t)
where nc is the number of experimental conditions, n, is the number of species for which mea-
surements are available, the indices c and s run over the conditions and species, respectively, Tc
is the length of the time course for condition c , ys,c(p, t) is the model output for species s and
condition c at time t with parameter setp , Ydata s,c(t) is the corresponding experimental mea-
surement, and as2c(t) is a weighting factor that is often taken as proportional to the uncertainty
of the experimental measurement.
There is a significant amount of work devoted to how best to solve this optimization problem
for biological models [10, 89, 125, 144]. In addition, work has been done on optimizing exper-
iments to improve the optimization problem [38, 144] This thesis looks at a related question:
Once the parameters are found, how accurately are they determined? One possibility is that
there is a single optimum value for parameters as determined by the data. This is the case the
model is termed identifiable [47]. Another possibility is that there is a unique optimum, but
that many of the parameters around the optimum are "good-enough". If the range of allowable
parameters is large, the model is called practically unidentifiable. It is widely believed that
models of systems biology are practically unidentifiable [84, 179, 78, 67, 144].
Previous work by Gutenkunst et. al has suggested that even with precise data sets, many
parameters are unknowable by measurements of time-course data [78]. What has not been fully
explored in these analyses is to what extent experimental design can improve the question of
parameter identifiably. One work that examines the effect of time varying stimulation on the
parameter optimization is by Faller et al. [56]. In that work, they found that the experimental
conditions could have a profound effect on the practical parameter identifiably. In Chapter 4
we present a method that is based on genetic manipulation of various proteins. Like Faller, we
find that through experimental design we are able to show that a model previously thought to
be practically unidentifiable can in fact be identified to high accuracy in only five experiments.
We examined this question in the context of a pathway model of epidermal growth factor
(EGF) and neuronal growth factor (NGF) signaling. Computationally, we generated a palette
of experimental perturbation data that included different doses of EGF and NGF as well as
single and multiple gene knockdowns and overexpressions. While no single experiment could
accurately estimate all of the parameters, experimental design methodology identified a set of
five complementary experiments that could. These results suggest that there is reason to be
optimistic about the prospects for parameter estimation in even large models, that the success
of parameter estimation is intimately linked to the experimental perturbations used, and that
experimental design methodology is important for parameter fitting of biological models.
1.4 A Standard Formulation for Chemical Kinetic Models
Data formats such as Systems Biology Markup Language (SBML) [62, 88] and Cell Markup
Language (CellML) [112] have standardized the representation of biological models, allowing
them to be shared between laboratories and encouraging the development of model repositories.
This has greatly increased the number of publicly available models [129]. However, unlike the
models themselves, computational methods have remained difficult to share. For the most part
they rely on one-off, and often proprietary, codes. As a result the methods have remained siloed
within individual software packages and are difficult to combine, customize, or apply in new
contexts. The problem is exacerbated by the fact that CellML and SBML allow for arbitrary
mathematical expressions for the rate laws. Designing general codes for the analysis of models
that may contain arbitrary mathematical structure leads to high computational overhead, or
spotty support.
The difficulty in implementing reusable computational tools arises, in part, from the fact
that there is no standard formulation for chemical kinetic models of biological signaling. This
makes it difficult implement general-purpose analytical and computational methods. Here, we
propose a general and concise formulation of mass action kinetics based on sparse matrices and
Kronecker products. This formulation has the advantage that the matrices are constant and
depend linearly on the rate parameters, and that the quadratic terms are expressed as Kronecker
products. We show that this formulation allows simple algebraic manipulation of the models
and can serve as the basis for efficient general-purpose codes. In particular, we formulate
numerical integration, steady state finding, sensitivity analysis, and model calibration. In this
work, we applied these methods to a series of models which demonstrated that they scale to
models of thousands of equations on standard desktop hardware, despite being implemented in
a high-level mathematics package [168].
1.4.1 The Law of Mass Action
Our formulation for chemical kinetics is based on the Law of Mass Action. The observation
that the rate of a chemical reaction is related to the concentration of the reactants dates back
to Wenzel in 1777 [105]. In 1867 Guldberg and Waage put this observation into a quantitative
form, noting that the rate of a reaction was proportional to the products of the concentrations
of the reactants [178]. Subsequently, it was showed by van't Hoff that this law could be derived
from the principles of thermodynamics [118].
Zeroth-order reaction:
0 A dA r (1.2)
First-order reaction:
A rB - =B =,r A (1.3)
Second-order reaction:
A+B r >C dA= dB=dC=rAB (1.4)
A modern interpretation of chemical kinetics can be derived from statistical mechanics
[120, 71, 72]. The basic assumption is that the probability of a reaction occurring is determined
by the concentration of reacting molecules. Put more precisely, given a system with n copies
of a molecule X there is some probability that over a fixed time step ot a reaction will occur
to produce one more or one fewer molecules of X. We call the probability of forming one more
molecule f, and one fewer r,. Likewise, for systems with n - 1 or n + 1 reactants there are
forward and reverse probabilities fj_, r,_1 and fn+1, gn+i respectively. If we let p, be the
probability that there are n molecules of X then the time evolution of pn is given by Equation 1.5.
dpn - (fn + gn)pn + (fn+1 + gn-1)pn-1 + gn+ 1pn+ 1 (1.5)
dt
If we are interested in the average number of molecules, then Equation 1.5 becomes:
d (n) = (fn) - (gn) (1.6)
di
Returning to our assumption that the rates of reactions are given by the products of the
concentrations of their reactants we have:
0 -> products f = (fn) = k
A -> products fn = kn (fn) = k (1.7)
A + B -> products fn, = nm (f) = k nm) k (n) (m)
V V V V
Often this average is referred to as the deterministic limit of the chemical master equation [71].
From this, we can see that our original empirical description of the kinetics represents a kind
of average limit of a Poisson process. Even though many biochemical species are present in low
numbers within a cell, variation about this average due to small number statistics is typically
not a major factor as biological data is averaged over many cells, each of which can be though
of as an independent realization of this Poisson process. However, a subtle approximation made
in Equation 1.7, that n and m are uncorrelated, keeps this relationship from being exact. In
cases of bifurcations, then, the deterministic solution may not describe the average even in the
limit of large numbers of molecules or realizations [71]. For the models considered here there is
no multistability so we opted for the deterministic solution. However, an interesting extension
to this work would be to apply it to systems where the stochastic solution is necessary.
1.4.2 The Quasi-Steady State Approximation
The style of modeling described above, which is based on networks of elementary reactions,
is not the most popular style of modeling. In fact, the majority of models in the literature
use additional levels of approximation. For example, the stepwise reaction [119] by which an
enzyme binds a substrate, modifies that substrate, and then releases it is represented as a
single aggregated-reaction with a Michaelis-Menten rate law [123, 261. We call these models
aggregated rate law (ARL) models to distinguish them from the mass action rate law (MRL)
models described above.
One class of simplification is based on separation of time scale arguments such as rapid
equilibrium [154, page 18], or quasi-steady state [154, page 505]. Another class is based on
approximations that hold over certain concentration regimes such as pseudo-first-order kinetics.
More complex multi-step or multi-enzyme mechanisms may be aggregated into a small number
of pseudo-reactions [74, 11, 69, 110]. Often these represent empirical fits rather than a physical
limit of a specific mechanism [192]. While aggregated rate laws (ARLs) generally simplify the set
of reactions, they increase the mathematical complexity of the rate laws which, in general, are
non-linear functions of substrate, product, activator, and inhibitor concentrations. Moreover,
ARL based models are valid only over a particular concentration and time regime [172, 154].
An example of an ARL is the Michaelis-Menten rate law for a uni-uni irreversible enzyme.
The chemical mechanism is shown in Equation 1.8:
E + S IV'E:S E + P (1.8)
k_1
The Michaelis-Menten rate law describes the rate of formation of product as a function only of
the substrate concentration. The range of validity of this rate law is derived in detail in [155].
One requirement is that approach to equilibration for the complex is fast compared to the
production of product:
Eactive(t) < (1+ (1.9)
KM + Stotal(t) k 2 ) KM/
However, in the case of a signaling cascade, the total amount of substrate (Stotai(t)) and the
total amount of active enzyme (Eactive(t)) change dynamically, and in many cases quite rapidly.
Therefore, for the approximation to hold the approach to equilibrium must also be fast compared
to the modulation of the enzyme and substrate by other mechanisms in the model.
The second criteria is that the amount of free substrate is approximately equal to the total
amount of substrate S(t) ~ Stotai(t). Put another way, it is assumed that the enzyme-substrate
complex does not significantly deplete the free substrate.
1 > Eactive(t) (1.10)
KM + Stotai(t)
However, in networks where the enzymes and their substrates are both proteins it is very
common for the concentration of the enzyme to exceed the concentration of the substrate and its
KM. For example, Ras is a kinase, which phosphorylates Raf. In HeLa cells, the concentration
of Ras is approximately 0.40 pM and the concentration of Raf is 0.013 pM [66]. Estimates
of the KM range from 0.0053 to 0.1 pM. Even at the highest value of KM condition 1.10
doesn't hold. Moreover, if this condition holds for a particular cell type, overexpression or
knockdown studies could push the system out of the regime where the approximation holds. It
is for these reasons that we prefer to use the elementary reaction formulation as it applies over
all concentration and time scales.
It is worth noting that while the models developed in this thesis are elementary mass action
rate laws, the experimental design methods developed in Chapters 2 and 4 apply to models of
both types.
1.4.3 Converting Non-Mass Action Models
One practical challenge in building mass action rate law (MRL) based models is the lack of
data available in the literature to parameterize these models. Much of the parameter data that
is available is expressed in terms of the parameters of aggregated rate laws (ARL)s, such as
vmax, KM, and K1 . Here we present a method that can automatically derive the elementary
mass action rate constants from these ARLs. This method is a significant improvement over
previous methods. It is able to accommodate a wider range of ARLs, and is computationally
more efficient. We apply these methods to construct a MRL of the Escherichia coli central
carbon metabolism based on an ARL model from the literature [41]. Results are presented that
show the two models perform similarly over the range of inputs for which the ARL model was
developed. Moreover, we argue that because the MRL model is based on fewer approximations
it has the potential to be accurate over a wider range of conditions.
1.5 Anticipated Impact of this Work
Generally speaking, development of these models can be divided into three tasks. First, the
model variables have to be selected. Usually this is the set of chemical species involved in the
system. Second, the model topology is determined. This is the set of physical and chemical
interactions that create, destroy, move, and interconvert the chemical species. Third, the models
usually contain many unknown parameters which must be set. Typically, this involves fitting
kinetic rate parameters and initial concentrations to experimental data [173]. This process is
often called parameter fitting or model calibration. In addition to these three steps, there is an
implicit zeroth-order decision, which is selecting the level of detail to model. This choice will
dictate how the various interactions will be represented mathematically.
The standard approach to model building is shown schematically in Figure 1-1. This method
Yes T
Yes
Figure 1-1: Schematic of the Standard Model Building Process
begins with a description of the biological process to be modeled. The model is then calibrated to
all of the available data. In some cases additional experiments may be performed to supplement
this data. Once a parameter set is found that can describe all of the available data, it is used
to make predictions about the experimental system. The model is considered "validated" if the
predictions agree with experimental observation. Implicit in this diagram is that if a model
matches all of the available data, it is allowed to pass to the next step of the process. For
example, if a set of parameters can be found such that the model matches the data available,
it is said to be calibrated and it is passed onto the prediction step. There is no notion of there
being sufficient data to fully calibrate the model, or that any given step is carried to completion.
The methods and results presented here are an attempt to close-the-loop on the various
....... . ............... .....
steps of this process. Our modified model building process is shown in Figure 1-2. The model
calibration work presented in Chapter 4 describes a method for designing experiments that
are capable of defining all of the parameters of a model. In addition, it defines a metric for
assessing the success or failure of the calibration step. The model selection work presented
in Chapter 2 describes methods for designing experiments that are capable of selecting the
correct model out of a set of candidate models. This, result is nontrivial as data from standard
experiments would be insufficient for this task. In Chapter 3, we use the insights gained
from the computational studies to design experiments that are informative of the detailed
mechanisms of EGFR signaling. We conclude the work with the development of a computational
modeling framework based on mass action kinetics. Taken together, the work presented here
will demonstrate that experimental design can be successfully used to improve the quality
of mechanism-based chemical kinetic models, and close-the-loop on some of these modeling
decisions.
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Figure 1-2: The Closed Loop Model Building Process. The work presented here provides
methods for designing the experiments at each step, as well as conditions for determining if a
step has been completed.
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Chapter 2
Stimulus Design for Model Selection
and Validation in Cell Signaling
2.1 Introduction
One goal of systems biology is to develop detailed models of complex biological systems that
quantitatively capture known mechanisms and behaviors, and also make useful predictions.
Such models serve as a basis for understanding, for the design of experiments, and for the
development of clinical intervention. In support of this goal, there has been a strong push to
build mechanistically correct kinetic models, often based on systems of ordinary differential
equations (ODEs), that are capable of recapitulating the dynamic behavior of a signaling net-
work. These models hold the promise of connecting biological and medical research to a class of
computational analysis and design tools that could revolutionize how we understand biological
processes and develop clinical therapies [97, 101].
One type of experiment for model validation involves stimulating a system with a step change
in the input (typically by adding a high concentration of ligand) and then measuring the change
of network readouts (the concentrations or activities of the various downstream species) as a
function of time. Candidate models are fit to the data and the best model is selected based on
criteria such as the quality of the fit, the simplicity of the model, and other factors. While it is
tempting to select a simple model consistent with the known biochemical mechanisms that fits
all available data, future experimentation may prove this choice incorrect. Rather, it may be
preferable to collect "all" models consistent with known mechanisms and data, and to design
follow-on experiments capable of distinguishing among the model candidates. Here we develop
an approach for designing these experiments using dynamic stimuli.
While the step-response experiment is attractive for its ease of implementation, dynamic
stimuli have the potential to uncover more subtle system dynamics and to improve model
selection in the cases where step-response experiments are not sufficiently discriminating. One
example that illustrates the use of a dynamic stimulus to distinguish between two models is
the work by Smith-Gill and co-workers on the detailed mechanism of antibody-antigen binding
[111]. Initial step-response experiments were compatible with either a one-step or two-step
binding mechanism, in which the ligand and antibody first come together in a loose encounter
complex before forming a fully bound complex. To resolve this ambiguity, the authors applied
a series of rectangular pulses of ligand concentration to their system. The resulting binding
curves produced by this dynamic stimulus were inconsistent with the one-step model but were
consistent with a two-step model and suggested the existence of an encounter complex, even
though such a complex could not be measured directly by the assay.
These results show that time varying inputs have the potential to distinguish closely related
models of biochemical systems. For the relatively simple antibody-antigen system, an appro-
priate dynamic input was deduced intuitively. However this sort of intuitive design is difficult,
especially in the case of more complex cell signaling pathway models, which may be described
by hundreds or thousands of differential equations. An automated approach that could design
experiments to test these complex systems has the potential to expand the scope of model
selection experiments.
Previous work in designing dynamic stimuli for the purpose of model discrimination in
systems biology has focused on choosing input trajectories that maximize the expected difference
in the output trajectories of competing models [23, 8, 48, 127, 29, 42, 100]. In addition to model
discrimination, a rich literature exists on experimental design in systems biology for the purpose
of estimating model parameters [101, 89, 174, 38]. These optimization approaches for model
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Figure 2-1: Schematic of Experiment Design. (A) A feedback controller is used to solve for
the stimulus u(t) that will drive the model system outputs ysimulation(t) to follow the design
trajectory Ydesign(t). The inputs to the feedback controller are the deviation from the desired
trajectory edesign(t) as well as the model state x(t). (B) The designed stimulus can be applied
to an unknown experimental system to assess the quality of the model. A stimulus based on
a good model should be able to drive the experimental system output y(t) through the design
trajectory.
discrimination have been applied to small biological systems, but the nonlinearity of the models
combined with the presence of many local minima has thus far limited their application [29].
There is a need to extend these methods to design experiments that may not be optimal
but are capable of discriminating between large pathway models. Instead of trying to design an
input signal that maximizes the predicted difference between two model readouts, we recast the
problem as a control problem (Figure 1). We choose a target trajectory, and then challenge a
model-based controller to drive the system to follow the target trajectory. The extent to which
the controller based upon a given model is able to drive the physical system is a measure of the
fitness of that model.
We demonstrate our methodology by applying it to the epidermal growth factor receptor
(EGFR) pathway. This pathway has been extensively studied and modeled [25, 181, 86, 95, 1521.
EGFR and its family members (Erb2, Erb3, and Erb4) are known to mediate cell-cell inter-
actions in organogenesis and adult tissues [33]. Overexpression of EGFR family members is
a marker of certain types of cancer, including head, neck, breast, bladder, and kidney [184].
Because of their clinical importance, the EGFR receptors themselves, as well as various down-
stream proteins, are targets of therapeutic intervention [122, 53]. Despite clinical interest in
the EGFR pathway and over 40 years of intense study, there is still much about the pathway
that is not known. For example, in three recent studies [191, 19, 133], a number of proteins
that changed phosphorylation state in response to EGF stimulation were found that were not
previously known to be part of the pathway. In addition, many of the known pathway proteins
are not part of any computational model [132].
The ordinary differential equation model of Hornberg et al. is a widely used mechanistic
model of EGFR signaling [86]. This model is a refinement of earlier models of the pathway
[95, 152, 59]. It describes signal transduction initiated at the surface by EGF binding to EGFR,
leading eventually to the dual phosphorylation of ERK as the most downstream outcome.
ERK then participates in a negative feedback to the top of the pathway. The elementary
molecular processes modeled include bimolecular association and dissociation, phosphorylation
and dephosphorylation, synthesis and degradation, as well as endocytosis and trafficking all
described with mass-action kinetics. The model contains 103 chemical species, 148 reactions,
97 independent reaction rates, and 103 initial conditions.
We applied our computational methods initially to a small portion of the EGFR model
for development and demonstration purposes, and then to the full model. In both cases, we
formulated a set of closely related models that exhibit similar step-response behavior. We built
a controller capable of controlling each candidate model and asked the controller to drive the
system output (doubly phosphorylated ERK) to a predetermined value. Finally, by applying
these designed inputs based on the reference and perturbed models, we show that it is possible
to discriminate between the various model alternatives.
2.2 Methods
2.2.1 Model Formulation
In this work, we consider mass-action kinetic models consisting of zeroth-, first-, and second-
order reactions described by ordinary differential equations. In the equations below, k signifies
a rate constant; A , B, and C represent species or concentrations of species, depending on the
context; and 0 is the empty set or nothing.
Zeroth-order reaction:
First-order reaction:
0-*A A= k
A-> AdB=kA (2.2)
Second-order reaction:
A+B--*C dA dBC =kAB7F dt- d t- (2.3)
Large systems of reactions of this form can be represented compactly using Equation 2.4.
Ai =Ajx+A 2 x x+ Biu+B 2 x 0u+k
y =Cx
(2.4)
The state vector x describes the chemical species concentrations that are free to evolve
in time according to the kinetics of the system. The input vector u represents the chemical
species concentrations controlled by the experimenter. Matrices A1 and B1 represent first-order
reactions, matricesA 2 and B 2 represent second-order reactions, and k represents constitutive
(zeroth-order) reactions. The symbol & denotes the Kronecker Product (also known as the
matrix direct product) [75]. For vectors, this operator generates a vector of all quadratic
products.
(2.1)
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The output of the model y is a linear combination of the state variables represented by the
matrixC.
2.2.2 Control Formulation
A controller was developed to solve for the input signal u(t) that best achieves a particular
objective in the output. We formulate this objective as a cost function G(u) that measures the
distance between the model output and the desired output.
T
G(u) j [y(u, t) - ydesig (t)] 2 dt (2.6)
Here, G(u) is the sum of squares error between y(u, t), the model output for a given input
u(t), and ydesign(t) the target output the controller is trying to match. T is the length of the
experiment. The control problem is then to find an input function u(t) that minimizes G(u).
Equation 2.6 depends on models of the form of Equation 2.4, which are nonlinear and poten-
tially high-order. This prevents us from solving the minimization problem directly. To address
this issue, we implement two different approximations. The first is based on controlling a model
formed from successive linearizations of Equation 2.4 (henceforth referred to as the tangent lin-
ear controller), and the second is based on a local search of the input space (henceforth referred
to as the dynamic optimization controller) [36].
2.2.3 Tangent Linear Controller
A first-order approximation to Equation 2.4 at time t was computed by taking the Taylor series
expansion about the current value of the state and input vectors (xt and ut).
dAx [Ai + A2(I Oxt + xt 9 I) + B2I ut] Ax + [B2xt 0 I1 Au (2.7)
y ~ C (Xt + Ax)
Equation 2.7 is a linear differential equation with state variable Ax and time varying forcing
term Au, which has both numerical and analytical solutions. However, this approximation
would tend to diverge from the solution to Equation 2.4 as At, the time beyond the linearization
point t, and as(Ax, Au), the distance from the linearization point (Xt, Ut), increases. To mitigate
this problem the true system (Equation 2.4) was propagated, and successive linearizations were
applied to improve the controller performance. Effectively, the linearization point is allowed to
slide along with the exact simulation.
Operationally, each time step was solved in three stages. First, the current state of the
nonlinear simulation was used to derive a linear approximation about the current time point.
Second, the linear system was solved to get the best input Au. The linear system was solved
numerically by discretizing the input as a series of scaled and shifted boxcar functions [177] of
width T. Numerical integration with the MATLAB routine odel5s [156] was used to compute
the system response to a unit boxcar input. The output of a linear time invariant system can
be expressed as a linear combination of scaled shifted impulse response functions. Thus, solving
for the input was achieved by computing the weights to apply to the input pulses that gave the
optimal output. This was solved as a linear system of equations with box constraints on the
input to limit the maximum and minimum concentration using the MATLAB routine lsqlin.
Third, the computed input signal was applied to the full nonlinear system for a short time step
r. The process was the repeated for the next time interval. Effectively, each step the algorithm
solves for an input signal Au that is piecewise constant. The width of the intervals -r as well as
the number of intervals is a parameter of the optimization and should be chosen based on the
accuracy of the linear system.
2.2.4 Dynamic Optimization Controller
In this controller formulation, rather than exactly solving the tangent linear system, we solved
the full nonlinear problem iteratively using a gradient optimization method. Application of
this method requires computation of the sensitivities of the least squares objective function
(Equation 2.6) with respect to the input parameterization p. An efficient way to compute
this quantity is to first solve for the adjoint sensitivities A [36]. For the dynamical system
(Equation 2.4) and the objective function (Equation 2.6), the adjoint equations are given by
Equation 2.8.
dA* A* [A1 + A2 (I 9 x + x & I) + B2 1 9 u] + 2 CT (Cx - Ydesign)dt
T (2.8)VpG(p) f A* [B1 + B 2 (x @ I)] Vpu(p)dt
0
Here, A* indicates the conjugate transpose. For piecewise linear input signals the ith com-
ponent of the gradient du is given by:
f 0 t<Ti iort ;> Ti+1
du 
-
-_1 < t < T (2.9)
M+1-0 T < t < T+1
The adjoint equations were solved in MATLAB using ode15s [156] and the optimization was
implemented using fmincon configured to use Quasi-Newton [165] with BFGS [131, 14] in the
MATLAB Optimization Toolbox Version 3.1.1.
2.2.5 Constraining Input Signals
Thus far the input signals have been unconstrained, except by the choice of the discretization.
However, in practice it may be desirable to restrict the space of input signals to those that could
be feasibly achieved by a given experimental setup. For example, in many experimental setups
it is easy to add material but difficult to take material away. Likewise, there may be a maximum
and minimum concentration for the input signals, or a maximum rate of change for the input
signal. We implemented these experimental constraints as linear inequality constraints of the
form of Equation 2.10.
Ap < b (2.10)
The matrix A and the vector b are passed as arguments to lsqlin in the case of the tangent
linear controller, or to fmincon in the case of the dynamic optimization controller. An example
of a linear constraint that might be applied is that the input increase monotonically. In this
case, A and b are given by Equation 2.11.
1-1 0 0
A [ --.. and b= (2.11)
0 1 -1 0
2.2.6 EGFR Signaling Model
We based our model of EGFR signaling on that of Hornberg et al. [86], which itself is a
refinement of earlier work [95, 152, 59]. The model contains 103 chemical species, and 148
elementary reactions; these reactions are of the type given by Equations 2.1, 2.2, and 2.3 and
may be reversible. The model is parameterized by 97 distinct reaction rate values and 103
initial conditions. The details of this model are given in Appendix A.2.
Here we also introduced a modified model of EGFR signaling, which contained six addi-
tional production/degradation reactions of the form of Equation 2.12, where X is one of of the
following: GAP, GRB2, SOS, RAS-GDP, SHC, or GRB2-SOS
k ynth
kdeg
The degradation rate kdeg was set such that the steady-state value of the species was the
same as the steady-state value in the unmodified model computed using Equation 2.13.
kdeg = ksynt /Xss (2.13)
In addition to the protein synthesis and degradation reactions, a GAP-catalyzed turnover
of RAS-GTP was implemented.
kon kcatRAS - GTP + GAP 7 RAS - GTP: GAP -4 RAS - GDP + GAP + Pi (2.14)
k~ff
The rate constants (kon, kff, and kcat) are 5 x 10- 7molecules- 1 cell-'s- 1 , 0.4s- 1 , and
0.023s-1, respectively. The rate constants kon and koff are taken from the analogous reaction
where GAP is part of the receptor complex and the kcat was fit so that the half-life of RAS-GTP
in the absence of EGF matched literature values [113].
Finally, a first-order turnover of internalized SOS was implemented with a rate constant of
10- 7s- 1 based on the turnover rate of EGFR.
SOS # SOS (2.15)
This augmented model had the additional property that if the input is removed (set to zero)
it will return to its initial condition.
2.2.7 MAPK Signaling Model
The mitogen activated protein kinase cascade is a signaling motif found repeated throughout
biology [59]. In each step of the cascade a substrate is multiply phosphorylated by a kinase,
which in turn is the input to the next layer in the cascade. The off signal, present in each
layer, is a phosphatase that removes the phosphate groups. Despite knowing all of the species
involved, the detailed mechanism of the enzymatic steps had been difficult to determine [59]. In
particular, it was unclear if the kinase acted in two distinct enzymatic steps, whereby it released
the substrate between phosphorylation steps (distributive mechanism) or if it performed both
phosphorylation steps before releasing the substrate (processive mechanism).
A MAP kinase cascade consisting or RAF, MEK, and ERK is contained in the Horn-
berg EGFR pathway model. We extracted a tier of this cascade consisting of a single kinase,
phosphatase, and substrate. The four reversible bimolecular reactions representing the phos-
phorylation of ERK by doubly phosphorylated MEK (MEKpp) and the dephosphorylation by
a phosphatase were used as the basis of a new model. The model contains a distributive dual
phosphorylation step catalyzed by MEKpp and a distributive dual dephosphorylation step cat-
alyzed by a phosphatase. MEKpp is the system input; doubly phosphorylated ERK (ERKpp)
is the output.
In addition to this basic model, three alternative models were also constructed that dif-
fered in their mechanism of phosphorylation and de-phosphorylation (processive or distribu-
tive). The set of four models (distributive-kinase - distributive-phosphatase, processive-kinase
- distributive-phosphatase, distributive-kinase - processive-phosphatase, processive-kinase -
processive-phosphatase) represents all possible combinations of processive and distributive phos-
phorylation and de-phosphorylation mechanisms (Figure 2-3A). The alternative models, which
contain some rate parameters not included in the distributive-kinase - distributive-phosphatase
base model, were parameterized by fitting the parameters to the step response of the double
distributive model, which included both a step-up and a step-down experiment. The details of
these four models are given in Appendix A.1.
2.3 Results
We have developed a method for designing input signals that are capable of controlling the
output of a candidate model. In practice, these input signals are useful for distinguishing
among sets of candidate models.
2.3.1 Simple Antibody Binding Models
The dynamic optimization controller was applied to design input stimuli for each of the two
alternative antibody binding reactions studied by Smith-Gill and co-workers [111]. For both
the one-step and the two-step model (Appendix A.1), the objective applied was to produce
a constant output of antibody-ligand complex from time zero onwards. In the experiment
performed by Smith-Gill and co-workers the measurement was a change in mass due to ligand
binding as measured by surface plasmon resonance. While the fully bound complex is more
stable than the postulated encounter complex, both have the same mass and would produce
the same output signal. Therefore, in the case of the two-step model, the output is the sum
of the encounter and fully bound complexes, whereas in the one-step model it is simply the
fully bound complex. The basis set for the input was a 50 point piecewise-linear function with
linear spacing. In the two-step model points were distributed evenly over the entire interval.
In the one-step model points were placed evenly from 500 s to 600 s to accommodate the sharp
transition.
The results are shown in Figure 2-2. Both controllers designed an input signal that starts
at high concentration to form the complex quickly and then drops to a lower concentration to
keep the complex from overshooting the desired value. However, the controller for the one-step
model drops abruptly while the controller for the two-step model drops more gradually. The
desired output is not recovered when the stimuli from the wrong models are applied. When the
one-step input was applied to the two-step system, the output produced an undershoot followed
by an overshoot. When the input designed for the two-step model was applied to the one-step
system, the complex concentration also produced an overshoot, but one that persisted. In both
cases, accounting for the presence or lack of the encounter complex was critical for controlling
the output correctly.
It is interesting to note that this method allows for the selection of both the more complex
model (if it is correct) as well as the simpler model. This is not possible using standard a
posteriori metrics, such as least squares, which will always favor the more complex model.
While there are methods that try to correct for this bias [24], properly accounting for model
complexity in large nonlinear systems remains an open problem [81]. Comparing our results
to the Smith-Gill pulse method (Figure 2-2B), it is clear that both computational experiments
permit the two models to be distinguished in favor of the two-step method. However, for larger
and more complex cases, it is unclear whether intuitive approaches or square pulse inputs will
be sufficient to design distinguishing experiments. Another feature of the simulations is that the
designed pulse produces a level output that does not require fine time resolution to accurately
measure. This can be a significant advantage for more complex experimental systems, such
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Figure 2-2: Analysis of Monovalent Antibody Binding (A) Two models of monovalent antibody
binding, a one-step version with no intermediate, and a two-step version with an association
intermediateC*. (B) The results of six simulated experiments are shown as designed in ref-3.
Each trace is the response of the system to a square pulse of ligand concentration. The width of
the pulse varies from 400s to 6, 000s. The pronounced elbow in the middle curves is indicative
of the two-state model. The one-step model cannot have compound off kinetics. (C) The set of
experiments designed by this algorithm as well as simulated results are shown. Each pulse was
designed to produce a level output when applied to the correct model (yellow boxes), which
was observed, and produced a distinctly different result when applied to the other models (blue
boxes). The red lines are the inputs (unbound L) the blue lines are the output (C or C + C*).
The smaller the gap between the blue and the black dashed line the better the model fits the
real system. Looking across one row shows a pair of experiments that would be run together.
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as cell signaling measurements, where limitations on experimental observations are even more
severe, whether in terms of numbers of species, time points or other factors.
2.3.2 MAPK Signaling
Mitogen activated protein kinase cascades have been extensively studied experimentally and
modeled computationally. While many variants exist, the canonical pathway consists of three
layers of kinases and phosphatases. For each layer, the kinase activates the downstream kinase
by dual-phosphorylation and the phosphatase deactivates the downstream kinase by removing
the phosphate groups. Knowing the general structure of this pathway, it was still difficult to
determine the details of the enzymatic steps. In particular, it was unknown if the kinase acted
in a processive mechanism (adding both phosphate groups in a single step), or if it acted in a
distributive mechanism (adding the phosphates in two distinct enzymatic steps). The difficulty
arose from the fact that, without measuring all of the phosphorylation forms, both mechanisms
could fit the step response data. The issue was eventually resolved by devising an experiment
that could separate all of the phosphorylation forms [59]. Here we show that, in principle,
the mechanisms could have been distinguished using our method, without adding additional
measurements.
To address this problem we generated four candidate models of a mitogen activated protein
kinase (MAPK) dual phosphorylation reaction. All four models contained forward phosphory-
lation and reverse dephosphorylation steps, but differed in the detailed mechanisms. For both
the forward and the reverse reactions we considered a processive (one-step) and a distributive
(two-step) mechanism (Figure 2-3A). Taking all combinations of distributive and processive
reactions produced four models. For each model the free kinase concentration was the input
variable and the concentration of doubly phosphorylated substrate was the output.
For each of the four models, a stimulus was developed using the tangent linear controller.
The objective was to drive the output to a fixed value that remained constant with time. Each
of the four designed signals was used to stimulate each of the four models, and the resulting 16
experiments are shown in Figure 2-3C. Along the diagonal, one can see that the input signal
derived from the correct model was able to effectively control the system. However, looking at
each off-diagonal entry shows that inputs from each wrong model did a poor job controlling each
system. In any real experiment, there is only one true system, which corresponds to performing
the experiments from a single row of the figure.
As with the antibody models, the algorithm was able to find a set of signals that dis-
tinguished amongst multiple models. It is worth noting that these solutions were generated
automatically from the candidate models and did not require explicit user supervision.
2.3.3 EGFR Pathway
A popular ordinary differential equation model of the EGFR pathway is that of Hornberg and
co-workers [86]. This model consists of 103 differential equations and includes ligand binding, re-
ceptor dimerization and activation, adaptor protein binding, trafficking of the receptor complex,
and activation of the MAPK cascade terminating with ERK dual phosphorylation (Figure 2-4).
This model was built as a set of successive refinements of earlier models [152, 95, 59], with
each refinement adding a new level of detail to the model. In its most recent formulation an
additional negative feedback loop was added whereby activated ERK phosphorylates SOS and
deactivates it. This model has been shown to agree with time course data collected in cell based
assays as well as literature values for parameters measured in vitro [152]. We compare the orig-
inal Hornberg model to a version with additional changes. We continue this model evolution by
modifying the Hornberg model so that, when the input (EGF) is removed, the model returns
to its initial conditions. This reset behavior is observed experimentally. The experimental data
presented by [152, 95], the cells were cultured in media containing EGF. Prior to stimulation
the cells were switched to serum and EGF free media for 12 h. Cells treated in this way are
able to recover from the EGF contained it their culture media, an, at least after twelve hours
return to an EGF responsive state [191].
In the Hornberg model, the dominant mechanism for desensitization and adaptation of
the pathway to EGF is endocytosis and degradation of the receptor complex. Opposing this
process are constitutive production and degradation reactions for the receptor, which allow the
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Figure 2-3: Analysis of MAPK Mechanisms. (A) Four alternative MAPK reaction schematics
are shown. These correspond to all combinations of processive and distributive kinase and
phosphatase mechanisms. Model I is the conical all-distributive mechanism. For each model the
input is the concentration of activated kinase (K) and the output is the doubly phosphorylated
substrate (S**) (B) All four MAPK models respond in very similar fashion to a step increase
in kinase input (u =1). (C) A set of 16 model-selection experiments. Each row is a different
experimental system and each column is a different candidate model. Red lines are inputs
(activated K), blue lines are the output (S**), and the black dashed line is the design output
trajectory. The experiments on the diagonal show that the correct model can control the system.
The off-diagonal experiments show that the wrong model does a worse job. This difference can
be used to select the correct model.
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Figure 2-4: Schematic of EGF Induced Signaling. This schematic of EGF induced signaling
shows the major steps in EGFR signaling. At the top of the pathway ligand binds to the receptor
and induces receptor dimerization and activation. The signal is then transduced through a series
of adaptor proteins SHC, GRB2, and SOS, which in turn activates the MAPK kinase cascade
RAF, MEK and ERK. There are two negative feedback loops: internalization and degradation
of the receptor complex, and ERK deactivating SOS.
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receptor level to return back to steady state after stimulation. This same process degrades
other proteins in the receptor complex (GAP, GRB2, SOS, and RAS), but the current model
does not contain synthesis terms for these proteins. As a result, prolonged stimulation depletes
these proteins and prevents the activation of RAF, MEK, and ERK. We added production and
degradation reactions analogous to the reactions for the receptor for all of the proteins in the
receptor complex. Rate constants were chosen such that the steady-state levels in the absence
of stimulation were the same as the initial conditions for the model and the exponential time
constant for the approach to steady state was the same as for EGFR.
The second modification to the model was in the RAS-GDP/RAS-GTP cycle. In the Horn-
berg model, activated receptor is needed to catalyze the recycling of RAS-GTP* (a molecule of
RAS-GTP that has already activated a molecule of RAF) that is waiting to be recycled to RAS-
GDP. If EGF is removed, RAS can be trapped in the RAS-GTP* form, preventing the system
from returning to steady state. We addressed this by adding an additional enzymatic step to
recycle RAS-GTP* back to RAS-GDP catalyzed by GAP and parameterized using literature
rate constants [113].
With the addition of these new reactions, the modified model returns to its initial conditions
after stimulation. For the remaining model parameters (the parameters shared with the original
model) we fit the modified model to the original using data from a simulated step-response
experiment (Figure 2-5A) constraining them to be within 10% of their original value. Despite
the introduction of these new mechanisms and the tight constraints on the parameters, the
step responses of the six molecular species modeling those presented in the original paper [152]
(Figure 2-5B) are very similar in the original model (blue curves) and the modified model (red
curves). The largest difference is in the SHC* time course, which has a very similar shape and
varies by at most 11%. While significant, this difference would be very difficult to detect in a
standard biological experiment. As such, the modified model is a reasonable alternative to the
original model, and it would be hard to reject either mechanism using the step-response data
alone.
From this starting point we used our methodology to design an experiment that could
distinguish between the current model and the modified model of the EGFR pathway. For each
model we tasked the dynamic optimization controller with driving the concentration of doubly
phosphorylated ERK to a constant level of 104 molecules per cell. The input basis set was 25
points linearly spaced over the interval. To model the experimental condition where it is easy to
add EGF to the dish of cells but difficult to remove, we implemented a monotonicity constraint.
Figure 2-5B shows the inputs designed for each of the two models applied to each system with
the resulting ERKpp time courses. Due to the negative feedback loops, both models required
a steadily increasing concentration of EGF to maintain a constant level of ERKpp. However,
the original model was much more difficult to control; as time progressed increasingly high
doses of EGFR were required to maintain a constant output. The modified model required
a much gentler increase in EGF concentration to maintain its level and was able to keep the
concentration of ERKpp high to the end of the time period. Trial calculations showed that
this result was robust to order of magnitude changes in the new rate parameters introduced in
the modified model. Applying these two signals in an experiment could be used to distinguish
between these two models, as demonstrated by the simulations.
2.4 Discussion
The most common stimulus-response protocol involves applying a step change in one or more
input concentrations and following the evolution of one or more downstream molecules. For
a linear system, this type of experiment can provide enough information to fully identify the
system [135]. However, even simple biochemical systems are nonlinear, and as such there is
no a priori reason to believe that a step-response experiment will be sufficient to uncover the
relevant dynamics of the system and allow for the selection of a unique model. As a result, it
is often possible, if not probable, that multiple mechanisms fit the same set of step-response
data. We have shown here that using dynamic stimulation can improve stimulus-response
experiments. Even in the context of complex pathways with limited numbers of inputs and
outputs, experiments can be designed that are capable of distinguishing amongst alternate
mechanisms. Moreover, for the EGFR pathway studied, the differences detected were in the
middle of the pathway, far from the location of the stimulus or the readouts.
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Figure 2-5: Comparison of Step Experiment to Designed Experiment for EGFR Pathway with
Original and Modified Models. (A) Both models respond similarly but not identically to a step
input in EGF over a range of concentrations. The red lines are the outputs of the modified
model and the blue lines are the outputs of the standard model. Often the blue lines are not
visible because they are under the red lines. (B) Two designed dynamic stimuli were applied
to two models of the EGFR pathway. The red lines show the input (EGF) concentration as a
function of time. The blue lines show the output concentrations (ERKpp). The dashed black
line shows the target ERKpp concentration. The controller for the standard model is unable
to keep the output level high and saturates. In contrast, the modified model requires a more
gradual increase in the input and can control the experiment over the course of the entire
time course. In both cases the controller based on the wrong model performs worse that the
controller based on the correct model.
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One possible explanation for the results presented here is that we have stimulated the
systems with high-frequency signals, and it is this fact that allows for model discrimination.
While the high-frequency content almost certainly plays a part, the fact that the differences
between models are observed at low frequency distinguishes our results from other standard test
signals. For example, in linear systems it is common to use random or pseudorandom signals
to discriminate among models. Figure 2-6 shows such an experiment. While the signal is
discriminating, the observed differences are high frequency and would be difficult to distinguish
in a standard biological assay, which are usually sampled sparsely in time.
Formulating experiment design as a control problem yielded a relatively straightforward
numerical solution, which allowed us to apply our method to large pathway models. While
the method does not yield optimal experiments, in the sense of maximizing the least squares
error between model ouputs, the results are still of practical benefit and appear sufficient
to distinguish amongst model candidates. In the systems studied here, the designed inputs
were able to substantially increase the differences observed between competing models when
compared to the corresponding step-response experiment. By prescribing the target output
trajectory, it should be possible to tailor the experiments to the available measurement methods,
thereby achieving the most benefit from existing assays. It is worth noting that in all of the
examples presented here, the target function was a constant output concentration. This was
chosen for simplicity rather than for any special property of these targets. The problem of
the best target function is an interesting one but is beyond the scope of this work. However,
in Figure 2-7 we show calculations for the antibody-ligand system using other simple target
functions, lines of constant slope, and find that designed inputs based on these signals have
similar discriminating power.
In each of the cases presented here, the dynamic stimuli allowed us to select the correct
mechanism from a set of plausible candidates. However, it is possible that for a particular
system and set of constraints, the algorithms presented here may fail to find a signal that is
sufficiently discriminating. In this case a different choice of target function or a more sophis-
ticated optimization approach may yield better results. However, it is worth noting that in
the systems studied here both methods were able to find very good solutions in all cases. In
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Figure 2-6: Random Pulse Experiment. This figure shows a series of pulses as input to the
one-step and two-step antibody ligand models for two different distributions of switching time.
In the slower switching time (A) the input signal changes at random with a mean of 900 s,
and in the faster switching time (C) the input switches at random with a mean of 90 s. (B)
The response of the two models to the slower input shows that the one-step model looks like a
smoothed out version of the two-step model. (D) The trend is similar with the faster varying
signal.
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general, the tangent linear controller was more computationally efficient and yielded smoother
signals, whereas the dynamic optimization controller was slower but did not require tuning of
parameters such as r.
One potential limitation of our method comes from our reliance on parameterized models.
The accuracy of the parameterizations will affect the quality of the predictions made by the con-
trollers and thus the ability to distinguish between models. To demonstrate this, we generated
100 different parameterizations of the one-step and two-step antibody models and then applied
the control signals designed using the nominal parameter set (Figure 2-8). The parameter
variation resulted in output trajectories that were quantitatively different from the predicted
output trajectories. However, the overall shape of the output trajectories was preserved.
All of the results presented here were in simulation. In practice, experimental error and
measurement noise will make it more difficult to distinguish between models. As a result, one
may only be able to effectively discard some candidate models, and reduce the pool of hypothe-
ses. However, these experimental challenges also motivate our method, as it has the potential
to increase the experimental observability of model differences when compared to a more tra-
ditional experiment, such as a step response. Moreover, the fact that potential mechanisms
can be evaluated without having to resort to additional inputs or outputs is especially valuable
in laboratory experiments, where adding additional inputs or outputs may require significant
effort, such as developing new experimental reagents.
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Figure 2-7: Matching Different Target Functions. The dynamic optimization controller was used
to design input signals to drive the one-step and two-step antibody ligand models. The target
functions (black dashes) are a set of lines of increasing slope. The input is the concentration
of free ligand (red) and the output is the amount of complex formed (blue). The figures on
the diagonal show that the controller based on the correct model is able to accurately drive
the systems to follow the target functions very closely. Whereas, the figures on the off diagonal
show that the inputs based on the wrong models cause either large over- or under-shoots of the
target function.
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Figure 2-8: The Effect of Parameterization Errors. A dynamic optimization controller was
constructed based on a nominal parameterization of the one-step and two-step antibody models.
The resulting input signal is shown in red and the output is shown in dark blue. These input
stimuli were then applied to a set of 100 different parameterizations of these two models (cyan
lines). The parameters were chosen from a log normal distribution with a mean centered on
the nominal value and a variance of 10%.
C
0
S 0
000
C
0
t 0
0.00
~0
Co 0
1
.8
.6
.4
2
1500
.. ........ ......... ..... .. ......................
66
Chapter 3
Using Time Varying Stimulation to
Understand the Multiple Feedback
Loops in Epidermal Growth Factor
Receptor Signaling
3.1 Introduction
Signaling downstream of epidermal growth factor receptor (EGFR) is regulated by a complex
network of multiple interconnected negative and positive feedback loops [185, 45, 3, 146, 116,
124]. The full biological implication of these loops is not well understood, but they have been
implicated in pattern formation during development [140, 143], carcinogenesis [82], and cell
motility [117, 91]. Because of their biological importance, EGFR, as well as many of the down-
stream kinases, are drug targets [55]. However, the efficacy of these drugs is highly context
dependent, and most exhibit significant patient-to-patient variability [138]. The biochemical
mechanism of this variability is not well understood [134, 37, 126]. One possible explanation is
that, depending on the state of the networks, these negative and positive feedback loops either
undermine or enhance the efficacy of a drug [98, 63]. This suggests that understanding the
structures and the regulation of these feedback processes may illuminate the differential phar-
macological responses to these drugs, suggest diagnostic biomarkers, and motivate improved
clinical regimens including cotherapy strategies.
The EGFR signaling cascade begins with the formation of an active signaling complex.
Epidermal growth factor (EGF) binds to the extracellular domain of EGFR, which stabilizes
receptor dimers and leads to auto-phosphorylation of several tyrosine residues on the cytoplas-
mic tail of the receptor. These phosphotyrosine residues serve as docking sites for a complex
network of adaptor proteins [90]. The adaptor proteins GRB2 and SOS binding to the receptor,
either directly or through Shc. completes the active signaling complex. Once completed, the sig-
naling complex can activate the small GTPase Ras which in turn activates the Raf/MEK/ERK
mitogen-activated protein kinase (MAPK) cascade.
Opposing this activating signaling cascade are several strong negative feedback loops. The
best characterized mechanism of signal attenuation involves the endocytosis, ubiquitination, and
degradation of the receptor [180, 32, 45, 184, 185]. Activated receptors cluster over clathrin-
coated pits driving vesicle formation. These vesicles are then transported to the sorting endo-
some. Some fraction of the receptor and the ligand are recycled to the surface, while a majority
of the activated receptors are trafficked to the late endosome and degraded. The fate of the
adaptor proteins that are associated with the receptor complexes during the degradation pro-
cess, however, is less clear. The decision to recycle or degrade the receptor is at least partially
regulated by the ubiquitin ligase Cbl [45].
In addition to the endocytic regulation, there are a number of post translational feedback
loops involved in silencing the EGFR signal. In one loop, MEK phosphorylates Raf on its
14-3-3o- binding site, which deactivates Raf. In another loop, ERK, a promiscuous kinase
which can phosphorylate more than 160 substrates in the cytoplasm and the nucleus [157, 186],
phosphorylates SOS, promoting the dissociation of SOS from GRB2 [27]. There is also evidence
that ERK can phosphorylate EGFR on threonine-669 which has been shown to lead to decreased
receptor internalization [83] and inhibited kinase activity [167]. ERK also activates a number
of transcription factors. Recent work by Amit et al. [3] has shown that stimulation with a
constant saturating dose of EGF leads to the rapid activation of a number of "delayed early
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Figure 3-1: Time Varying Stimulation of EGFR Network. (a) shows schematically the EGFR
signaling network. (b) shows the EGF time course that was used to stimulate the network.
genes". This set of genes is enriched for negative regulators of the EGFR pathway, including
the dual specify protein phosphatases (DUSPs), one of which, DUSP6, is known to be able to
dephosphorylate ERK in vivo [20]. Amit et al. hypothesized that upregulation of the DUSPs
formed a negative feedback loop that shut off ERK. To test this hypothesis, cells were pretreated
with cycloheximide (a protein synthesis inhibitor) 10 minutes prior to EGF stimulation, with
the intent of blocking transcriptional feedback from producing more phosphatase. The result
of the cycloheximide treatment was a prolonged phospho-ERK signal [3], which is consistent
with their hypothesis. None of the current computational models of the full pathway include
this negative feedback loop. However, this mechanism has been observed and modeled by
Bluthgen et al. in a synthetic system where ERK is activated by the inducible expression of a
constitutively active RAS.
In addition to the negative feedback loops, there is a negative feedforward loop controlled
by Ras GTPase activating protein (Ras-GAP). When Ras-GAP is bound to Ras, it greatly
increases the rate of GTP hydrolysis, which converts Ras from the active form (Ras-GTP) to
the inactive form (Ras-GDP). It should be noted that Ras-GAP is a major point of crosstalk
between signaling networks and can be activated by many receptors including other Erb Family
members [43, 18], TrkA [149] and insulin receptor [21].
To help decipher this complex network of feedback loops, a number of computational models
of this pathway have been produced. While these models match the observed data well, they
contain a diverse set of mechanisms and are controlled by different principles. One popular
model of EGF signaling from the literature was developed by Hornberg and coworkers [86] as a
refinement of earlier models [95, 152, 59]. This model includes the formation of an active recep-
tor signaling complex leading to the activation of the MAPK cascade, and contains two negative
feedback loops: the endocytosis and degradation of the receptor complex and inhibition of SOS
by direct ERK phosphorylation. A very similar model was created by Brightman and Fell [27].
It contains all of the same biophysical processes as the Hornberg model. Despite implementing
similar mechanisms, the models operate by very different principles. The Hornberg model is
dominated by the endocytosis loop, and removal of the ERK negative feedback loop does not
significantly affect the model step response [152]. By comparison, the Brightman and Fell [27]
model, is dominated by the ERK to SOS negative feedback loop. Other models developed by
Sasagawa et al. [149] and Brown et al. [31] include an additional negative feedforward loop from
EGFR to Ras-GAP. However, the Sasagawa model does not include receptor recycling and the
Brown model does not include any receptor trafficking. The Hornberg and Brightman models
do not model Ras-GAP explicitly. Instead both models abstract this process and allow the
activated receptor complex to catalyze both the activation (Ras-GDP to Ras-GTP) and the
deactivation (Ras-GTP to Ras-GDP) reactions.
One possible reason for the lack of consistency between these models is that the experi-
ments used to validate these models are largely insensitive to the weights given to the different
mechanisms. The typical experiment for model validation involves stimulating cells in culture
with a saturating dose of EGF and then measuring the concentrations of various downstream
species at various time points. We call this type of experiment a step response experiment.
We have shown previously that such experiments are not particularly well suited to distinguish
between different mechanisms [5]. In particular, they are not strongly affected by the details of
the negative feedback loop. We believe that the reliance on step response data has led to the
ambiguity that exits in models of EGFR signaling. However, in our work we also showed that
a time varying stimulus could yield data that was more informative of the detailed mechanism.
In this study, we tested the idea that a time-varying EGF stimulation could reveal more of
the subtle regulation of the EGFR network and help elucidate the relative effects of the different
feedback loops. Rather than investigate all of the negative feedback loops, we focused on the
detailed mechanism of the endocytotic feedback loop. In particular, we tested the mechanistic
assumptions of the Hornberg model that lead to the dominance in that model. The stimulus we
chose was pulses of EGF separated by different lengths of time (Figure 3-1(b)). The results show
that the Hornberg model does not accurately predict the response of the network to this time
varying stimulation. We also show that some simple changes that we previously suggested [5]
do lead to improved predictions, but that the mechanism proposed is not correct. Based on
our findings we suggest some alternative mechanisms that are consistent with this new data,
as well as previous results. Although our focus here was on the endocytosis feedback loop,
the data presented here seem to be highly sensitive to the impact of of other feedback process.
Taken together, these results suggest that this experimental strategy of pulsing the network
with EGF combined with specific inhibitors may be an effective strategy to unravel the details
of this complex multi-feedback network.
3.2 Results
3.2.1 Modeling Prediction
In the EGF signaling developed by Hornberg and coworkers [86], the endocytosis and degrada-
tion of the receptor complex is the dominant negative feedback mechanism. The model assumes
that in the late endosome all of the proteins in the receptor complex are degraded. This in-
cludes the receptor and all adaptor proteins or kinases bound to the complex. The affect of
this assumption is that stimulus with EGF depletes the cytoplasm of adaptor proteins, effec-
tively severing the receptor from the downstream signaling events. While the model includes
synthesis terms that replace the degraded receptor, there are no similar terms for the adaptor
proteins. As a consequence, this model makes an interesting prediction, that endocytosis and
degradation of the receptor complex should make the network insensitive to EGF after an initial
stimulation, and that this insensitivity should be persistent. This mechanism has been propa-
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Figure 3-2: Two Pulses of EGF Applied to Models With and Without Adaptor Protein Recy-
cling. Two five-minute pulses of EGF were applied at time zero to the Hornberg model without
adaptor protein recycling (blue lines) and to the Hornberg model with adaptor protein recycling
added (red lines) The pulses were applied at t = 0 min and then again at t = 95 min. Both
models respond roughly equally to the first and second pulse at the level of EGFR and Shc,.
However, the model without adaptor protein does not respond to the second pulse at the level
of Ras-GTP or below.
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gated to newer versions of this model [43]; however, our intuition about the system is that given
sufficient amount of time the network should be able to reset from an transient pulse of EGF.
In previous work, we proposed adding adaptor protein recycling via constitutive synthesis and
degradation [5]. Like the Hornberg model, the model with recycling is still strongly regulated
by endocytosis and degradation. Unlike the Hornberg model, the model with recycling is able to
recover to its pre-stimulated state after transient EGF stimulation. Interestingly, the addition
of these reactions did not significantly change the step response behavior of the network. How-
ever, it was shown that the two models responded very differently to a time varying stimulus
that consisted of a ramping dose of EGF. The stimulation described in that work would be
difficult to realize experimentally. Instead, a simpler time varying stimulus was used.
In this study we stimulated cells with five-minute pulses of EGF (50 ng/mL) separated by
a variable waiting time were applied to cells in culture. The idea behind this stimulus is that
the first pulse activates the network, including all of the feedback loops. The second pulse then,
probes the state of the network at a later time. However, we expect that as the response to the
first pulse evolves, different feedback mechanisms will increase or decrease in importance. By
comparing the response of the network the second pulse delivered at various times we hoped to
be able to detect the timescale and relative importance of the various feedback mechanisms. In
particular, we were interested to see if we waited long enough after the first pulse, would the
network recover and become sensitive to EGF again. To accesses the potential for this type
of experiment we simulated applying two pulses separated by 90 minute pulse waiting time
(Figure 3-2). At the head of the pathway, the models with recycling (red lines) and without
recycling (blue lines) respond similarly to the first and the second pulse. However, the model
without recycling predicts that the signals downstream of the adaptor proteins will not be
strongly affected by the second EGF pulse. In contrast, the model with recycling predicts that
the response to the second pulse will be similar to the response to the first pulse. This difference
between these two models is the greatest in the ppERK response.
To test this hypothesis, we conducted series of experiments in which cells were stimulated
with two 5-minute pulses of EGF. The experimental system we choose was 184A1 human
mammary epithelial cells (HMEC) [163]. This cell line has been well studied for its response
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Figure 3-3: Varying the Time Between EGF Pulses. Cells were stimulated with two 5-minute
pulses of EGF (50 ng/mL). The time between pulses was varied (30 min, 90 min, 3 hr, and 9
hr). The lanes are labeled with the time between the two pulses, and 0 indicates the first pulse.
As the protocol for the first pulse is the same, it was not repeated for each pulse waiting time.
Cell lysates were collected just before and just after each pulse. The lysates that were taken
after the pulse are indicated with a star.
to EGF [191]. The stimulation protocol is described in detail in the methods section, but, in
brief, at time 0 EGF was added to plates of HMEC cells. After 5 minutes, the EGF containing
media was removed, the plates were washed quickly with warm PBS, and then fresh serum free
media was added. After the pulse waiting period (variable), EGF was again added to the plates
and the cells were allowed to incubate for an additional 5 min. Cell lysates were collected just
before and just after the first pulse and just before and just after the second pulse.
3.2.2 The EGFR Network Can Reset After a Pulse of EGF
To establish how long the network would take to reset (if at all), we performed an initial survey
experiment with four different pulse waiting times: 30 min, 90 min, 3 hr, 9 hr. The output
of the network, doubly phosphorylated ERK (ppErk), was measured just before and just after
each pulse by western blot. As the first pulse is identical for the four pulse waiting times, these
measurements were not repeated. The results of this experiment are shown in Figure 3-3.
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3.2.3 The EGFR Network Desensitizes to EGF Possibly Due to Cross Talk
From the Insulin Pathway
Our expectation from the modeling results was that the longer the time between pulses of EGF
the stronger the ppERK response would be in response to the second pulse. This is due to the
network having more time to replace the degraded proteins. However, what we saw from this
study was just the opposite. If the pulse waiting time was 30 min then the responses to the first
pulse and the second pulse were about equal. However, if the pulse waiting time was 90 min, 3
hr, or 9 hr then there was almost no response to the second pulse. These results suggest that
there is some kind of desensitization that happens after the first pulse but does not become
apparent until between 30 and 90 minutes.
One possible explanation for this apparent desensitization is that the initial pulse of EGF
activated an endocytic process that over time depleted the surface of EGFR. However, the anti-
EGFR western blots indicate that the total amount of EGFR is roughly constant over all of the
time courses. This measurement cannot distinguish EGFR on the extra cellular membrane from
internalized EGFR. However, the fact that the level of EGFR is roughly constant over 9 hours,
and the fact that after the first five minutes there is no EGF stimulus to drive endocytosis,
suggests that this was not responsible for the observed desensitization.
Another possible explanation for this result was that 12 hr serum starvation had induced
some kind of cell death or senescence. To test this, we repeated the pulse experiments, this
time adding back in the growth media components to the pre-treatment media (Figure 3-4).
As before, the media was changed 12 hours prior to EGF stimulation. In one experiment,
the pre-treatment media was supplemented with 1% fetal bovine serum (FBS). In another
experiment the pre-treatment media was supplemented or 1% FBS and 25 ng/mL EGF. The
serum free media results from before are repeated here for comparison. The most striking
difference between these two sets is the high background phosphorylation of ERK, presumably
due to the FBS and EGF in the media. However, the cells pretreated with media containing
1% FBS behave in a similar fashion to the serum starved cells. The background in the FBS
and EGF pretreated cells is too high to draw a firm conclusion. However, it is worth noting
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Figure 3-4: Double Pulse Experiments Without Serum Starving. The double pulse experiments
were repeated under different pre-stimulus media conditions. Cells were stimulated with two
5-minute pulses of EGF (50 ng/mL). The time between pulses was varied (30 min, 90 min, 3
hr, and 9 hr). The lanes are labeled with the time between the two pulses, and 0 indicates the
first pulse. As the protocol for the first pulse is the same, it was not repeated for each pulse
waiting time. Cell lysates were collected just before and just after each pulse. The lysates that
were taken after the pulse are indicated with a star. The media conditions are indicated to the
right of the corresponding blots. In all three cases, the media was changed 12 hours prior to
stimulation. -/- indicates that the media was serum free media. + serum indicates 1% fetal
bovine serum was added and + EGF indicates that 25 ng/mL of EGF was added to the media.
that the darkest band is observed when using a 30 min pulse waiting time, just as in the serum
free experiments. These results suggest that the desensitization to EGF is not the result of the
12 hr serum starving.
Another possible explanation for this result is that washing the cells with PBS and then
changing the media produced mechanical stresses on the cells that lead to the desensitization of
EGF. One possible mechanism for this would be signaling through the integrins. We repeated
the first set of experiments but either skipped PBS wash and very gently changed the media,
or washed twice with PBS swirling the plates during each wash. Both treatments produced
similar results to the first data set (data not shown).
Another possible explanation for this result is that some component of the serum free media
added after the first pulse was inducing the desensitization. In particular, the media contained
DMSO Cycloheximide Standards
L 0 5 30 35 90 95 0 5 30 35 90 95 S16S8 S4 S2 S1
Shc(pY317)
cRaf(pS259)
MEK1/2(pS217pS221) "04 ow - up OW
MEK1/2 a oft amsa*s00
ERK1/2(pT202pY204) 40....
E RK1/2 w aww" we wowwwmawne w *Am
Figure 3-5: Stimulating HMEC cells with pulses of EGF. HMEC cells were stimulated with two
5-minute pulses of EGF (50 ng/mL). Lysates were taken just before and just after each pulse.
In one experiment, the pulses were applied at 0 minutes and 35 minutes (lanes 0,5,30,35). In a
second experiment, pulses were applied at 0 minutes and 95 minutes (lanes 0,5, 90, 95). As the
protocol for the first pulse is the same in the two experiments, the lysates were not duplicated.
The full experiment was repeated twice: without drug treatment (DMSO), and with a protein
synthesis inhibitor (cycloheximide).
20 pg/mL insulin. We repeated the double pulse experiment this time with just two pulse
waiting times (30 min, and 90 min). We used the same serum free media as in the first
experiments but with the insulin removed. The results are shown in Figure 3-5. Unlike all
of the previous experiments, the ppERK response after a pulse at either 30 or 90 minutes is
roughly equal to the response to the first pulse. In addition, the level of ppERK 30 minutes
after the first pulse (before a second pulse) is much higher than before. This suggests that
insulin was playing a major role in turning off the ppERK signal even at 30 minutes. One
possible mechanism for this is insulin induced activation of Ras-GAP. However, the fact that
even without insulin ppERK is down significantly 90 minutes after the first pulse indicates that
there are other mechanisms working as well.
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3.2.4 Resetting the Network Does Not Require New Protein Translation
The time course of the results without insulin agree well with the computational model with
recycling. In the computational model, the network is able to reset after a transient EGF
stimulus due to the constitutive (and fast) synthesis and degradation of adaptor proteins.
If this mechanism is correct then transiently inhibiting protein synthesis should prevent the
network from responding to a second pulse of EGF. In addition, other studies have shown
that cycloheximide treatment results in an stronger and more prolonged ppERK signal [3] in
response to a constant dose of EGF. This effect has been attributed to a rapid turnover of
phosphatases especially the dual specify protein phosphatase 6 (DUSP6) [20]. Therefore, we
expected cycloheximide treated cells to exhibit a prolonged response to the first EGF pulse,
and a diminished response to the second pulse, at least at the level of ppERK.
However, the results in Figure 3-5 confounded this expectation. In the cycloheximide treat-
ments the ppERK response to the first pulse is slightly elevated at 5 minutes but significantly
diminished 30 minutes after the pulse. Moreover, the cycloheximide treated cells responded
just as strongly to second pulses of EGF after 30 minutes, and an only slightly weaker response
to the 90 minute pulse when compared to the non-drug treated cells. Interestingly, the ppERK
levels are elevated 90 minutes after the first pulse when compared to the non-drug treated cells,
consistent with the idea of a DUSP6 negative feedback loop.
These results show that the network is, in fact, able to reset after an initial pulse of EGF
and the mechanism does not require the new synthesis of proteins. In addition, the negative
transcriptional loops that have been described do not seem to be necessary to shut off the EGF
signaling after a five-minute pulse.
3.2.5 Phosphorylation of C-Raf on Serine-259
The MEK response is somewhat less after the 90 minute pulse. This may be due to deactivation
of C-Raf by phosphorylation at S259 which is the 14-3-3o- binding site [162]. Phosphorylation
at the site is higher 30 minutes after the first pulse and significantly higher 90 minutes after
the first pulse. However, the fact that there is still strong activation of MEK indicates there
is at least some active C-Raf. An interesting followup experiment would be to apply a second
pulse later than 90 minutes to see if at later times inhibition of C-Raf builds to a level to be
sufficient to block the activation of MEK.
Another unexpected result is that phosphorylation at pS259 is diminished in the cyclohex-
imide treatment. It is unclear what mechanism would lead to this effect, especially since MEK
is strongly activated under these conditions.
3.3 Discussion and Future Directions
Like many cell signaling models, current computational models of EGFR signaling were devel-
oped to describe steady state and step response data [43, 95, 152, 59, 21, 86], and less care is
taken model how the systems recover after the initial stimulus. We have shown here that the
EGFR signaling network can indeed reset after a pulse of EGF. The combined experimental
and computational results presented here indicate that existing models of the EGFR signal-
ing are missing a mechanism for the network to reset and to become sensitive to EGF again.
However, we have also shown that the mechanism we previously proposed for the network to
reset, the synthesis of new receptor and adaptor proteins, does not seem to be the primary
mechanism. One possible alternative mechanism that is consistent with this data is that the
receptor complex dissociates in the endosome and releases the adaptor proteins. This would
replenish the cytoplasmic pools of adaptors without needing new protein synthesis. However,
additional experiments are needed to test this hypothesis. In particular, it is unclear from this
data if the network could reset after a longer pulse EGF without new protein synthesis.
In addition, the results presented here suggest that even a small amount of insulin may be
sufficient to modulate the ERK response to EGF stimulation. A recent model of EGF and
insulin crosstalk describes some of the mechanisms by which this could happen [21]. In the
model, insulin receptor activates Ras-GAP which in turn inhibits Ras. However, the model
also describes the activation of IRS which binds to GRB2 and SOS leading to the activation of
Ras. The study found that cotreament of insulin and EGF lead to increased ERK activation.
The results presented here suggest that if insulin had been administered first it would have
suppressed ERK activation. Very similar types of crosstalk have been implemented in other
RTK models. In the Sasagawa EGF/NGF model, Ras-GAP can be activated by both EGFR
and TrkA [149]. In the Birtwistle model, various Erb dimers activate Ras-GAP [18].
An additional feedback mechanism that could be added to these models is the phosphoryla-
tion of C-Raf by MEK on S259. These results show that phosphorylation at this site is slowly
building over 90 minutes. An additional followup study to this could vary the pulse duration
and waiting times to see if phosphorylation at this site ever built up to a level where C-Raf
could no longer effectively activate MEK. In addition, it would be interesting to see if the rate
of S259 phosphorylation depended on the amplitude or duration of the EGF pulse. All of the
models presented in this work are intended to capture acute signaling on the timescale of 0-120
min. Adding in effects such as this S259 phosphorylation may be necessary for the models to
capture the longer time dynamics of the system.
In one sense, these results are frustrating to a modeler. They seem to confound the existing
models and mechanism. However, in another sense these results are encouraging to future
modeling efforts in so far as they suggest that it is possible to construct experiments that are
sensitive to the details of the various feedback loops. In particular, the strategy put forth in
this work of combining pulsatile simulation with inhibitors that can cut particular feedback
processes may be be a very powerful technique for understanding these complex multi-feedback
regulated networks.
3.4 Materials and Methods
3.4.1 Cell Culture
184A1 parental human mammary epithelial cells [163] were a kind gift from Martha Stampfer
(Lawrence Berkeley Laboratory, Berkeley, CA) and were maintained in MEBM (Lonza Catalog
No. CC-3150) supplemented with 35 pg/mL bovine pituitary extract (BPE), 12.5 ng/mL
epidermal growth factor (EGF), 1 pg/mL insulin, 28 pM hydrocortisone, 5 pg/mL transferin,
1 ng/mL cholera toxin, 100 pg/mol penicillin and streptomycin, 1% (v/v) fetal bovine serum
(FBS) (all from Sigma). Cells were plated in 10-cm plates (~ 2 x 106) and allowed to grow until
80% confluence was reached. The cells were then washed with PBS and serum starved for 12
hours in serum-free media (MEBM without EGF, BPE, or FBS). In some of the experiments,
the "serum-free" media was made with FBS, or FBS and EGF. In other experiments, the
serum-free media was made without EGF, BPE, FBS, or insulin.
3.4.2 Stimulation
Cells were pre-treated for ten minutes with either cycloheximide (Sigma C4859) or DMSO
(Sigma D2438) diluted in PBS. Cells were then stimulated by the addition of epidermal growth
factor (50 ng/mL). After 5 minutes the media was removed and replaced with fresh serum-free
media containing either cycloheximide or DMSO. After either 30 or 90 minutes, the cells were
stimulated a second time with epidermal growth factor (50 ng/mL) for 5 minutes. Cells were
lysed at 0 and 5 minutes post stimulation and then again at either 35 and 40 or 95 and 100
minutes, depending on the pulse times. Cells were lysed in 250 pL RIPA lysis and extraction
buffer (Thermo 89900) with Halt protease and phosphatase inhibitor (Thermo 78440) and 0.5
mM EDTA.
3.4.3 Western Blot Analysis
30 g of protein from each sample was mixed with 4x sample buffer (250 mM Tris-HCl pH 6.8,
8% SDS, 40% glycerol, 0.04% bromophenol blue, and 400 mM dithiothreitol) and boiled for 5
min. Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes.
After blocking for 1 hour with Odyssey Blocking Buffer (Licor) at room temperature, mem-
branes were incubated overnight at 4 C in primary antibody, washed three times for 5 min
in TBS-Tween 20 (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, and 0.3% Tween 20), incubated
for 1 hour at room temperature in secondary antibody (dilution 1:10000 IRDye 800CW and
700CW conjugated goat anti-rabbit) (Licor), and finally washed three times for 5 min with
TBS-Tween 20. Blots were imaged with an Odyssey infrared imaging system (Licor). Primary
antibodies used were from Cell Signaling Technologies: MEK1/2 (4694), EGF Receptor (2239),
Phospho-c-Raf(Ser289/296/301) (9431), Phospho-Shc (Tyr239/240) (2434), Phospho-Erkl/2
(Thr202/Tyr2O4) (4377), Erkl/2(9107).
Chapter 4
Sloppy Models, Parameter
Uncertainty, and the Role of
Experimental Design
4.1 Introduction
One of the goals of systems biology is the construction of computational models that can
accurately predict the response of a biological system to novel stimuli [97, 101, 181]. Such
models serve to encapsulate our current understanding of biological systems, can indicate gaps
in that understanding, and have the potential to provide a basis for the rational design of
experiments [42, 5, 52], clinical interventions [102, 130, 63], and synthetic biological systems [54].
There are many varieties of computational models ranging from abstracted data-driven models
to highly detailed molecular-mechanics ones. In this report we focus on the popular class of
ordinary differential equation (ODE) models [50, 57, 64, 80, 87, 92, 139, 152] typically used to
describe systems at the biochemical and pharmacokinetic level, but they are also appropriate at
more abstract levels. Constructing an ODE model is comprised of writing kinetic rate equations
that describe the time rate of change of the various chemical species (representing the model
topology), and determining the unknown parameters in those equations (typically rate constants
and initial concentrations). Unknown parameters are estimated from a variety of data that
often includes time-course measurements of concentration or activity. In this study, we have
focused on the estimation of parameters, which is often referred to as model calibration. Using
computational modeling and experimental design methodology, we have found that selection of
a set of experiments whose members provide complementary information can lead to efficient
model calibration.
In this work we formulate the model calibration problem as a nonlinear least squares op-
timization problem, where the goal is to find the set of parameters that minimizes the fit
metric [78],
2 _ [Ys,c(p, t) - ys,c(p*, t)] 2 dt (4.1)S T = oc(p*,t)
where nc is the number of experimental conditions, n, is the number of species for which
measurements are available, the indices c and s run over the conditions and species, respectively,
Tc is the length of the time course for condition c , YS,c(p, t) is the model output for species
s and condition c at time t with parameter set p, ys,c(p*, t) is the corresponding output for
the true model parameterization, and oc(p*, t) is a weighting factor that is often taken as
proportional to the uncertainty of the experimental measurement.
There is a significant amount of work devoted to how best to solve this optimization problem
for biological models [10, 89, 125, 144]. However, in any experimental system, there will always
be uncertainty in the data, which means there will be some range of parameter values that,
while not optimal, cannot be excluded based on the data. Given a maximum acceptable fitting
error (X2 ), the calibration problem becomes that of finding all parameters such that the
error is less than this threshold. In a neighborhood around the optimum parameterization (p*
) the least squares cost function can be approximated by its Taylor series expansion:
[Xax - X2(p *)T [log(p)H [log(p - log p*)] . (4.2)
Equation 4.2 describes an np-dimensional ellipsoid in log-parameter space (n, being the number
of fitted parameters), where all of the parameterizations inside the ellipsoid are feasible. Here
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Figure 4-1: Schematic View of Combining Experiments. (A) Uncertainty ellipse for a simple
two-parameter system. The parameters inside the ellipse are feasible. The major and minor
axis of the ellipse are proportional to A-1/ 2 and A21/ 2. The grey contours are lines of equal
objective function value. The bounding box (dashed magenta lines) show the single parameter
errors. The length and width of the bounding box is the range of values for the individual
parameters. (B) Two non-complementary experiments (C) Two complementary experiments.
When two experiments (blue and green ellipses) are combined the resulting parameter estimate
(red ellipses) can improved as in the case of panel C or not as in the case of panel B depending
on the complementarily of the component experiments.
we define log p = [log(pi), log(p2), .- -, log(pnp)]T. The size and shape of this ellipsoid describe
the multidimensional parameter uncertainty. For example, the longest principal axis of the
ellipsoid corresponds to the parameter direction (that is, the linear combination of parame-
ters) with the worst error. Likewise, the axis-parallel bounding box defines the error range for
individual parameters. Figure 4-1 shows an example for a two-dimensional system. An im-
portant distinction illustrated in Figure 4-1A that is some parameter directions can have very
small uncertainty, while the individual parameters can be quite uncertain [78]. For example,
forward and reverse kinetic constants for a binding reaction may be poorly constrained, yet the
equilibrium constant (given by their ratio), can be well defined.
H , the matrix of second derivatives of the fit metric is known as the Hessian, where Hij is
the derivative of x2 with respect to log(pi) and log(pj) .
1 ~ T dy.,c(p,t) dyc(p) r _0 P*01 d2Y,(pt)
Hi (p) = nncTc a(p) a (p) + Lysc p, dys,c p ' log(pi)dlog(p ) dt (4.3)
s 0 s,c 0
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The derivative is taken with respect to the natural logarithm of pi to obtain a relative uncer-
tainty. We can dissect the parameter uncertainty in terms of the eigenvalues A2 and eigenvectors
vi of H. The eigenvectors form a natural coordinate system for the ellipsoid, pointing along
the principal axes. The lengths of the axes are proportional to Ai 1/2, meaning that smaller
eigenvalues correspond to larger relative parameter error [10].
Recently Gutenkunst et al. [78] examined parameter uncertainty for 17 models in the EMBL
BioModels Database [106]. In their study, the authors assumed noise-free measurements of
every model species sampled continuously in time. The study found that the eigenvalues of the
Hessian spanned a large range (> 106). From result this they suggested that, while it may be
possible to estimate some parameters from system-wide data, in practice it would be difficult
or impossible to estimate most of the parameters even from an unrealistically high-quality data
set [38, 78, 179]. Moreover, they pointed out that due to the high eccentricity and skewness of
the uncertainly ellipses in parameter space, system-wide data can define system behavior better
than independent measurements of each parameter and may also produce better predictions in
some circumstances.
Here we extend the previous work by more fully considering the effect of experimental
perturbations on the parameter estimation problem and use experimental design to probe for
particularly effective perturbation experiments. Equation 4.1 shows that the value of the fit
metric depends on both the model and the set of experimental conditions; in the current work
we use effectively continuous-time data, but most experiments require the selection of discrete
time points for measurements to be taken [52]. It is well established in the systems biology
literature that optimal experimental design can have an impact on the parameter estimation
problem for a single experiment [7, 8, 38, 56, 103]. For example, work by Faller et al. has shown
for a small model of a mitogen activated protein kinase (MAPK) cascade that the application
of time-varying stimulation significantly improved the parameter estimation problem [56]. Es-
sentially this corresponds to finding the time-varying input signal that gives the best shaped
error ellipsoid.
In this work, we apply a related approach and examine the extent to which multiple comple-
mentary experiments can be combined to improve the overall parameter estimation problem.
Figure 4-1B,C shows the result of combining data from two separate experiments. The pa-
rameter estimates from the individual data sets (blue and green ellipses) tightly constrain one
parameter direction and weakly constrain the other. In Figure 4-1B, the weakly constrained
parameter directions are very similar, so the parameter estimates from the combined data set
are about the same as the estimates from the individual experiments (red ellipse); by contrast,
in Figure 4-1C the experiments are complementary and together dramatically constrain the
parameter estimates.
Because complementary experiments can constrain parameter estimation space, we have
developed an approach to identify sets of complementary experiments to optimally minimize
parameter uncertainty in a large pathway model of signaling in response to EGF and NGF [31].
We have selected this model so that our results may be directly compared to the previously
published analysis of this model performed by Gutenkunst et al. [78]. For consistency, where
possible we have used their methods and formalisms. In selecting sets of complementary ex-
periments, we have explored a pallet of candidate experiments consisting of overexpression or
knockdown of single and multiple genes combined with different doses of EGF and NGF, either
alone or in combination.
Computational experimental design methods determined all 48 free parameters to within
10% of their value using just five complementary experiments. Selection of complementary
experiments was essential, as the same level of model calibration could not be achieved with
arbitrary experiments or even with a larger number of "highly informative" experiments. More-
over, we argue that predictions that are sensitive to information complementary to that used to
parameterize a model could be significantly in error. Experimental design methods can provide
sufficient coverage for all parameter directions and thus guide model calibration for a given
topology to maximize predictive accuracy. As systems biology models are applied to target
identification and clinical trial design, the use of experimental design approaches to improve
model prediction quality could be of crucial importance.
4.2 Results
Experimental design and computer simulations were applied in tandem to select a collection
of experiments that together could most directly establish each of the rate constant param-
eters for the EGF/NGF signaling pathway modeled here. To define all 48 rate parameters,
experimental design procedures must select a set of experiments that together exercise the
model in complementary and sufficiently different ways, rather than simply choosing multi-
ple different experiments that exercise the model in similar ways. For this work we chose a
palette of experimental perturbations consisting of stimulation with EGF (107, 105 , 103 , 10, or
0 molecules/cell-volume) or NGF (4.52 x 107 , 4.52 x 105 , 4.52 x 103 , 45.2, or 0 molecules/cell-
volume) individually, or combined treatment with both ligands. We supplemented this choice
of ligand stimulation with a panel of experiments in which protein expression levels could be
modulated by 100-fold overexpression or knockdown for individual proteins in the network.
We then constructed candidate experiments from the combination of ligand choice and protein
expression level changes; specifically, each experiment was allowed to comprise one stimulation
pattern and up to three simultaneous changes in protein expression level. This experimental
set- up resulted in a trial perturbation set of 164,500 individual computational experiments.
4.2.1 All Parameters Can Be Determined to High Accuracy
Each individual experiment in the trial perturbation set was evaluated and the number of
rate parameter directions determined to within 10% of their nominal value was recorded. The
best individual experiment in this set defined only 29 of the 48 rate parameter directions
to this high level of accuracy. In order to improve on this result, each single experiment
was re-evaluated to determine how many new rate parameter directions could be defined to
within 10% of their nominal value when combined with the best experiment. In this manner,
a greedy algorithm was applied to sequentially select sets of experiments based on their ability
to generate tighter bounds on rate constant estimation. The results of this greedy algorithm
are shown in Figure 4-2A. The parameter uncertainties are expressed as an eigenspectrum for
each combination of single experiments, with increasingly larger experimental sets displayed
along the abscissa and eigenvalues displayed along the ordinate. The horizontal dashed line
indicates the 10% error level, and the number of eigenvalues above the dashed line represents
the number of parameter directions determined to the 10% error level. In Figure 4-2D, the
number of parameters estimated to the 10% error level is shown as a function of the number
of experiments within the experimental set. It is important to note that, by properly choosing
the correct combination of experiments, only five total experiments are sufficient to determine
all 48 directions (and, indeed, all 48 actual parameters) to within 10% accuracy. This result
indicates that parameter uncertainty, rather than being inherent to biological models, can be
progressively reduced by perturbation experiments.
The five experiments determined here to elucidate all 48 parameters are listed in Table 4.1.
The selected experiments include a tendency for dual stimulation with both EGF and NGF,
combined with multiple protein-expression changes, and a preference for overexpression as op-
posed to knockdown of given proteins. Interestingly, the experiments do not appear to system-
atically explore all regions of the perturbation space. For instance, four of the five experiments
have low dose of EGF stimulation, and three of the five experiments have high dose of NGF
stimulation. Additionally, NGF stimulation occurs in the absence of EGF stimulation in one
experiment, but EGF stimulation alone is never utilized. The combination of experiments and
the manner in which they explore different aspects of the model in order to adequately define
all parameters is not readily apparent from selected experiments. However, as will be discussed
below, there are some general trends and insights to be gained from the analysis of the results.
Figure 4-7 shows the location of parameters in the model determined after each new ex-
periment was added in sequence to the set. The thickness of each reaction arrow in the figure
indicates whether 0 (thin arrow), 1 (medium arrow), or 2 (thick arrow) of the parameters associ-
ated with the arrow are known to within 10% at that point in the experimental sequence. Note
that parameters closer to the top of the pathway tend to be determined first, while parameters
toward the bottom of the pathway, further from the application of ligand stimulation, tend to
be determined only after multiple experiments are combined.
The selection of complementary experiments resulting from our experimental design proce-
dure is non-trivial. For example, if experiments were added sequentially based on their ability
Exp EGF NGF Over Expressed Knocked Down
(mol./cell) (mol./cell)
1 1.00 x 105  4.56 x 107  Sos, Ras, C3G
2 1.00 x 101 4.56 x 101 Mek, Erk RaflPPtase
3 0.00 4.56 x 105 BRaf, Rap1 RapGap
4 1.00 x 101 4.56 x 107  P90Rsk, P13K, Akt
5 1.00 x 103  4.56 x 103  Raf1 RasGap
Table 4.1: Parameter-Defining Experimental Set For Triples Design. These are the set exper-
iments selected by the greedy search. The pallet of experiments included different doses of
EGF/NGF in combination with triple knockdowns and overexpressions.
to determine a large number of parameters when applied on their own (Figure 4-2B) or if experi-
ments were added randomly (Figure 4-2C), the performance was much worse; neither procedure
could determine the full 48 parameters with up to 20 experiments, whereas the greedy experi-
mental design procedure required only five (Figure 4-2D). Interestingly, the "random" procedure
was about as effective as the "best singles" beyond the initial few experiments, which suggests
that selecting "good" or "bad" experiments isn't nearly as important as choosing complemen-
tary ones For example, most of the "best singles" experiments tended to involve stimulation
with EGF and NGF simultaneously (Figure 4-7), but the type of complementarity required to
tease apart all the parameter directions can be achieved by more subtle variation (Table 4.1).
Together these results show that selection of complementary experiments can very efficiently
lead to full parameterization of complex models and that experimental design procedures are
important to select an appropriately complementary set.
4.2.2 Relative Resolving Power of Different Experiment Types
There should be a cost-benefit relationship between the complexity of experimental perturba-
tions used and the amount of information obtained. Intuitively, we expect it may take more
simple experiments to obtain the same knowledge gleaned from a smaller number of more com-
plex experiments. The above results included experiments that simultaneously modified three
protein concentrations. To probe whether simpler experiments could achieve similar results,
we repeated the search but limited the experiments to EGF/NGF doses only (Figure 3A,B),
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Figure 4-2: Experiment Design for EGF/NGF Model. (A) Search result for sets of experiments
that maximize the number of parameters estimated. Each spectra is the eigenspectrum of the
estimation problem. The goal of the design is to maximize the number of parameters with
errors less than 10% (dashed line). (B) Design based on selecting the best single experiments.
(C) Design based on selecting random experiments. (D) The number of parameters estimated
by each search method. By the fifth experiment the greedy algorithm is able to estimate all
48 parameters to the desired accuracy. The error bars show the standard deviation for 10000
random searches.
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EGF/NGF doses and single knockdowns and overexpressions (Figure 4-3C,D), or EGF/NGF
doses and up to double knockdowns and overexpressions (Figure 4-3E,F). For comparison,
results for the full set of experiments with up to triple expression changes are shown in Fig-
ure 4-3G,H. An experimental set with up to forty experiments was constructed for each using
our greedy experimental design approach, and the maximum number of parameters determined
to within 10% are shown. For each pair of figure panels, the left panel shows the location in
the network of parameters established by the experimental set, with the same arrow thickness
scheme as in Figure 4-7 of thicker arrows indicating more parameters defined. The eigenvector
matrix, a representation of best determined to least well-determined directions in rate-constant
space, is displayed in the right panel for each sub-section of Figure 4-3. The eigenvector matrix
shows which individual parameters contribute to each parameter direction. All rate constants
could be determined with up to triple expression changes (as shown above, with five experi-
ments) and 47 of 48 parameters with up to double expression changes (requiring 8 experiments,
with no improvement from the next 32 most complementary experiments). Most rate con-
stants could be determined using single changes in protein expression (45 of 48, but requiring
17 experiments), but doses of EGF/NGF alone were only able to establish just over half of
the rate constants (25 of 48, requiring just 2 experiments with no improvement resulting from
the remaining 23 experiments in the class). Thus, more complex perturbation experiments
improved model calibration through establishing a greater number of parameters and generally
doing so with fewer, albeit more difficult, experiments. The tradeoff is such that in many cases
the greater complexity may be more than justified by the reduced number of total experiments
required. Modifications to future versions of the optimization could be biased towards reuse of
genetic modifications in experiments with different dosage treatments, so that the greater effort
of the former might be better leveraged.
4.2.3 Biochemical Basis for Complementarity of Experiments
Analysis of the five experiments sufficient for determining all the parameters suggests that
one role for some selected experiments is to specifically adjust conditions of enzymatic re-
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periment. (A-B) Doses of EGF and NGF alone. (C-D) Single knockouts/overexpressions. (E-
F) Double knockouts/overexpressions. (G-H) Triple knockouts/overexpressions. The network
diagrams show the individual parameter errors. Each arrow represents a reaction (black for
activating, red for inhibitory). Each reaction is parameterized by two parameters. If both pa-
rameters are estimated to 10% the line is thick. If only one of the two parameters are estimated
the line is medium. And if neither parameter is estimated then the line is thin. The eigenvector
matrices pictures on the right show the vector perspective. The eigenvalues decrease from left
to right. The green lines indicates the cutoff for 10% relative error. The yellow and red lines
indicate directions with 100% and 1000% error.
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actions so that kcat and KM could be independently determined. Because the calculations
were done in log parameter space, the (+kcat, +KM) direction corresponds to log(kcat) +
log(KM) = log(kcat/KM). Interestingly, the (+kcat, -KM) parameter direction, correspond-
ing to log(kcat/KM), is easily estimated for many reactions here because in the wild type many
enzymes operate under kcat/KM conditions with substrate concentration below KM. Selected
experimental perturbation appear to have been chosen because they drive substrate concen-
tration sufficiently high as to move beyond kcat/KM conditions to determine kcat and KM
independently (Figure 4-4)
4.2.4 More Stringent Parameterization Can be Achieved with Greater Ex-
perimental Effort
It is important to consider whether there are fundamental limits to how accurately biological
models can be parameterized - essentially whether there exist model parameters that are es-
sentially unknowable. As one step to addressing the question of knowability, we repeated the
optimal experimental design calculations using up to three expression changes, but with differ-
ent values of the error threshold. Our previous results were computed with the requirement that
parameters be established to within 10% of their nominal values. The full set of results is shown
in Figure 4-5. While five experiments were required to establish all 48 parameters to within
10% error, only four experiments were required for the less stringent 37% error. Likewise, as the
stringency was increased, greater experimental effort was required to establish a given number
of parameters. Together these results suggest that more stringent parameterization can gener-
ally be achieved with greater experimental effort, although experimental design procedures may
be necessary to define how best to apply additional effort towards determining new knowledge.
Additional experimental complexity may be necessary to dissect particularly difficult parameter
combinations. Whether such effort is worthwhile may depend on the sensitivity of predictions
made by model to such difficult parameter combinations.
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Figure 4-4: Experimental Perturbations Push Enzymes From Pperating in Pure kcat/KM Con-
ditions to Facilitate Estimation of kcat and KM Individually. Experiment #4 calls for the
overexpression of the three enzymes P90Rsk, Akt, and P13K, which are substrates for the en-
zymes (A,B) ERK, (C,D) P13K, and (E,F) EGFR, respectively. The top row shows the rate
of reaction for each enzyme as a function of its substrate concentration (solid black line), the
linearized rate law at low substrate concentration r ~ e0St (dashed black line), and a his-
togram of concentration in experiment #1 (blue shading) and in experiment #4 (red shading).
The bottom row shows the corresponding parameter uncertainty, with KM on the abscissa and
kcat on the ordinate. Uncertainty is shown for experiment #1 alone (blue ellipse), experiment
#4 alone (red ellipse), and the combination of both experiments (green ellipse). In experiment
#1 only the linear region of the enzyme rate curve is explored (blue shading in top row). The
linear regime specifies kcat/KM (represented as log(kcat) - log(KM) in log parameter space and
corresponds to the blue ellipses in the bottom row of the Figure). The blue ellipses are extended
along the y = x direction, indicating very little uncertainty in log(kcat) - log(KM) but great
uncertainty in log(kcat) + log(KM). In experiment #4 all three substrates are overexpressed
and the saturating portion of the rate curve is populated, where r ~~ eokcat, which specifies the
log(kcat) but not the log(KM) direction, as indicated by the red ellipses being aligned nearly
along the abscissa. Combining both experiments specifies both rate parameters, as indicated
by the small extent of the green ellipses.
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Figure 4-5: Experimental Design with Different Relative Parameter Errors. The violet line
is the original design with 10% uncertainty. It is interesting to note that with an objective
of 37% uncertainty (gold line) that all but two of the parameters can be estimated with two
experiments, and all parameters can be estimated with four experiments.
4.3 Discussion
In this study computer simulations and experimental design methods were used to probe the
relationship between experimental perturbations applied to a complex biological system and
the relative certainty with which model parameters describing that system can be established.
These in silico experiments resolve an important question in computational systems biology.
They imply that uncertainty is not inherent to biological network models-rather, uncertainty
can be progressively diminished through sequential addition of perturbation experiments to a
cumulative data set used for model calibration. In the case studied here, a cellular network
activated in response to stimulation by EGF and NGF important for cell growth and differen-
tiation, all 48 rate constant parameters could in principle be fit to within 10% of their nominal
value using concentration time courses from five multi-perturbation experiments. While the
accuracy of the measurements and the desired accuracy of the parameters affect the number
of required experiments and their complexity, all parameters could be estimated to very high
accuracy.
An important characteristic of minimal sets of experiments that together define all model
parameters is that the members are mutually complementary. That is, while they may contain
some overlapping information, each member also contains information that is not provided
by the others. The overall parameter uncertainty of a set of experiments is related to the
intersection of the parameter uncertainty associated with each individual experiment. Thus, the
intersection diagrams of Figures 1 and 4 should not be interpreted to mean that complementary
experiments must contain non-overlapping large uncertainties, but rather that the directions of
large uncertainty in one experiment should correspond to a direction of smaller uncertainty in
at least one other experiment. This form of complementarity is non-obvious and non-trivial, but
experimental design methodology can efficiently identify sets possessing this property. In the
current example, running enzymes under both kcat/KM and kcat regimes was one important
form of complementarity. Single experiments were generally incapable of spending sufficient
time in each regime, and different experiments were required for each. The design of single
experiments that visit both regimes could be beneficial.
The current case also exhibited a tendency for protein overexpression as opposed to knock-
downs, although the generality of this result remains to be seen. Operationally, in many cases
it may be possible and convenient to alter the activity of proteins with selective inhibitors
while leaving the expression level constant. Small molecule inhibitors or activators also enable
time-dependent perturbation, thereby providing important new degrees of freedom that may
permit improved model calibration with fewer experimental manipulations [5]. However, we
found certain parameter directions for which overexpressions were important for their explo-
ration. In the work described here, we used full trajectories of all concentrations in the model in
fitting; however, current experimental technology generally probes only a subset of species and
time points. The experimental design framework described here can be used to determine the
most productive species and time point measurements to make in order to most expeditiously
calibrate model parameters.
While a variety of experimental interventions can be used to change protein expression,
another possibility is to make use of natural variation. An examination of the expression levels
of the proteins that correspond to the 19 proteins in the EGF/NGF signaling model as reported
in the GNF SymAtlas database [166] is shown in Figure 4-8 and indicates expression ranges
of 100 fold or more across tissues and cell types. Natural variation on this scale suggests that
collecting data in multiple cell types may be an alternative to using genetic manipulation, but
it also suggests that accurate estimation of parameters and quantification of protein expression
levels may be necessary for a model to be applicable across different cell and tissue types.
However, using multiple cell lines introduces additional complications, as differences in biology
and un-modeled effects may dominate the results. In this case, having a well-calibrated model
may make it easier to distinguish between calibration issues and real biological differences.
Many different sets of experiments can be mutually complementary and each can define all
the parameters equally well. Furthermore, tradeoffs exist between the complexity of experi-
ments available and the number of experiments required to probe fully all parameter. Multiple
genetic changes were particularly effective in the EGF/NGF network studied here, with a larger
number of simpler experiments performing less well overall. Here we designed sets of experi-
ments to define the parameters of a pre-existing model, as this would allow us to most directly
address the theoretical feasibility of the approach. One result is that rather complex exper-
iments were called for, and we were curious whether this was a necessity of the underlying
biological system or an artifact of the model itself. We noticed that a few KM values in the
model were quite large, and we built an alternative model with more standard KM values that
fit the experimental as well as the original model (Figure 4-9). We applied our experimental
design methodology but only permitted an experiment to consist of an EGF/NGF and 100-fold
expression change of one protein; all 48 parameters could be determined using this simpler
experimental set in just 15 experiments (Figure 4-9). Interestingly, in this case protein overex-
pression experiments dominated underexpression again. Moreover, three genetic perturbations
were re-used, and in two pairs of experiments the same gene was used in both overexpression
and underexpression experiments. Thus, it is likely that numerous but simple experiments can
be used to quantitatively understand and describe even complex biological systems.
In our analysis we have considered the value of the Hessian only at the optimal parameter
set when computing our parameter uncertainty. This corresponds to assuming that the log
parameter errors are Gaussian, an assumption which may not be true for poorly determined
parameter directions. However, as more complementary experiments are added, and as the
parameter uncertainty is reduced, this approximation will become increasingly accurate [114].
Throughout this work, we have stressed the importance of fully determining the parameters
of a model. However, as has been observed by others [78], this may not be necessary to make
a particular prediction. In fact, the corollary to no single experiment determining all of the
parameters is that no single prediction depends on all of the parameters. This result suggests
a potential variation to our method. If a particular model was only to be used in a narrowly
defined context where only certain parameters were sensitive, then the method could choose
experiments to define the parameters directions that spanned the sensitive parameter directions.
For example, if the substrate of an enzyme could never be expressed at a level above the KM of
any of the enzymes that modify it, you could decide to ignore the parameter errors that pointed
in the ([+ log(kcat), + log(KM)]) direction. However, the results presented here suggest that the
saving in terms of experimental effort may be minimal, as a small number of experiments was
able to cover the entire parameter space, and it comes at the cost of decreasing the predictive
power of the model.
If a complementary set of experiments is used to fully parameterize a model, then there
exists no perturbation to the system for which the parameterization is inadequate. This is an
important statement. The identification of therapeutic approaches, drug targets, and treatment
regimens essentially corresponds to identifying perturbations that produce desirable outcomes.
To be meaningfully accurate, such predictions must still be adequately parameterized by the
calibration experiments. The construction of a complementary set of experiments sequentially
reduces all directions of parameter uncertainty. Intuitively, once all the parameters are well
determined, the model will make extremely good predictions whose error can be bounded
through propagation of the remaining uncertainty. (These statements are predicated on the
model topology being sufficiently correct to accurately describe system dynamics and on the
absence of bifurcations and other anomalies within the remaining parameter uncertainty.) On
the other hand, if a model is calibrated with an incomplete set of experiments, then there exist
parameter directions with large uncertainty. Any experimental prediction whose outcome is
sensitive to the undetermined parameter directions, such as the effects of drug therapy, for
instance, could be grossly incorrect. In fact, such an experiment might be a poor therapy but
an excellent calibration tool. Our results demonstrate that it is not necessary to modulate
the expression level of every protein in the network in order to determine all parameters and
thus fully define the behavior of the system. Rather, only a complete set of complementary
experiments need be used for model calibration; in principle, excellent predictions should follow.
4.4 Methods
4.4.1 The Model
In this work we examined a model of EGF and NGF signaling [17, 30, 31, 32, 184, 185]. The
model can be found in the BioModels database (BIOMDOOOOOOO033) [106]. The model consists
of 19 distinct proteins, two extracellular proteins (EGF and NGF, which act as inputs), two
cell surface receptors (EGFR and NGFR), and 15 intracellular proteins. The two receptors and
11 of the cytoplasmic proteins can be either in an active or an inactive state. The remaining
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four intracellular proteins are constitutively active, resulting in a total of 32 distinct chemical
species, 26 chemical reactions and 48 parameters (22 Michaelis constants KM; 22 catalytic
rate constants kcat; 2 second-order association constants, kon, and 2 first-order dissociation
constants koff. Note that all initial concentrations are assumed to be known). Twenty-two of the
reactions are implemented with Michaelis-Menten kinetics, while the remaining four reactions
are the mass-action binding reactions of EGF and NGF to their respective receptors. One
modification was made to the model, which was to put free EGF and NGF into an extracellular
compartment having a volume 1000 times the volume of the intracellular compartment. This
was chosen to better reflect a typical experiment, where the extracellular volume greatly exceeds
the intracellular volume. Preliminary calculations using a variety of different volumes for the
extracellular compartment demonstrated that the results did not depend strongly on the value
for this volume (data not shown).
4.4.2 Objective Function
The goal of experimental design for model calibration can be expressed as selecting the experi-
mental conditions such that the resulting parameter uncertainty ellipsoid will be prescriptively
small. In this work, we focused on maximizing the number of parameters with uncertainty less
than a given threshold. Equation 4.4 shows this metric as functions of the eigenvalues Ai of H,
FN = thresh(Ai, Athresh) where thresh(Ai, Athresh) = 1 Ai > Athresh
Ai/(Athreshnp) otherwise
(4.4)
where np is the total number of parameter directions and Athresh is determined below. We
chose to include some contribution to our objective function from parameters that did not meet
the threshold to break ties between experiments with the same number of good parameter
directions (thus the Ai/(Athreshnp) term instead of zero). Essentially FN counts up the number
of eigenvalues lambdai greater than a threshold. By choosing this threshold to correspond to a
10% relative parameter uncertainty, the function counts up the number of parameter directions
with uncertainty less than 10%.
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In this work, we assume that our data has Gaussian relative error with zero mean error and
10% standard deviation. We weighted concentration differences in Equation 4.1 by the variance
in the measured value us,c(p*, t) = f x ys,c(p*, t), which makes our least squares estimator a
maximum likelihood estimator. Here, f is the relative measurement error which we set to 0.10
(10%). Equation 4.1, describes the information from an average data point, where the average
is over species, conditions, and time. Following the method of Gutenkunst et al. [78] we scale
the fit metric by nd. This corresponds to collecting nd independent measurements of the system,
where nd is large enough so that sample mean approaches the mean. In this work, we assumed
100 times the number of species, to correspond to discreetly sampling the system at 100 time
points. Note, that as the number of conditions increase we do not increase the number of data
points, as this provides a useful normalization.
The variance of the parameter uncertainty can be computed by the Cramer-Rao bound [153].
The maximum likelihood estimator is asymptotically normal, unbiased, and efficient, so in the
limit of a large number of data points the variance (o2 ) of the log parameter uncertainty
in the ith log parameter eigendirection (vi) can be approximated as:
0-2 __f _(-5
ovf log(p) = (4.5)
We define the relative parameter error to be the ratio of the upper and lower values of the
parameter corresponding to the 95% or two standard deviation confidence interval [15]. Com-
puting this involves exponentiation the bounds of log parameter error.
exp(of log(p*) + 2 o y
E o~p VT ~ v 2o~* -I- u log(p)) - 1 = exp(4orTlga ) 1 (4.6)log(p)g(p*) 
- 2 lo (,))
As an example ET log(p) = 0.10, means that the ratio of the maximum parameter value to the
minimum parameter value is 1.1, which corresponds to relative error at the 95% confidence
interval. We solved for a Athresh that corresponded to a desired parameter error by solving
Equations 4.5 and 4.5. For f = 0.10 and EVTlog(p*) = 0.10 Athresh = 0.005. We used this value,
except where noted otherwise.
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4.4.3 Experimental Design
Equation 4.1 shows that the least squares objective function is a sum over conditions. Likewise,
the Hessian of the least squares objective function can also be constructed as a sum of the
Hessians from each individual condition,
H (C, p) = Z Hc (p) (4.7)
nc EcEC
where C is a set of experimental conditions, c indexes the individual experimental conditions
in the set, and nc is the number of conditions in set C. Thus, we formulated the experimental
design problem as the process of selecting the subset of all possible experiments such that the
sum of the Hessians has the desired properties. Operationally, we simulated each individual
experimental condition in the trial space and computed the Hessian. We then performed a
greedy search to find the best set of nc experiments. At each step of the algorithm, the
Hessian from the previous step was added to the Hessian for each candidate experiment, and
the objective function was evaluated. The trial experiment that led to the best new Hessian
was added to the set. The search terminated if the goal was met or if the maximum number
of experiments was reached. The choice of a greedy search does not necessarily produce the
optimal subset of a given size, indicating that these results are an upper-bound on the number
of experiments required to achieve a particular goal.
4.4.4 Computing Hessians
We computed the individual Hessians of this least squares cost function for each species in each
condition using the MATLAB SymBio Toolbox v2.4 [169] following the method of Gutenkunst et
al. [78]. The ODE system was integrated using ODE15s [156] and sensitivities were computed by
complex-step finite differencing [115]. The entries in the Hessian were computed by numerical
integration with the trapezoidal rule. Because we evaluated the Hessian at p* = p, then
Ys,c(p, t) - ys,c(p*, t) = 0 for all time points, species, and conditions; thus, the second term
in the integrand of Equation 3 (containing the second derivatives of y,,c) was also zero. For
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Exp. EGF NGF Over Expressed Knocked Down
(mol./cell) (mol./cell)
1 1.00 x 107  4.56 x 107  PP2A
2 1.00 x 101 4.56 x 103  RasGap
3 1.00 x 107  4.56 x 103  P90Rsk
4 0.00 4.56 x 105  RapGap
5 1.00 x 107  4.56 x 105  Sos
6 1.00 x 107 4.56 x 105  Akt
7 0.00 4.56 x 103 P13K
8 1.00 x 103  4.56 x 101 BRaf
9 1.00 x 107  0.00 Mek
10 1.00 x 107  4.56 x 105  Raf1
11 1.00 x 107 0.00 P13K
12 1.00 x 107  4.56 x 101 Erk
13 1.00 x 107 4.56 x 101 PP2A
14 1.00 x 107  4.56 x 103  Mek
15 1.00 x 107  4.56 x 107  Sos
Table 4.2: Parameter-Defining Experimental Set For Singles Design.
the purpose of this study we dropped this term. Note that even with imperfect data it may
be possible to approximate the Hessian using only first derivatives if the fit to the data is
sufficiently good that the second derivative term is negligible. If this is not the case then the
full Hessian equation should be used, and the rest of the analysis remains unchanged. The
computations were performed in parallel on 128 processors using approximately 800 cpu hours
in total.
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Figure 4-6: Parameter Elucidation Determined by Greedy Search. Thick lines indicate both
parameters associated with the reaction were determined to within 10% by the bounding box
metric. Medium lines indicate that one of the two parameters associated with the reaction were
determined to within 10%. Thin line indicate that neither were determined to within 10%.
(A) Experiment 1 only, (B) Experiments 1 and 2. (C) Experiments 1-3 (D) Experiments 1-4,
(E) Experiments 1-5. Overall the first parameters discovered were in the core SOS to ERK
pathway followed by the C3G to BRAF then the P13K, AKT pathway.
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Figure 4-7: Histogram of the Number of Parameters Determined to 10% Relative Error for
Each Single Experiment. The blue bars shows the results for all experiments; the cyan line is
the subset of experiments that used an EGF and a NGF stimulus; the red line are the subset
that used only one stimulus (EGF or NGF); the purple lines is for EGF alone; and green line is
for NGF alone. In general, the double stimuli performed better than the singles, but not twice
as good, and there is a long tail to the single subset.
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Parameter Name
kEGF
KmEGF
kdSos
KmdSos
kRasGap
KmRasGap
kpRafl
KmpRaf1
kpMekCytoplasmic
KmpMekCytoplasmic
kdErk
KmdErk
kpP90Rsk
KmpP90Rsk
kAkt
KmAkt
kdRaflByAkt
KmRaflByAkt
kRapGap
KmRapGap
kRap1ToBRaf
KmRapIToBRaf
kdBRaf
KmdBRaf
Parameter
Original
694.731
6.09 x 106
1611.97
8.96896 x 105
1509.36
1.43 x 106
185.759
4.77 x 106
9.85367
1.01 x 106
8.8912
3.50 x 106
0.0213697
7.63523 x 105
0.0566279
6.53951 x 105
15.1212
1.19355 x 105
27.265
2.9599 x 105
2.20995
1.03 x 106
441.287
1.09 x 107
Table 4.3: Modified Parameters at Alternative Parameterization Parameter Value. Catalytic
rates start with a 'k' and are in units of molecules (cell-volume)-' s-1. Michaelis constants
start with a 'Km' and have units molecules (cell-volume) -1.
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Value
Modified
41.0944
3.60 x 10'
647.019
3.60 x 105
77.6942
73733.3
70.122
1.80 x 106
7.652
782264
4.14072
1.63 x 106
0.0100758
3.60 x 105
0.0311737
3.60 x 105
1.99935
15781.3
4.04006
43859.1
0.775829
3.60 x 105
0.0832448
2052.32
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Figure 4-8: Histogram of Expression Levels for Genes that Code for the Proteins in the Model.
(A) Results from different cell types and tissues in Rats. (B) Results for various cell types and
tissues in Humans. The expression levels of almost all of the genes vary by 10-fold or more with
about half varying 100-fold.
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Figure 4-9: Design with Single Genetic Perturbations at Another Feasible Parameterization.
The parameters of the model were changed such that KM for each enzyme could not be greater
than three its maximum substrate concentration. (A) The results of simulating the model
at the original parameterization (solid lines) the modified parameterization (dashed lines), and
experimental data (circles with error bars). The line colors indicate the experimental condition:
100 ng/mL NGF (blue), 50 ng/mL NGF (green), 30 ng/mL EGF (red), 100 ng/mL EGF
(cyan), 100 ng/mL EGF with 50x EGF overexpression (magenta). The experiment design
methodology was applied with EGF/NGF doses and single gene changes. (B) Eigenspectrum
of experiments. (C) Number of parameters determined by each step of the search. With the
modified parameterization all 48 of the parameters could be determined to 10% R.E. (black
dashed line) with 15 experiments, and to within 100% R.E with seven experiments (red dashed
line).
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Chapter 5
Formulation of Mass Action Models
of Biological Systems Using
Kronecker Productsi
5.1 Abstract
Mechanism-based chemical kinetic models are increasingly used to describe biological signaling.
Such models serve to encapsulate current understanding of pathways and to enable insight into
complex biological processes. Currently, there is no standard formulation for these models,
making it difficult implement general-purpose analytical and computational methods. Here,
we propose a general and concise formulation of mass action kinetics based on sparse matrices
and Kronecker products. We show that this formulation allows any mass action model and its
partial derivatives to be represented by simple matrix equations, allowing for the straightforward
application of numerical techniques. Based on this result, we implemented three standard
analytical methods: dose response analysis, model simulation and calibration. In each of these,
we exploited our formulation to derive an efficient implementation in a high-level mathematics
'This chapter is adapted from a manuscript currently in preparation: Apgar JF*, Toettcher JE*, Tidor B,
and White J. Formulation of Mass Action Models of Biological Systems Using Kronecker Products. * These
authors contributed equally to this work.
package. For example, sensitivities are computed by an adjoint method. We applied these
methods to a series of models which demonstrated that they scale to models of thousands of
equations on standard desktop hardware.
5.2 Introduction
One goal of systems biology is to develop detailed models of complex biological systems that
quantitatively capture known mechanisms and behaviors, and also make useful predictions.
Such models serve as a basis for understanding, for the design of experiments, and for the
development of clinical intervention. In support of this goal, there has been a strong push to
build mechanistically correct kinetic models, often based on systems of ordinary differential
equations (ODEs), that are capable of recapitulating the dynamic behavior of a signaling net-
work. These models hold the promise of connecting biological and medical research to a class of
computational analysis and design tools that could revolutionize how we understand biological
processes and develop clinical therapies [101, 97].
Data formats such as Systems Biology Markup Language (SBML) [62, 88] and Cell markup
language (CellML) [112] have standardized the representation of biological models, allowing
them to be shared between laboratories and encouraging the development of model repositories.
This has greatly increased the number of publicly available models [129]. However, unlike the
models themselves, computational methods have remained difficult to share. For the most part
they rely on one-off, and often proprietary codes. As a result the methods have remained siloed
within individual software packages and are difficult to combine, customize, or apply in new
contexts. The problem is exacerbated by the fact that CellML and SBML allow for arbitrary
mathematical expressions for the rate laws. Designing general codes for the analysis of models
that may contain arbitrary mathematical structure leads to high computational overhead, or
spotty support.
However, the fundamental chemistry, as described by the mass action kinetics of elementary
reactions, is more limited in mathematical structure. Working within this reduced instruction
set allows for efficient and straightforward implementation of numerical methods. Furthermore,
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this simplified basis allows for a standardized model representation, which can easily be imple-
mentation in a high-level language. Together this lends itself to the development of efficient
numerical methods that can be ported between projects.
We present here a standardized formulation of mass action chemical kinetics as a simple
matrix equation (Equation 5.6). This formulation has the advantage that the matrices are con-
stant and depend linearly on the rate parameters, and that the quadratic terms are expressed
as Kronecker products. We show that this formulation allows simple algebraic manipulation of
the models and can serve as the basis for efficient general-purpose codes. In particular, we for-
mulate numerical integration, steady state finding, sensitivity analysis, and model calibration.
Despite being implemented in a high-level mathematics package [168], we were able to obtain
good performance on models with thousands of equations.
5.3 Background
5.3.1 Chemical Kinetics and the Law of Mass Action
In chemical kinetics, the law of mass action describes the mathematical relationship between
the concentration of reactant species and the rate of reaction [178]. In this work, we consider
mass action kinetic models consisting of zeroth-, first-, and second-order reactions described by
ordinary differential equations. In the equations below, k signifies a rate constant; A, B, and
C represent species or concentrations of species, depending on the context; and 0 is the empty
set or nothing.
Zeroth-order reaction:
0 -A i= r (5.1)
First-order reaction:
A7F B -- = = r A (5.2)
Second-order reaction:
A+B A C d = B = = r A B (5.3)
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5.3.2 Biological Models
Biochemical models are often described as networks of chemical reactions where the time deriva-
tive of any species is given by sum over all reactions that species participates in. Mathematically
these networks can be represented as systems of ordinary differential equations.
dxd = f (x, u (t), r)
dt
x (O) = x0
(5.4)
(5.5)
If the model consists solely of reactions of the form of Equations 5.1-5.3 then f can be
represented compactly as shown in Equation 5.6.
f = Aix + A2 (x O9x) + Biu + B 2 (x 0 u) + k (5.6)
The state vector x describes the chemical species concentrations that are free to evolve in
time according to the kinetics of the system. The input vector u (t) represents the chemical
species concentrations controlled by the experimenter. Matrices A1 (r) and B1 (r) represent
first-order reactions, matricesA 2 (r) and B 2 (r) represent second-order reactions, and c (r) rep-
resents constitutive (zeroth-order) reactions. The symbol 9 denotes the Kronecker product
(also known as the matrix direct product) [75]. For vectors, this operator generates a vector of
all quadratic products (Equation 5.7).
XOU=
0 [
The output of the model y is a linear combination
X 1U 1
X 2 U1
(5.7)
[ XUh I
of the state variables represented by the
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matrix C.
y = C x (5.8)
Finally, such a model can be fully parameterized by p, the augmented set of rate constants
and initial species concentrations (Equation 5.5).
r
p = (5.9)
X0
We define number of parameters, species, inputs and outputs as nx , n,, nu and ny, respec-
tively.
5.3.3 Partial derivatives of the model
Many analysis methods applied to such models require the computation of various partial
derivatives of the system of Equations 5.4. Using properties of the Kronecker product, and the
fact that the Ai and B2 matrices and k vector are linearly dependent on rate constants, the
first- and second-order partial derivatives can be written as shown in Equations 5.10-5.14.
fx = A1 + A 2 (I Ox + x 0 1) + B 2 (I 0 u)
fp = A1,px + A 2,p(x 0 x) + B 1 ,pu + B 2,p(x 0 u) + kp
fxx = 2A 2
fpp = 0
fxp = A1,p + A 2,p(I x + X 01 ) + B 2,p(I 0 u)
(5.10)
(5.11)
(5.12)
(5.13)
(5.14)
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In Equations 5.11 and 5.14, we define the augmented matrices Ai,p and Bi,p as the stacked
matrices shown in Equation 5.15, and reshape the right-hand sides to the appropriate matrix
sizes.
dpi
Mp = :(5.15)
Care must be taken to reshape the second derivatives of Equations 5.12-5.14 to consist of
the proper order of partial derivatives; following [136] for all such second derivatives, we use the
convention of Equation 5.15. Similarly, this matrix can be reshaped to give the (npnx) x nx
matrix fpx.
The advantage of our formulation is that the model and its partial derivatives can be suc-
cinctly represented by a small number of matrix equations. Such a simple, abstract representa-
tion obviates the need for complex tools such as automatic code differentiation, and allows the
straightforward application of numerical techniques.
5.4 Analysis Applications
5.4.1 Dose response analysis
Biological system models are commonly analyzed by computing a dose response curve, defined
as the steady state output of the system as a function of input concentration. Solving for steady
states can be accomplished by solving for the concentration x that makes the right hand side
of Equation 5.6 equal to zero. This problem can be solved by Newton's method.
fx()u, p)Ax = -f(xi), u, p) (5.16)
x(i+1) - xI +Ax (5.17)
For many biological networks fx (also called the Jacobian) is not full rank: linearly de-
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pendent rows correspond to mass conservation relationships within the network. As a result,
Equation 5.16 cannot be solved directly. One refinement to this method is to compute the sin-
gular value decomposition of fx and solve over its non-null subspace. An alternative solution is
to simultaneously minimize the flux with mass-constraint violation Mx - Mxo [58, 150] where
the matrix Mx is a constant for all trajectories of the system .
min {fTf + (Mx - Mxo)T(Mx - Mxo)} (5.18)
xX
The minimization problem of Equation 5.18 can be solved by gradient descent methods.
This requiring the gradient G given by Equation 5.19
G = 2 fTfx + 2 (Mx - Mxo)T M (5.19)
Timing results for both methods are presented in Section 5.6.
5.4.2 Simulation
Another analysis technique often applied to biological models is the time integration of the
model equations, often referred to simply as simulation or "running the model". This may
be the autonomous system response, or the response to a time varying stimulus. We have
implemented an implicit integration method using a commercial stiff ODE solver ode15s [156].
Stiff solvers rely on the the ability to efficiently compute the time derivative of x and the
Jacobian of the system (fx) [35, 6]. Both of of these quantities can be computed efficiently for
our formulation (Equation 5.10).
5.4.3 Sensitivity Analysis
Often, the modeler is interested in computing the full state sensitivitiesxp (t), the sensitivity
of the smaller set of model outputs y, or the sensitivity of an auxiliary function XP (p) (e.g. a
scalar cost function for optimization). These quantities can be computed by solving the system
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of Equations 5.20, and 5.21, consisting of a system of ODEs of size np x nx.
d
d ,=fxzp + fp (5.20)
0 0XP (0) = (5.21)
0 in,
In cases where the full concentration sensitivities are not required, an adjoint formation of
the sensitivity equations can greatly speed up the calculation. For ODE systems of the form of
Equation 5.6 the adjoint sensitivities are given by Equations 5.22, 5.23, and 5.24 [36].
dA*dt = A*fx -gx (5.22)dt
A* (T) = 0 (5.23)
T
d4'(p) _ {
dp = ( (A*fp + gp) dt + A* (0) xp (0) (5.24)
0
Whereas the forward sensitivity method involved integrating np x nx coupled ODEs, the
adjoint method requires solving nx coupled ODEs followed by np integrals for a total of np + nx
equations.
5.4.4 Hessian Vector Products
Gradient-based minimization methods require the evaluation of the gradient of the objective
as well as directional second-order derivatives (computed as the product of the Hessian and a
direction vector v (Equation 5.16). An adjoint formulation[136, 137 also allows the efficient
computation of these Hessian-vector products.
A = fxs - fp (5.25)
s (0) = xp (0) v (5.26)
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p = -gxxs - gxpv - fxp -- (A 9 In.) (fxpu + fxxs)
(T) = 0 (5.28)
T
d2 ''
d 2 9v gpxs -+ gppv + fpp + (A 0 In,) (fppu + fpxs) dt (5.29)dp2
0
5.4.5 Model calibration
One important problem in model construction and validation is model calibration. In this,
model parameters and initial conditions are varied so as to cause the model to match experi-
mental observations. Typically the level of agreement between the model and the experimental
observations is expressed as a scalar metric, such as the sum of the squares error of the observed
outputs versus the predicted outputs. These observations may be continuous (Equation 5.30)
or discrete (Equation 5.31).
Tj(p) = ly(x(p, t)) Ydata(t) 1 dt (5.30)
(P) y(x(p, ti)) - Ydata(ti)| 2  (5.31)
In either case the calibration problem can be phrased as a nonlinear optimization problem
(Equation 5.32).
min 41(p) (5.32)
lbi<pi<ubi
We have implemented model calibration using MATLAB's fmincon, a constrained nonlinear
optimizer. We configured fmincon to use the active set algorithm [701 which is a Quasi-Newton
method. Gradients of the objective function are computed using adjoint methods as described
in Section 5.4.3.
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(5.27)
5.5 Implementation Details
We implemented the numerical procedures described in Section 5.4 and applied them to three
classes of biochemical models: a discretized PDE of antibody penetration into a tumor, the
enzymatic cascade (EC) consisting of an interacting chain of the modules studied in [73], and
a canonical MAP kinase model [87].
Our PDE model consists of a simple binding reaction in which a mobile antibody binds to
immobilized tumor antigen. In this model, the unbound antibody is free to diffuse through
the tumor. We model this process as a discretized PDE, noting that diffusion can be repre-
sented within the mass action framework as a first-order reaction. We vary the number of
compartments to generate models of different scale.
The enzymatic cascade model is comprised of a chain of enzymatic push-pull loops. For
each loop there is an activating enzyme which activates a substrate and a deactivating enzyme
that deactivates the substrate. The active substrate is the activating enzyme for the next loop
in the cascade. As with the PDE example, we generate models of different scales by changing
the number of loops in the cascade.
5.5.1 Sparse Matrix Implementation
The matrices specifying mass action models can be very large (for example, the A 2 matrix size
scales as n3). However, a typical biological model does not densely populate these matrices.
Physically, this derives from the fact that each chemical species does not directly react with
all other species. The total number of non-zero entries in the A1 , A 2 , B 1 , and B 2 matrices
scales with 9 (m - n,,), where m is the average number of reactions participated in by each
species. For protein-protein interaction networks, a typical value of m might be 3.5-7.0 [79],
a range consistent with the models used in this study (Table 5.1). Thus, we choose a sparse
implementation for all matrices.
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Model Reactions Per Species
MAPK [87] 3.1
PDE 3.0
EC [73] 2.8
Table 5.1: Average number of reactions per species for the models implemented in this work.
Model No. Modules Not Pre-computed Pre-computed
PDE 500 24.307 s 4.862 s
EC 100 13.511 s 2.998 s
Table 5.2: Simulation Results With or Without the Pre-computed Kronecker Products. The
not pre-computed column shows the timing results for simulations that use sparse matrices.
The pre-computed column shows timing results that used sparse matrices and pre-computation
of the terms in x 0 x and x 0 I that were needed. The result is a 5-fold improvement for the
PDE model and 4.5-fold improvement for the enzyme cascade.
5.5.2 Sparse Kronecker Product
In addition to overall sparsity of the A2 matrix, most of the columns of A 2 are all zero. To
further improve performance, we pre-compute the terms in the x 0 x vector and the x 0 I
and I 3 x matrices that will be multiplied by non-zero columns of A 2 . We only evaluate these
non-zero products. The effect of this pre-computation on simulation times is shown in Table 5.2.
Because scalar multiplication is commutative, the Kronecker product x 0 x double-counts
products by including both xi, x and xj, xi terms. We chose to implement second-order re-
actions by dividing the flux between each of the two terms to preserve the symmetry of this
matrix. We do not find that this choice significantly affects our computational capabilities;
however, such a refinement could be easily implemented.
5.6 Results
To validate an implementation of the modeling framework and methods described above, we
performed dose response analysis, simulation, and calibration of models of varying size and
complexity. All results were generated on an Intel Core 2 Duo 1GHz desktop with 2 GB RAM
running Windows XP.
Model SVD + Newton's Method Constrained Optimization
EC, lON 0.13 s 7.32 s
MAPK N/A 19.6 s
Table 5.3: Dose Response Curve Results for Two Biochemical Models. Inputs were swept over
four orders of magnitude for each model. N/A indicates that the method did not converge.
Number of species PDE EC
N 0.0302 s 0.0560 s
5N 0.0332 s 0.1016 s
ION 0.0343 s 0.1185 s
50N 0.0834 s 0.7823 s
1ON 0.2502 s 2.969 s
50ON 4.8688 s 80.95 s
1000N 19.231 s 365.4 s
Table 5.4: Simulation Run Times in Seconds for Models of Varying Size. The number of
equations per model scales with the number of sub-models (e.g. PDE compartments or EC
cycles) with the number of equations per sub-model N.
5.6.1 Newton's Method and Dose Response Analysis
We ran both dose response tools on the MAPK model and 100-step EC model. The results are
summarized in Table 5.3. In general, we find that the SVD method is faster but that it fails to
converge on some problems where the constrained optimization can find a solution.
5.6.2 Simulation
To demonstrate that our implementation was capable of integrating large models, we imple-
mented a series of models of increasing size. The results of this study are shown in Table 5.4.
We find that simulation time grows less than quadratically for models of up to thousands of
species. This can be seen in Figure 5-1 as a slope of less than two on the log-log plot. It
should be noted that biochemical models comprising thousands of equations are rarely found
in the current literature. Our results validate that a sparse matrix implementation was crucial
for handling models of this size, as the dense matrices would not have fit into memory on the
machine used.
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Figure 5-1: Simulation Run Times in Seconds for Models of Varying Size.
5.6.3 Model Calibration
We generated data from a nominal parameter set. These data comprised the full time-dependent
trajectories for the model outputs which were a subset of the full state trajectories. The data
was generated using a nominal parameter set. We then calibrated the model to the data
beginning with a randomized initial guess. Optimization was performed using the integrated
squared error objective function (Equation 5.30) and the active set algorithm of fmincond.
Figure 5-2 shows the objective function at each iteration of the algorithm for three models. We
find that the method converges super-linearly. While the details of convergence do depend on
the initial guess, we find that the method converged to a good solution for nearly all random
parameterizations tested (data not shown).
5.7 Conclusions
In this work, we have developed a concise mathematical formulation of mass action kinet-
ics based on sparse matrices and Kronecker products. We have shown that this formulation
leads to a straightforward implementation of many numerical methods. In particular, we have
demonstrated that dose response analysis, simulation and model calibration can be performed
efficiently within this framework for a variety of models of up to thousands of equations. This is
surprising given that all of these methods are implemented in MATLAB, high-level mathematics
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Figure 5-2: Convergence Curves for Model Calibration Using Three Models. For all three
models the integrated squared error (ISQE) falls rapidly. The results are normalized by the
ISQEo, the value of the metric at the initial guess. By the 13th iteration all three models have
improved by a factor of 10,000.
package.
In this work, we have focused on a set of core numerical methods. These general methods
have application in almost any systems biology project. In addition these methods can also serve
as the underpinning of more specialized methods. One example is that parameter optimization
methods described here form the basis of the dynamic optimization controller used for model
selection (Chapter 2). Another example, is sensitivity analysis code is the basis for experiment
design for parameter estimation (Chapter 4). Finally, the optimization methods presented
here can be applied to other features of biological systems aside from just the concentrations
of species at particular times. For example, this code was adapted to allow for optimization
based on the timing of particular events in the cell cycle [170]. Taken together, these results
demonstrate the utility, and flexibility of the methods presented here.
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Chapter 6
Converting Aggregated Rate Law
Models to Mass Action
6.1 Introduction
Dynamic cell signaling and metabolic network models are predominantly implemented with
ARLs. These laws simplify complex enzyme mechanisms by aggregating systems of elemen-
tary reactions into a single rate law. For example, the stepwise reaction [119] by which an
enzyme binds a substrate, modifies that substrate, and then releases it is represented as a sin-
gle aggregated reaction with a Michaelis-Menten rate law [123, 26]. One class of simplification
is based on separation of time scale arguments such as rapid equilibrium [154, page 18], or
steady state [154, page 505]. Another class is based on approximations that hold over certain
concentration regimes such as pseudo-first order kinetics. In addition, more complex multi-
step or multi-enzyme mechanisms may be aggregated into a small number of pseudo-reactions
[74, 11, 69, 110]. Often these represent empirical fits rather than a physical limit of a specific
mechanism [192]. While ARLs generally simplify the set of reactions, they increase the math-
ematical complexity of the rate laws which, in general, are non-linear functions of substrate,
product, activator, and inhibitor concentrations. Moreover, ARL based models are valid only
over a particular concentration and time regime [172, 154].
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An alternative modeling technique is to use mass action rate laws (MRLs). In this method,
every reaction is an elementary chemical reaction [119] whose rate is described by the law of
mass action [178]. These types of models have the advantage that the law of mass action is
valid over all time scales and concentration regimes. However, this type of model suffers from
two principal disadvantages. First, MRL can be difficult to solve numerically. Second, much
of the data that exists for individual enzymes are not the elementary rate constants but rather
are equilibrium binding constants [13, 40, 39].
The numerical difficulty of solving MRL models comes from two sources. First, by replacing
aggregate reactions with many more elementary reactions, the number of differential equations
increases. Second, MRL models tend to be stiff, which is to say that some species, such
as enzyme substrate complexes, equilibrate quickly, while others, such as the production of
products, proceed more slowly [68]. In oscillating systems or in enzyme cascades these fast
modes can persist over the length of the simulation. Both of these problems have been greatly
mitigated by improvements in stiff solvers [35, 6] and a general increase in computing power.
In the previous chapter we simulated enzyme cascades with thousands of elementary reactions
on conventional desktop hardware. In this work, we also used the Kronecker Bio toolkit which
uses the stiff solver odel5s (see Figure 6-5.)
The second problem, that of limited data, is more fundamental. Much of the data available
for enzymes is in vitro data and expressed in terms of the parameters of ARLs. For example,
the BRENDA database contains vmax, KM, and K1 for many bacterial enzymes [40, 39]. Foun-
dational work by King and Altman [96] and Cleland [46] provides one solution to this problem.
In that work the authors describe a graphical method to derive the steady state rate law from a
system of elementary reactions. This method has since been developed into a formal algorithm
[49] and is available as a web tool [104]. We will refer generally to this scheme of automati-
cally transforming a MRL into a stead state ARL as the King-Altman method. Through this
method it is possible to automatically derive an ARL rate law that is the steady state limit
of the system of mass action reactions. This provides a bridge between the elementary rate
constants of the mass action model and the parameters of the ARL.
Some recent work has applied the King-Altman method to compute elementary rate con-
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stants from an ARL model [192]. In that work, individual ARLs were converted into MRLs.
The particular ARLs were Michaelis-Menten steady-state rate laws. Because of the special form
of these rate laws, it was possible to relate term by term the coefficients in the original ARL
implementation with the steady state expressions derived from the MRL using the King-Altman
method. The parameters were then solved by constructing a hybrid model in which a single
enzyme mechanism from the ARL model was replaced by its equivalent system of elementary
reactions. The newly introduced parameters were fit to data generated by the intact ARL model
using a dynamic optimization procedure and subject to the equality constraints introduced by
the King-Altman method. The method was applied to a model of Escherichia coli central car-
bon metabolism [41]. Ultimately, this method has two major shortcomings. First, it could only
be applied in situations where there was a direct term-by-term correspondence between the rate
law produced by the King-Altman method and the ARL model. This is because the equality
constraints used in the optimization relate particular terms in the ARL to a set of elementary
rate constants. In cases where the ARL is based on an empirical rate law, or simply based on
some other approximation (such as Hill binding, or pseudo-first order) the method could not
be applied. Second, the fact that the parameters are estimated in the context of the remainder
of the ARL greatly increased the computational cost. Together, these two facts limited the
application of this method to only 9 of the 30 enzymes in the model.
Here we present a similar approach that has a broader applicability. Like the previous
method, we constructed an elementary reaction implementation of for each enzyme mecha-
nism. We then derived a steady state rate law using the King-Altman method. Finally we
compared this rate law to the original ARL model. However, unlike the previous work, we com-
pared the rate laws directly by minimizing the velocity vs. substrate curve for each enzyme.
Operationally, this involved computing the steady state reaction velocity at all values of the
substrate, product, inhibitor, and activator concentrations. Using this data we then computed
the least squares difference between ARL model and the MRL. We then solved for the value
of the elementary rate constants that minimized this difference. Once the individual enzymatic
steps were parameterized, we assembled the full MRL model and compared its time dynamics
to the ARL. Additional parameter fitting could have been done at this stage. However, for the
127
model considered here, this was not necessary.
There are several advantage of this method: First, the calculations depend only on a single
enzyme at a time. As a result the the problem can be decomposed into small pieces which are
easier to solve and can be solve in parallel. Second the fact that we are computing the steady-
state rate curve means that the optimization procedure does not involve solving differential
equations. Finally, there does not have to be a one-to-one correspondence between terms in
our steady state rate law and the original ARL. This allows us to match a larger set of
approximations than the previous method. Together, these advantages allowed us to convert
more complicated mechanisms than was previously possible.
To demonstrate the utility of this method we have applied it to the same model of E.
coli central carbon metabolism [41]. We demonstrate that using our method we were able to
convert all 30 enzymes from the ARL original models. For each enzyme we are able to find a
set of parameters such that the steady state rate law agrees well with the original ARL model.
Moreover, simulations of the full MRL model agrees well with the original ARL. Note that this
is despite the fact that no time course data was used to train the MRL model. This suggests
that it is possible to convert ARL models into a MRL representation using our method.
6.2 Methods
6.3 Problem Formulation
We converted the aggregated rate law (ARL) model to a mass action rate law (MRL) model
one enzyme at a time. This is possible because every ARL in this model is a function only
of metabolite concentrations, and (implicitly) of the concentration of a single enzyme through
the vmax parameter. These rate laws take on a variety of mathematical forms, so they are
represented here as a general nonlinear function of metabolite concentrations.
dx~ dx8
- -- - rARL(X) (6.1)dt dt
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Where x is the vector of metabolite concentrations, X. is a substrate of the enzyme, and xy
is a product. In addition to substrates and products, many rate laws are modulated by the
concentration of activators and inhibitors. While in general the rate law could depend on many
or all of the metabolite concentrations, in this work the most was four.
6.4 Selecting a Mass Action Mechanism
To convert the aggregated rate law (ARL) model of an enzyme to a mass action rate law (MRL)
model the first step was to choose a reaction scheme comprised of elementary reactions. In most
cases this mechanism was stated explicitly in the model. However, in a few cases the mechanism
had to be inferred from the mathematical structure of the ARL. Next, an expression for the
steady state limit of the MRL was derived using the King-Altman method. This gave a new
rate law of the form:
n(k) ] xJz
rss =H(6.2)
di(k) ]x"
where, ni, and di are a polynomials of k the vector of elementary rate constants a, 3 and fi,j
are non-negative integers.
6.5 Solving for Elementary Rate Constants
To solve for the various elementary rate constants we optimized the elementary rate constants
so as to minimize the average least squares difference between the steady state limit of the mass
action rate-law and that of the aggregated rate-law:
p = arg min [rARL(C) - rss(c, p)]2 dc. (63)
The integral was implemented by using the trapezoidal rule with concentrations sampled at
log spaced intervals. The optimization itself was implemented using MATLAB's fmincon with
the active set algorithm [70] and complex step finite difference gradients. In a few cases, the
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optimizer would get stuck in a local minima. In these cases, the pattern search algorithm
[171, 107, 108, 109, 9] was used to produce an improved initial guess which was then refined
using active-set.
6.5.1 Software
The elementary reactions schemes were represented as biokin files [104]. These files were pro-
cessed using the biokin web-tool which produces a steady state rate law as a C-function. This
function takes a vector of concentrations and a vector of elementary rate constants and re-
turns the steady state rate. The C-function was translated into a MATLAB to allow it to be
incorporated into the overall optimization procedure.
6.5.2 Under-determined Parameters
The MRLs have more parameters than the ARLs that they are fit to. As a result, the mass
action parameters are underdetermined. To address this, we set some of the free parameters to
physically reasonable values. Which particular parameters were set is discussed below with the
individual reaction mechanism, but in general the on-rates of substrates binding to enzymes
were chosen to be approximately the diffusion limit (106 mM-1-1) for protein small molecule
binding [60]. This is a reasonable assumption, as many small molecule substrates bind with
this approximate on-rate [121]. In addition, choosing a fast on-rate helps to ensure that the
MRLs approach their steady state quickly where they will match the ARLs. Ultimately, these
constraints are artificial and should be fit to data from a properly designed experiment.
6.6 Results and Discussion
In this work, we converted the Chassagnole model [41] of Escherichia coli central carbon
metabolism from aggregated rate law to mass action rate law. The original model consists
of 30 Enzymes and 17 metabolites. The model does not describe the production of various en-
ergy molecules and cofactors including ATP, ADP, AMP, NAD, NADH, NADP, and NADPH.
For this work, these concentrations were considered to be constants [175].
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Scheme 6.1: Constitutive Production
1  k3S + E E:S - E+P
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Scheme 6.2: A Uni-Uni Irreversable Enzyme
Our general approach was to fit a mass action mechanism to each individual enzyme mech-
anism. Below we show the mass action mechanism for the various enzymes. Each mechanism
was compared to the original ARL mechanism. We compared the the rate vs. concentration
surface by computing the pseudo-steady state reaction rate at a range of substrate, activator,
and inhibitor concentrations. Where there was more than two concentrations that affected the
rate we plotted one- and two-diminutional projections of this multidimensional surface. How-
ever, the comparison used in the optimization was for the full surface. We also compared the
time dynamics of the enzyme by performing a simulation starting a the model initial conditions.
To test the various levels of approximation we plot the results for the ARL model, the both the
full mass action model and the steady state limit of the mass action model. A representative
set of these plots are shown below, and the full set of these plots are shown in Appendix B.
6.6.1 Constant Synthesis Reactions
The major source of carbon in the Chassagnole model is glucose uptake. However, pyruvate
(PYR) andglyceraldehyde-3-phosphate (GAP) enter the system as the product of other cellular
metabolic processes. In particular, tryptophan synthesis produces GAP and PYR and methio-
nine synthesis produces PYR. These are modeled at constant synthesis terms with ksynth equal
to the rate from the ARL model.
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6.6.2 Uni-Uni Irreversible Reactions
A number of enzymes are modeled as a uni-uni irreversible enzyme (Table 6.1) with a Michaelis-
Menten rate law:
TARL VmS/Km (6.4)
1 + S/KM
A mass action mechanism that can lead to this rate law is given by Scheme 6.2, where:
k2 + k3KM-= (6.5)ki
Vmax E ok3. (6.6)
With three rate constants and one additional species, the mass-action mechanism has two
degrees of freedom more than the original rate law. To prescribe these parameters we made two
somewhat arbitrary choices. First, the total enzyme concentration was set to 10- 3mM which
is a typical bacterial enzyme concentration [99]. Second, kon was set to 106 mM-Is- 1 , which
is a typical diffusion limit for protein small molecule interactions [121, 60]. Given these two
choices we can solve for the remaining parameters.
ki 10 6 mM-lS1  (6.7)
k2 Kmkon-vmax/Eo (6.8)
k3 vmax/Eo (6.9)
Note that it is possible to generate a k2 that is negative. While this did not occur for any of the
enzymes in this model the solution would be to increase kon such that kon > Vmax/(EoKM). The
result for glucose-6-phosphate-dehydrogenase is shown in Figure 6.6.2. Figure 6.6.2 (a) shows
the rate vs substrate curve for the enzyme. The ARL mechanism (solid blue line) and the
MRL mechanism over-plot exactly. Figure 6.6.2(b) shows a simulation for this enzyme starting
from the model initial conditions for enzyme concentration, as well as the concentration of 6-
phosphogluconate (6PG) and glucose-6-phosphate (G6P). The solid lines show the ARL model,
the xs show the steady state rate law derived by the King-Altman method, and the Os show
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Figure 6-1: Fit of G6PDH Mass Action Mechanism to Aggregated Rate Law mechanism. (a)
Rate vs. substrate plot. (b)
Enzyme Substrate Product Elaboration
ribose phosphate pyrophosphokinase ribulose-5-phosphate nucleotide
glycerol 3-phosphate-dehydrogenase dihydroxyacetone phosphate glycerol
serine synthesis 3-phosphoglycerate serine
synthesis 1 phosphoenolpyruvate carbohydrates, mureine
synthesis 2 pyruvate isolucine
glucose-6-phosphate dehydrogenase glucose-6-phosphate 6-phosphogluconate
6-phosphogluconate dehydrogenase 6-phosphogluconate ribose-5-phosphate
mureine synthesis fructose-6-phosphate Mureine Pseudo-Oth-order
PEP carboxylase phosphoenolpyruvate organic amino acids Cooperative activation
pyruvate kinase phosphoenolpyruvate pyruvate Cooperative Substrate binding
Cooperative activation
pyruvate dehydrogenase pyruvate acetyl-coenzyme A Cooperative substrate binding
phosphoglucoisomerase glucose-6-phosphate fructose- 1,6-bisphosphate Allosteric inhibition
Table 6.1: Uni-Uni Irreversable Enzymes in the E. coli Model.
the full MRL model. Note that even at very short time scales all three models over-plot almost
exactly.
6.6.3 Variations on the Uni-Uni Irreversible Mechanism
In addition to the basic uni-uni irreversible mechanism, there are a number of related mecha-
nisms. In general, these variations arise from the fact the enzymes contain allosteric activating
and inhibitory sites. In addition, many of the enzymes exist in multi-enzyme complexes.
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Pseudo-Zeroth-Order Reactions
In the Chassagnole model [41], mureine (Mur) synthesis is modeled as a zeroth-order-reaction.
Essentially this means that fructose-6-phosphate (F6P) is shunted into the mureine synthesis
pathway at a constant rate that is independent of any of the model species.
F6P k* Mur dF6P dMur = k (6.10)dt dt - (-0
Reactions of this type do not have the proper saturation behavior. In particular, if the concen-
tration of F6P becomes 0 in the model it will continue to be consumed by the reaction and will
become negative. In subsequent design work on this pathway, this was a persistent problem
and caused many of the ARL simulations not to converge.
In reality, synthesis of Mureine (Mur) is a complex multi-step process that combines UDP-
N-acetylglucosamine from fructose-6-phosphate with UDP-N-acetylmuramic acid from UDP-N-
acetylglucosamine, UDP-N-acetylmuramyl-pentapeptide from UDP-N-acetylmuramic acid, and
D-glutamic acid and dipeptide D-alanyl-D-alanine [12]. A more complete model of this process
would have to take into account all of these steps. However, for the purposes of this work we
model the first step of this synthesis pathway glucosamine-6-phosphate synthase converting F6P
to glucosamine-6-phospate. We model the process as a uni-uni irreversible enzyme as described
in Section 6.6.2 in the pseudo-zeroth-order limit. In this limit where S > KM Equation 6.4
becomes:
dSd V max (6.11)
which matches the given rate law 6.10.
The parameters for the MRL model are determined as with the uni-uni irreversible enzyme,
with the exception that a value for KM is not provided by the ARL. We chose to use KM =
0.2mM which is the observed KM of glucosamine-6-phosphate synthase for F6P [51]. The
results of the fit are shown in Figure 6-2.
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Figure 6-2: Parameter Fitting for Murine Synthesis a Pseudo-Zerorth-Order Mechanism. (a)
shows the rate of production of mureine as a function of F6P concentration. The blue line shows
the rate for the ARL and the red dashed line for the MRL. (b) Simulation of murine synthesis
starting from the model initial conditions. Note that the ARL model (solid lines) eventually
goes negative as the pool of F6P is depleted. Both the MRL model 0 and the steady state
limit of the MRL x saturates as the concentration of F6P approaches zero.
Uni-Uni Irreversible with Cooperative Activator Binding
PEP carboxylase (PEPCxylase) catalyzes the reaction from phosphoenolpyruvate (PEP) to
form organic amino acids. This reaction is activated by binding to an allosteric activator
fructose-1,6-bisphosphate (FDP). In the Chassagnole model, the activation is modeled with
fourth-order Hill binding. Scheme 6.3 shows a network of elementary reactions that can give
this effect. Figure 6-3 shows the comparison between the ARL and the MRL models. The
scheme shows that this mechanism can be extended to arbitrary numbers of activators. For the
purposes of matching a particular Hill coefficient, the n the number of activators that can be
bound must be larger than the desired Hill coefficient [154].
Uni-Uni Irreversible with Cooperative Substrate Binding
The enzyme pyruvate dehydrogenase (PDH) is one of three enzymes in the pyruvate dehy-
drogenase complex. Together these three enzymes convert PYR, Coenzyme A, and NAD+ to
acetyl-CoA, C0 2 , and H+. PDH catalyses the first step in this reaction, which involves the evo-
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Figure 6-3: Fit of PEPCxylase Mass Action Mechanism to Aggregated Rate Law mechanism.
(a) Rate vs. substrate plot . (b)
136
#
lution of C0 2, making it irreversible. This is also the rate limiting step in the overall reaction
performed by the pyruvate dehydrogenase complex, making PDH the key checkpoint between
glycolysis and the tricarboxylic acid cycle (TCA cycle).
The pyruvate dehydrogenase complex is a multi-subunit complex that in many organisms
is formed into a protein pseudo crystal. However, each subunit of this complex contains two
molecules of PDH, each of which have two catalytic sites. Chassagnole models a PDH subunit
as a single uni-uni irreversible enzyme with cooperative substrate binding and a Hill coefficient
of 4. This simplification corresponds to the assumption that each subunit acts as a perfectly
cooperative enzyme with four binding sites, and that subunits are independent of each other.
Following this simplification, we model PDH using Scheme 6.4.
E + nA V_' E : A I + (n - 1) A .. E: An
E + (n - 1)A + P E : An-1 + P
Scheme 6.4: Uni-Uni Irrev with Cooperative Substrate Binding
Uni-Uni Irreversible with Cooperative Binding and Cooperative Allosteric Activa-
tion
The tetrameric phosphofructokinase (PFK) is a multi-site irreversible enzyme that catalyzes
the conversion F6P to FDP. Chassagnole models the substrate binding as cooperative with
a Hill coefficient of 11. To achieve such a high order Hill coefficient in the MRL model the
enzyme is modeled as having 11 substrate binding sites. In the ARL model, PEP binds with a
Hill coefficient of 4 which is more plausible given there is one allosteric site per PFK monomer.
Scheme 6.5 shows the general MRL mechanism. To agree with the Chassagnole model, we
chose n of 11 and m of 4. Figure 6-4 shows that there is good agreement between the two
mechanisms.
While our MRL implementation gives good agreement with the ARL model (Figure 6-4),
it doesn't represent a very plausible mechanism. One possible explanation for such a high Hill
coefficient for this enzyme is more likely due to product activation [85]. PEP is an allosteric
137
+ mB # E: B + (m - 1)B ... Bm
E
+ nA E: A1 + (n -- 1)A E ... # :AN
I I
E + (n - 1)A + P E: An-1 + P
Scheme 6.5: Mechanism of Phosphofructokinase
(a) (b)
Aggregated Rate Law 3 F6P
- PEPAJ
2.5 X F6PPSS
1000 1000 PEPPss
x FDPPss
500 0 2 0 F6PMA
1 
- a PEPN0 0.5 2 a FDP
10" PEP -1 -0.5 F6P
F6SP e1,5 -
Mas Action 
1000
0O 200000 
_15 
8@0 OD_&1-0.5 
@
PEP -1 -01 10 10 10 10
Tim (S)
Figure 6-4: Parameter fit for Phosphofructokinase Mass Action Mechanism to Aggregated Rate
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inhibitor of PFK.
6.6.4 Uni-Uni Reversible Reactions
A number of the reactions in the Chassagnole model are uni-uni reversible enzymes. These
reactions have rate laws with the following prototype:
vmax(S - P/Keq) (6.12)
rARL =-(-2
KM + S + P/Kp
One mass action mechanism that can give a steady state rate law of this form is:
S + E E:S E:P -E + P. (6.13)
k2 k3 k6
...... ... . . . ...
Enzyme Substrate Product Elaboration
triosphospahte isomerase dihydroxyacetone phosphate glyceraldehyde-3-phosphate
glyceraldehyde 3-phosphate dehydrogenase glucose-6-phosphate 6-phosphogluconate
phosphogylcerate kinase 1,3-diphosphosphoglycerate 3-phosphoglycerate
phosphoglycerate mutase 3-phosphoglycerate 2-phosphoglycerate
enolase 2-phosphoglycerate phosphoenolpyruvate
phosphoglucomutase glucose-6-phosphate glucose- 1-phosphate
phosphoglucoisomerase glucose-6-phosphate fructose-6-phosphate Inhihition
ribulose phosphate isomerase ribose-5-phosphate xylulose-5-phosphate Pseudo 1st-Order
ribulose phosphate epimerise rihose-5-phosphate rihulose-5-phosphate Pseudo 1st-Order
glucose 1-phosphate adenyltransferase glucose 1-phosphate polysaccharides Cooperative Activation
phosphofructokinase fructose-6-phosphate fructose 1,6-hisphosphate Cooperative Activation
Cooperative Inhihition
Table 6.2: Uni-Uni Reversible Enzymes in the E. colt Model. The table lists the enzymes along
with their substrates and products, and notes any variations on the basic mechanism.
The steady state rate law (as determined by the King-Altman method) is:
k1k3 k5 S - k2 k4 k6 P
rss (k4 k6 + k2k6 + k3k6)P + (k1k5 + k1k4 + k1k3)S + (k2k5 + k2 k4 + k3k5)
(6.14)
As with the uni-uni irreversible mechanism, there are more rate constants in the MRL model
than there are in the ARL model. As before, the enzyme concentration is assumed to be
10-3mM and the on-rates ki and k6 are assumed to be 106 mM s-1s. Because of the simple
structure, it is possible to directly solve for the elementary rate constants that match the ARL.
ki = 106 TM-Is-1
= KMKp(EoKEQKmk1k6 - (k1 + KEQk6)Vmax)
EoKEQKk 6 KP - (KEQKM + KP)Vmax
KEQKmk6KPVmax
BoKEEQKmk 6KP - (KEQKM + Kp)vmax
KMklKvmax
4 EoKq(K)kl - (KEQKM + Kp)vmax
KmKp(EoKEQKMk1k6 - (k1 + KEQk6)Vmax)
0 - Kq.M )k1
k6 = 106TmM-ls-1
(KEQKM + Kp)Vmax
The results for enolase (Eno) are shown in Figure 6-5.
(6.15)
As with the uni-uni irreversible
mechanism, the fits are perfect because an exact value for the elementary rate constants can
be found and used as an initial guess for the optimizer.
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Pseudo-First-Order Reversible Reactions
Chassagnole models the enzymes ribulose phosphate isomerase (Ru5P) and ribulose phosphate
epimerise (R5P1) as pseudo-first-order reversible enzymes. Both rate laws have the following
form:
r = Vmax(S - P/Keq). (6.16)
This rate law represent a limit first-order reversible mechanism at low substrate concentrations.
In this limit, KM > S + P/Kp, so the usual uni-uni reversible rate law can be approximated
as:
r ~ vm (S - P/Keq).Km (6.17)
We implemented these two enzyme mechanism as uni-uni reversible enzymes. This mechanism
requires two additional parameters not specified by the pseudo-first-order rate law, KM and
Kp. Both constants were chosen to be 102 mM, which is 100x greater than the maximum
substrate or product concentration in the Chassagnole model.
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Variations on Uni-Uni Reversible
As with the irreversible enzymes, the basic uni-uni reversible mechanism can be modified with
inhibitors, activators, and cooperative binding. Table 6.2 shows the general mechanisms. These
mechanisms can be quite complex, but our general approach is to model each enzyme complex
explicitly. The detailed mechanisms for these rate laws can be seen in Table A.13, and the
resulting fits after optimization can be seen in Appendix B. This approach greatly increases
the number of parameters and the number of equations.
6.6.5 Bi-Uni Irreversible Reactions with Hill Substrate Binding
There is one bi-uni irreversible enzyme, 3-deoxy-arabino-heptulosonate-7-phosphate synthase
(DHAPS) in the Chassagnole model. It catalyzes the condensation of erythrose-4-phosphate
(E4P) and PEP and is the first step in the aromatic amino acid synthesis pathway. There is one
isoform of DHAPS for each of the three aromatic amino acids. Each isoform performs the same
reaction but has an different allosteric inhibition that is specific for one of the three aromatic
amino acids. In E. coli the reaction is known to be sequential with PEP binding first [2]. The
enzymes exist as dimers and exhibit significant cooperativity. We modeled the dimers as two
bimolecular sites. The complete reaction mechanism can seen in Table A.13, and the resulting
fits after optimization can be seen in Appendix B.
6.6.6 Uni-Bi Ordered Reversible Reactions
Aldolase catalyses the reversible conversion of the hexose FDP into two triose sugars dihydrox-
yacetone phosphate (DHAP), and GAP. The forward reaction involves the ring breaking of
FDP, followed by sequential unbinding of DHAP, and then GAP. We model the reaction as
a uni-bi ordered reversible enzyme. The elementary reaction scheme is shown in Scheme 6.6.
The pseudo steady state rate law obtained by the King-Altman method [96, 49, 154], is shown
in Equation 6.19. The resulting fits after optimization can be seen in Appendix B.
k 3  k5  , -E+A E:A E:XY E:X+Q E+Q+P
k1 k2 k4 K6
Scheme 6.6: Mechanism of Uni-Bi Ordered Reversible Enzyme
ni = -kik 3 k5 k7
n2 = +kok 2k4 k6
d1 = k3 k5k7 + k1k5 k7 + k2 k5 k7
d2 = k0 k3 ks + kk 2 k5
d3 = kik 3 k5  (6.18)
d4 = k1 k3k7 +k 1 k4 k7 +k 2k4 k7
d5 = kok 3k 6 +kok 4 k6 +kok 2 k6 +kok 2k4
d6 = k1k 3k6 +k 1k4k6 +k 2k4k6
n1 PQ + n2A
d1PQ + d2AQ + d3 Q + d4 P + d5 A +d6
6.6.7 The Full MRL Model
Once parameters were found for all of the individual enzyme mechanisms, the individual mech-
anism were assembled into a full pathway model. Tables A.13, A.14, and A.15 show the detailed
mechanisms and parameters. To validate the model we recapitulated the experiments shown
in the Chassagnole paper. First, we confirmed that the steady state of our MRL model was
the same as the ARL model. Second, we reproduced the glucose pulse experiments in which
a momentary injection of glucose increased the extracellular glucose concentration to 1.4 mM.
Figure 6-6 shows the trajectories for the ARL model (red lines) and the MRL model (blue lines).
In both cases, the models were allowed to run for 10 minutes to demonstrate the steady state.
The two models performed remarkably similarly, despite the fact that all of the parameters
were fit in the steady state limit of the enzyme rate laws, and did not require fine-tuning using
time course data.
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Figure 6-6: Comparison of the ARL to the MRL Model. This figure shows the response of the
ARL model (red lines) and the MRL model (blue lines) to a pulse of glucose applied at t = 0.
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In both of these simulations, we set the concentration of the co-metabolites to a constant
value. To gauge the effect of this choice, we compared the two models to experimental data
[41]. Figure 6-7 shows the results of this comparison. Both models match the data (diamonds)
at short times (1 minute), however, the models quickly diverge from the data. In Chassagnole
they correct for this by measuring the co-metabolite concentrations and then applying them
as inputs to the system. This does improve the fit to the data, however, it greatly limits the
applicability of the model if the time courses of co-metabolites need to be measured before the
model can make a prediction. Others have used the Chassagnole model with the assumption
of constant co-metabolites to good effect [175].
6.7 Discussion
We have shown here that a complex ARL model can be converted into a MRL. Moreover, we
have shown that the MRL can perform similarly in the range of conditions where the ARL
was developed. One limitation of both models is that the consumption and production of co-
metabolites is not modeled. Simply updating the model to consume the co-metabolites (where
appropriate) would not fix this problem, because it does not address the production of new
high energy co-metabolites by the downstream metabolism. One way to address this would
be to expand the model to include these networks, in particular, the TCA cycle and oxidative
phosphorylation which would close the loop on these co-metabolites.
One possible path for implementing these reactions would be to incorporate existing models
of these processes. Singh et al. have developed a model of the TCA cycle in E. coli [160] that
is based on ARLs. Wu et al. have developed a model that includes oxidative phosphorylation
in eukaryotes which could be adapted for bacteria. In addition, databases such as EcoCyc [93]
and BRENDA [39] contain extensive lists of bacterial enzymes and ARL parameters.
Despite not having these reactions, it may still be possible to use this model for strain
design. Vital et al. performed optimization on the Chassagnole model to find optimal enzyme
concentrations [175]. In that work they had to assume constant co-metabolite concentrations.
Within this limit it is our expectation that the MRL model will behave in a more physically
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reasonable way as it leaves the concentration- and time-scales where the ARLs are valid. In
particular, MRLs will saturate at both low and high substrate concentrations. It remains to be
seen but we are optimistic that this will result in higher quality predictions.
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Figure 6-7: Comparison of the ARL and MRL to Experimental Time Course Data. This figure
shows the fit of the ARL model (red lines) and the MRL model (blue lines) to a pulse of glucose
applied at t = 0. In both cases the fit is rather poor after 5 minutes.
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6.8 Abbreviations
ARL aggregated rate law
PSS pseudo steady state
MR L mass action rate law
TCA cycle tricarboxylic acid cycle
6.8.1 Metabolites
RIB5P ribulose-5-phosphate
G6P glucose-6-phosphate
F6P fructose-6-phosphate
G1P glucose-i-phosphate
FDP fructose-1,6-bisphosphate
DHAP dihydroxyacetone phosphate
PYR pyruvate
PEP phosphoenolpyruvate
GAP glyceraldehyde-3-phosphate
Mur Mureine
6PG 6-phosphogluconate
SED7P sedoheptulose-7-phosphate
E4P erythrose-4-phosphate
XYL5P xylulose-5-phosphate
PGP 1,3-diphosphosphoglycerate
3PG 3-phosphoglycerate
2PG 2-phosphoglycerate
RIBU5P ribose-5-phosphate
accoa acetyl-coenzyme A
6.8.2 Enzymes
PTS phosphotransferase system
PGI phosphoglucoisomerase
PFK phosphofructokinase
ALDO aldolase
TIS triosphospahte isomerase
GADPH glyceraldehyde 3-phosphate
dehydrogenase
PGK phosphogylcerate kinase
PGIuMu phosphoglycerate mutase
Eno enolase
PK pyruvate kinase
PDH pyruvate dehydrogenase
PEPCxylase PEP carboxylase
PGM phosphoglucomutase
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G1PAT glucose 1-phosphate
adenyltransferase
RPPK ribose phosphate pyrophosphokinase
G3PDH glycerol 3-phosphate-dehydrogenase
SerSynth serine synthesis
MurSynth mureine synthesis
DHAPS
3-deoxy-arabino-heptulosonate-7-phosphate
synthase
TrpSynth tryptophan synthesis
MetSynth methionine synthesis
G6PDH glucose-6-phosphate dehydrogenase
PDGH 6-phosphogluconate dehydrogenase
Ru5P ribulose phosphate isomerase
R5P1 ribulose phosphate epimerise
TKa transketolase a
TKb transketolase b
TA transaldolase
Synth1 synthesis 1
Synth2 synthesis 2
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Chapter 7
Conclusions and Future Directions
The promise of the genomics era and the "one gene - one disease paradigm" has largely not
been realized [34]. Frustrating those efforts is the fact that disease mechanisms are complex
and require a quantitative understanding to rationally develop therapies. Mechanistic dynamic
models could provide a quantitative substrate to assist in this effort. One mode of analysis
would be to systematically search pathways for good drug targets by computationally inhibiting
every enzyme. By necessity, this will push the systems into unfamiliar and untested regions of
their concentration space. Having models that are mechanistically correct and well calibrated
should improve the quality of these extrapolations and make the results of such an analysis
more relevant to and useful for decision-making. Despite the potential of these models, a
number of challenges frustrate the construction of these high-quality models. These challenges
include a lack of methods and theory to guide model formulation, model selection, and model
calibration. The work presented here addresses these challenges and advanced the state of the
art in experiment design for systems biology.
7.1 Dynamic Stimulation Improves Model Selection
One of the principle challenges in model construction is the fact that chemical and physical
mechanisms that control biochemical processes are only partially understood. As a result, it is
possible that mechanistically distinct models will fit available data and known chemistry. In
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this work, we have developed a strategy for dealing with this ambiguity. This method uses the
candidate modes to stimulus-response experiments, which are designed to distinguish among
models with different reaction mechanisms. The results presented here show that time varying
stimuli designed with these tools can allow the experimenter to distinguish among even closely
related models.
We have developed two algorithms to solve these inputs. One is based on a tangent lin-
earization, and the other is based on dynamic optimization. We evaluated our method on
models of antibody-ligand binding, mitogen-activated protein kinase phosphorylation and de-
phosphorylation, and larger models of the epidermal growth factor receptor (EGFR) pathway.
In each of these cases, a step response experiment was insufficient to distinguish between the
models. We found that both design methods are able to find time varying inputs capable of
distinguishing among all of the model alternatives.
One limitation of this method is that the input stimuli designed by our method could be
difficult to realize experimentally. One remedy for this would be to use constraints on the
input signals to restrict the optimization to the experimentally feasible space. We presented
results for a monotonicity constraint which represents the situation where material can be
added but not removed. Even complex inputs of this form could be generated with a computer
controlled syringe pump. An alternative approach would be to use microfluidic based cell
culture [77]. These systems offer very fine spatial and temporal control of the environment
around cells. In particular, these systems have the potential to drive input signals up and down
at high frequency. Another novel way to deliver a time varying stimulation is to use a light-
switchable gene promoter system [159]. In this system, a gene can be activated or deactivated
with different colors of light. One disadvantage of this approach is that the frequency of these
inputs are limited by the rates of transcription and translation. However, a major advantage of
this method is being able to introduce time varying inputs at multiple points in the network.
Combining any of these input technologies with real-time measures of cell signaling would make
for a powerful experimental platform for model building [145].
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Figure 7-1: Schematic of a Microfluidics Chamber for the Delivery of Time Varying Stimulation.
7.2 Experiment Design Improves Parameter Estimation
Another modeling challenge addressed by this work is the fact that chemical kinetic models
contain many unknown parameters, at least some of which must be estimated by fitting to time-
course data. We examined this question in the context of a pathway model of epidermal growth
factor (EGF) and neuronal growth factor (NGF) signaling. Computationally, we generated a
palette of experimental perturbation data that included different doses of EGF and NGF as well
as single and multiple gene knockdowns and overexpressions. While no single experiment could
accurately estimate all of the parameters, we identified a set of five complementary experiments
that could. These results suggest that there is reason to be optimistic about the prospects for
parameter estimation in even large models.
The perturbations used in this work were all at the level of changing protein concentrations
by knockdown or overexpressions. However, other experimental perturbations would also be
interesting to consider, such as small molecule inhibitors. With the exception of EGF and NGF
doses, all of the perturbations used in this work were static. An interesting extension to these
methods would be to use inducible promoters to allow for more dynamic perturbation within
the network. These types of inputs should be particularly helpful for mass action models that
reactions that happen on vastly different time scales.
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7.3 Experiment Design Could Improve Model Predictions
Models of biological pathways provide a substrate for understanding, manipulating, and even-
tually controlling complex biological processes. Many of the manipulations of these systems can
be expressed in terms of changing the parameters of the system [1]. For example, overexpressing
a protein can be modeled by increasing the protein's synthesis rate, or changing the protein's
initial condition. The effect of a drug can be modeled by turning down the catalytic rate of
drug's target enzyme. The dynamic equations of the model relate these parameter changes to
the changes in the model outputs. However, as these models become more complicated, the
relationships between the parameters and the model outputs becomes difficult to understand.
As a result, it may not be possible to intuit the effect of changing parameter values on the
model outputs by directly analyzing the model equations.
One of the main methods to address this challenge is sensitivity analysis [142, 189]. This is
a numerical method in which the effect of changing a parameter is approximated by computing
the derivative of the model output 0 with respect to the parameters p (Equation 7.1).
(p* + Ap) =p + Ap d (7.1)
.dp p=p-
These outputs may be the concentrations of some chemical species at a particular time, or a more
complicated feature of the network [183, 182, 190]. Sensitivity analysis is local in two senses:
First, it is based on a linear expansion of the full nonlinear effect of changing the parameters.
This approximation will become less accurate as change in parameter (Ap) becomes larger.
Second, the linearization is about a nominal parameterization p*. If p* is not accurate, then
the conclusions drawn from sensitivity analysis may not be accurate even in the limit of small
parameter perturbations. It is for this second reason that this method is often referred to as
local sensitivity analysis.
There are many variations on the local sensitivity method that try to mitigate the im-
portance of the nominal parameter value [142]. Global sensitivity analysis refers to a class of
methods that try to characterize the parameter space in a more holistic sense. This may be
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accomplished by computing the local sensitivities at many points in parameter space, by esti-
mating higher order derivatives, or other methods [148]. While these methods tend to reduce
the importance of the nominal parameterization, they also tend to emphasize sensitivities that
are consistent across the entire parameter space. Where these directions exist, this can provide
reliable predictions that are independent of the nominal parameter set. However, it greatly
limits the predictive power of the model as only global trends are captured.
The methods we have developed in Chapter 4 have the potential to impact the application
of sensitivity analysis. In this work, we used experiment design to greatly reduce the set of
feasible parameters. If local sensitivity analysis is performed after our method is used to refine
the parameter set, then there would be additional confidence that the nominal parameter set
is close to the true parameter set. Moreover, we know that the directions where the parameter
uncertainty is high correspond to directions of low sensitivity. Together, theses facts suggest
that our design procedure for improving parameter estimates would also improve the accuracy
of local sensitivity analysis.
7.4 EGFR Modeling: Moving Beyond Step Response Experi-
ments
Throughout this work we have endeavored to show that mechanistic modeling combined with
experiment design is a powerful combination for understanding systems biology. The work
has demonstrated a real need to improve models of growth factor signaling. However, the
results presented here are mostly methods development and proof of concept studies. As a
future direction, it is our hope that these methods will be applied to this important signaling
pathway.
Much of our understanding of cell signaling comes from steady state and step response
experiments. This imposes a kind of bias on the way we think about signaling biology and the
importance of particular mechanisms. In Chapter 3, we showed that even widely used models
may not accurately predict the response to perturbations other than a single step change in the
input. Many physiological signals vary with time, and drug regimens are often delivered on a
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periodic schedule. As a result, this step response bias may ultimately limit the ability of these
models to make predictions that go beyond the laboratory.
In this work we tested the idea that pulses of EGF could help elucidate the relative contri-
bution of different feedback loops within the EGFR network. The idea behind this stimulus is
that the first pulse activates the network, including all of the feedback loops. We expect that as
the response to the first pulse evolves, different feedback mechanisms will increase or decrease
in importance. The second pulse then probes the state of the network at a later time. By
comparing the response of the network to a second pulse delivered at various times, we hoped
to be able to detect the timescale and relative importance of the various feedback mechanisms.
We believe that this approach could be very general and have applications in understanding
multiply connected feedback mechanisms that are common in cell signaling. In addition, these
methods could be useful in understanding crosstalk between pathways. For example, the first
pulse could be with one ligand and the second pulse with another. Finding waiting times where
the first pulse interferes with the response to the second pulse could be an effective way of
finding points of crosstalk.
These experimental results suggest that models from the literature do not accurately rep-
resent the relative strength of the various feedback loops in this pathway. In particular, we
observed that the endocytosis and feedback loop was less strong than predicted by models from
the literature [86, 431, and that other feedback mechanisms were likely necessary to deactivate
ERK after EGF stimulation. A possible next step would be to repeat the pulse experiments
presented in Chapter 3 at shorter and longer waiting times. This should give a better sense
for the time scale over which the pathway resets and various feedback loops become active. In
addition, various drugs that block broad biological functions could be used to help elucidate the
physical mechanisms that underlie this process. One example would be to treat the cells with
the endocytosis inhibitor phenylarsine oxide. Another possibility would be to use a tethered
ligand that could not be endocytose.
The experimental results also suggest that the response of the experimental system is highly
sensitive to the presence of other signaling molecules. Even a small dose of insulin appeared to
radically change the network response to EGF. Often times, biologists talk about various cues
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causing the network to rewire. This implies that the basic biochemical processes have been
altered or changed. These results motivate a different interpretation. Instead of the network
rewiring, environmental cues can modulate the weights of the various feedback mechanisms.
This type of effect could explain the observed patient-to-patient variability observed in drugs
that target molecules in this pathway.
7.5 A Standardized Formulation of Chemical Kinetics Leads to
Reusable Methods and Software
Currently, there is no standard formulation for chemical kinetic models of biological signaling.
Here we have developed a general and concise formulation of mass action kinetics based on
sparse matrices and Kronecker products. This formulation allowed us to represent any mass
action model and its partial derivatives with simple matrix equations. Based on this formalism
we built several numerical methods, including the design methods presented in this work. We
show the generality of this formulation by converting models that use other rate laws such as
Michaelis-Menten can be converted to our formulation. We demonstrate this by converting a
model of Escherichia coli central carbon metabolism to be fully mass action. The dynamics
of the new model is similar to the original model. However, we argue that because our model
is based on fewer approximations, it has the potential to be more accurate over a wider range
of conditions. In addition, using the same methods we can automatically convert mass action
mechanisms into the corresponding aggregated rate law mechanisms. Because the reactions
are elementary reactions, the same systems of equations could be simulated in a stochastic
framework. This places the mass action models in a unique position to bridge the gap between
more abstracted, and more detailed simulation methods.
More important than any performance considerations was the fact that standardizing on a
formulation of chemical kinetics allowed us to develop methods and code without regard for the
details of any particular model. This greatly improved our productivity, and allowed for the
development of a diverse set of tools. It is our hope that this development continues.
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7.6 Biological Robustness Does Not Imply Parameters or
Mechanism are Unknowable
A strange consequence of the fact that standard step-response experiments are poor at distin-
guishing among multiple mechanism and parameter sets is that there is a sense in the field that
detailed mechanisms and accurate parameters are unimportant and unknowable from reason-
able amounts of data. This makes a kind of sense. If it were really true that no experiment
could distinguish two mechanism, then it seems unlikely that the choice of mechanism would
have any impact on a prediction.
The notion that multiple mechanism and parameter sets are somehow equivalent is often
conflated with the idea of biological robustness. A sketch of the argument, as it applies to
parameters, is as follows: from Barkai and Liebler's foundational work [11] we know that
biological systems are robust to parametric variation. From Sethn'a work [78] we know that
it is impossible to know most if not all of the parameters of a network. Therefore, the exact
values of parameters do not matter. The work presented here shows that the second statement
is wrong. It is possible to determine the parameters of a network to high accuracy. The problem
with the first statement is more subtle. Barkai and Liebler showed that certain overall features
of a network could be robust to parametric variation. In the case of bacterial chemotaxis, the
ability of the network to adapt perfectly was robust to parameter variation. This feature is a
requirement for the biological function of the network, sensing gradients. So the parametric
robustness captures a kind of functional robustness or robustness of phenotype. However, if
you were to plot two trajectories of the signaling molecules of the network at two different
parameterizations, they might look quite different. Moreover, even global network properties
such as the adaptation time were shown to be sensitive to parameter changes. The fact that
some features of the network are robust to parameter changes does not imply that different
parameterizations are indistinguishable or unimportant.
So how is it that models that exist today, which are poorly calibrated and contain incomplete
or wrong mechanisms, can ever make good predictions? Sethna's point made more precisely
provides one possible answer. His work showed that for any particular prediction only a subset
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of the parameters were important. If that subset was well calibrated by the initial experiments,
then the prediction is likely to be good. The relationship between model calibration and
prediction accuracy is discussed in detail in [16]. This result suggests a potential variation
on our method. If somehow you knew ahead of time that the predictions you wanted to make
were only sensitive to certain parameter directions, then when you were choosing experiments to
define the parameters you could select the experiments that covered the subspace of parameter
directions that were important for your problem. A concrete example of this is that if you
knew certain proteins were never expressed at a level above the KM of any of the enzymes
that modify them, you could decide to ignore the parameter directions that pointed in the
(+ log kcat, + log KM) direction. However, the results presented here suggest that it may not
be worth optimizing on the subspace of parameters to determine. Especially since a small
number of experiments was able to cover the entire parameter space. In addition, if the models
are to be used in systematic computational experiments, such as computational screening for
drug targets or designing bacterial strains for bioreactors, it is likely that most if not all of the
parameters will be important for some prediction of the design.
7.7 Experiment Design Can Improve the Quality of Models
The work presented here has shown that experiment design can be used to improve the quality
of models. We have shown this in terms of selecting the best possible mechanisms, and we
have shown this in terms of improving parameter accuracy. Taken together, the work presented
here demonstrates that experimental design can be successfully used to improve the quality of
mechanism-based chemical kinetic models.
The focus of this work has been on experiment design. However, the methods developed
in this thesis have potential applications to therapeutic design. For example, instead of using
the control methods for experiment design, they could be used as the basis for controlling a
biological system. One way to achieve this is to pick a target function that corresponds to a
desired biological outcome. The choice of target function is essentially arbitrary. In Figure 7-2,
we show that the same controller can cause the output (doubly phosphorylated ERK) to spell
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the word MIT. While this is a contrived example, one could imagine a situation where the
input is the concentration of a drug and the output is a particular physiological process. In
fact, the emerging field of chronotherapeutics [141] is one attempt to do just that. Much of
modern drug delivery has focused on the delivery of constant (with respect to time) dose of
bioactive agents. However, asthma, arthritis, duodenal ulcer, cancer, diabetes, cardiovascular
disease, hypercholesterolemia, and neuronal disorders have all been shown to have a temporal
component to their pathophysiology and to respond differentially to different time courses of
treatment [187]. A new generation of rapid release drug delivery technologies are creating the
possibility of delivering more complex time varying drug stimuli [94].
If these methods were to be used in therapies, issues of robustness would become critical.
One modification to the method detailed here would be to incorporate robust optimization. This
could account for uncertainty in the underlying model, the parameters, or even the parameters
of the clinical intervention. Even within the confines of experiment design, the use of robustness
metrics could improve the practical utility of the designed experiments.
Increasingly, synthetic biologists have turned to mechanistic models to help in design, opti-
mization, and analysis of novel biological systems [54]. As with any model based engineering,
the quality of the models directly impacts their ability to guide decision-making. The techniques
presented here could have a direct impact on high quality engineering models. In addition the
optimization methods presented here could be easily adapted to synthetic biology design ques-
tions such as the optimal parameterization for a biological part. As was the case with the
therapy design, the incorporation of robustness metrics would make these methods even more
useful to the synthetic biology community.
Ultimately, the success or failure of any of these applications is greatly influenced by the data
that is used to construct, calibrate, and validate the models that support them. The methods,
practices, and experiments developed here provide a set of tools to improve the model building
processes, and promote the highest possible model quality.
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Appendix A
Kronecker Models
A.1 Models of Antibody-Ligand Binding
Table A.1: One Step Antibody-Ligand Model Reactions
Reactant 1 Reactant 2 Product kforward kreverse
A L C kl+ k1-
Table A.2: One Step Antibody Ligand Model Parameters.
Parameter Value
kl+ 1.30 x 10-03
k1- 9.92 x 10-05
Table A.3: One Step Antibody-Ligand Model Species.
Species Initial Concentration Is Input
L 0 yes
P 1 no
C 0 no
Table A.4: Two Step Antibody- Ligand Model Reactions
Reactant 1 Reactant 2 Product kforward kreverse
L P C* kl+ k1-
C* 0 C k2+ k2-
Table A.5: Two Step Antibody Ligand Model Parameters.
Parameter Value
kit 1.20 x 10-02
ki- 1.20 x 10-02
k2+ 1.30 X 10-03
K2- 1.10 X 10-04
Table A.6: Two Step Antibody-Ligand Model Species.
Species Initial Concentration Is Input
L 0 yes
P 1 no
C* 0 no
C 0 no
A.2 A Model EGFR Signaling With Additional Recycling Re-
actions
Table A.7: Expanded EGFR model Reactions.
Reactant 1 Reactant 2 Product kforward kreverse
GAP 0 0 kd214 k200
Grb2 0 0 kd222 k200
Sos 0 0 kd224 k200
Ras-GDP 0 0 kd226 k200
Shc 0 0 kd231 k200
Grb2-Sos 0 0 kd230 k200
EGFRi 0 0 k60 kd60
EGFi 0 0 k61 kd61
(EGF-EGFRi*)2 0 0 k60 kd60
(EGF-EGFRi*)2-GAP 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-Grb2 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-Grb2-Sos 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GDP 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GTP 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-SHC 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-SHC* 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-SHC*-Grb2 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GDP 0 0 k60 kd60
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GTP 0 0 k60 kd60
phosphatase3 ERK-PP ERK-PP-phosphatase3 k56 kd56
phosphatase3 ERK-P ERK-PP-phosphatase3 k57 kd57
phosphatase3 ERK-P ERK-P-phosphatase3 k58 kd58
phosphatase3 ERK ERK-P-phosphatase3 k57 kd57
phosphatase3 ERKi-PP ERKi-PP-phosphatase3 k56 kd56
Continued on next page
Table A.7 - continued from previous page
Reactant 1 Reactant 2 Product kforward kreverse
phosphatase3
phosphatase3
phosphatase3
MEK-PP
MEK-PP
MEK-PP
ERK-PP
MEKi-PP
MEKi-PP
MEKi-PP
ERKi-PP
(EGF-EGFR*)2-GAP-Grb2
(EGF-EGFRi*)2-GAP-Grb2
EGFR
(EGF-EGFR*)2
(EGF-EGFR*)2-GAP-Grb2
Proti
(EGF-EGFR*)2-GAP
(EGF-EGFR*)2-GAP-SHC
(EGF-EGFR*)2-GAP-SHC*
(EGF-EGFR*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-SHC*-Grb2
(EGF-EGFR*)2-GAP-SHC*-Grb2
(EGF-EGFRi*)2-GAP-SHC*-Grb2
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
phosphatase2
phosphatase2
phosphatase2
phosphatase2
phosphatase2
phosphatase2
phosphatase2
phosphatase2
(EGF-EGFR*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
ERKi-P
ERKi-P
ERK
ERK
ERK-P
ERK-P
MEK-PP
ERK
ERKi-P
ERKi-P
MEKi-PP
Prot
Proti
0
0
0
0
0
0
0
0
Prot
Proti
0
Prot
Proti
0
Prot
Proti
0
Prot
Proti
0
Prot
Proti
0
Prot
Proti
0
Prot
Prodi
MEK-PP
MEK-P
MEK-P
MEK
MEKi-PP
MEKi-P
MEKi-P
MEK
ERK-PP
ERKi-PP
ERK-PP
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ERKi-PP-phosphatase3
ERKi-P-phosphatase3
ERKi-P-phosphatase3
ERK-MEK-PP
ERK-MEK-PP
ERK-P-MEK-PP
ER:K-P-MEK-PP
ERKi-MEKi-PP
ERKi-MEKi-PP
ERKi-P-MEKi-PP
ERKi-P-MEKi-PP
(EGF-EGFR*)2-GAP-Grb2-Prot
(EGP-EGFR*)2-GAP-Grb2-Prot
EGFRi
(EGF-EGFPi*)2
(EGF-EGFRi*)2-GAP-Grb2
Prot
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP-SHC
(EGF-EGFRi*)2-GAP-SHC*
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-Grb2-Sos-Prot
(EGF-EGFR*)2-GAP-Grb2-Sos-Prot
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP-Prot
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP-Prot
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP-Prot
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP-Prot
(EGF-EGFRi*)2-GAP-SHC*-Grb2
(EGF-EGFR*)2-GAP-SHC*-Grb2-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Prot
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Prot
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP-Prot
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP-Prot
MEK-PP-phosphatase2
MEK-PP-phosphatase2
MEK-P-phosphatase2
MEK-P-phosphatase2
MEKi-PP-phosphatase2
MEKi-PP-phosphatase2
MEi-P-phosphatase2
MEKi-P-phosphatase2
(EGF-EGFR*)2-GAP-Grb2-Sos-ERK-PP
(EGF-EGFRi*)2-GAP-Grb2-Sos-ERKi-PP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-ERK-PP
k57 kd57
k58 kd58
k57 kd57
k52 kd44
k53 kd53
k52 kd44
k55 kd55
k52 kd44
k53 kd53
k52 kd44
k55 kd55
k4 kd4
k5 kd5
k6 kd6
k6 kd6
k6 kd6
k15 kd15
k6 kd6
k6 kd6
k6 kd6
k6 kd6
k4 kd4
k5 kd5
k6 kd6
k4 kd4
k5 kd5
k6 kd6
k4 kd4
k5 kd5
k6 kd6
k4 kd4
k5 kd5
k6 kd6
k4 5d4
k5 kd5
k6 kd6
k4 kd4
k5 kd5
k6 kd6
k4 kd4
k5 kd5
k48 kd48
k49 kd49
k50 kd50
k49 kd49
k48 kd48
k49 kd49
k50 kd50
k49 kd49
5126 kd126
k126 kd126
k126 kd126
Continued on next page
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Reactant 1 Reactant 2 Product kforward kreverse
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
ERK-PP
ERKi-PP
ERK-PP
ERK-PP
ERK-PP
ERKi-PP
ERKi-PP
ERKi-PP
Phosphatasel
Phosphatasel
Phosphatasel
Phosphatasel
Raf*
MEK-P
MEK-P
MEK-PP
Rafi*
MEKi-P
MEKi-P
MEKi-PP
Ras-GTP
Ras-GTP*
Ras-GTPi
Ras-GTPi*
(EGF-EGFR*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2
(EGF-EGFR*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
EGFR
EGF-EGFR
(EGF-EGFR)2
EGFRi
EGF-EGFRi
(EGF-EGFRi)2
0
(EGF-EGFR*)2
(EGF-EGFR*)2-GAP
(EGF-EGFR*)2-GAP-Grb2
ERKi-PP
Sos
Sos
0
0
Sosi
0
0
Sosi
Raf*
Raf
Raf is
Raf
MEK
Raf*
Raf*
Raf*
MEK
Rafi*
Raf i*
Raf i*
Raf
Raft
Raf
Raf i
Ras-GDP
Ras-GTP
Ras-GDP
Ras-GTP
Ras-GDP
Ras-GTPi
Ras -GDP
Ras-GTPi
GAP
Ras-GTP*
Ras-GDP
Ras-GTP*
Ras-GDP
Ras-GTPi*
Ras-GDP
Ras-GTPi*
Ras-GDP
EGF
EGF-EGFR
0
EGFi
EGF-EGFRi
GAP
Grb2
Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-ERKi-PP
Sos-ERK-PP
Sos-ERKi-PP
(EGF-EGFR*)2-GAP-Grb2-Sos-ERK-PP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-ERK-PP
Sos-ERK-PP
(EGF-EGFRi*)2-GAP-Grb2-Sos-ERKi-PP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-ERKi-PP
Sos-ERKi-PP
Raf*-phosphatasel
Raf*-phosphatasel
Rafi*-phosphatasel
Rafi*-phosphatasel
MEK-Raf*
MEK-Raf*
MEK-P-Raf*
MEK-P-Raf*
MEK-Rafi*
MEK-Rafi*
MEK-P-Raf i*
MEK-P-Raf i*
Raf-Ras-GTP
Raf-Ras-GTP
Raf-Ras-GTPi
Raf-Ras-GTPi
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GTP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
EGF-EGFR
(EGF-EGFR)2
(EGF-EGFR*)2
EGF-EGFRi
(EGF-EGFRi)2
(EGF-EGFRi*)2
EGFR
(EGF-EGFR*)2-GAP
(EGF-EGFR*)2-GAP-Grb2
(EGF-EGFR*)2-GAP-Grb2-Sos
k126 kd126
k126 kd126
k126 kd126
k127 kd127
k127 kd127
k127 kd127
k127 kd127
k127 kd127
k127 kd127
k42 kd42
k43 kd43
k42 kd42
k43 kd43
k44 kd52
k45 kd45
k44 kd52
k47 kd47
k44 kd52
k45 kd45
k44 kd52
k47 kd47
k28 kd28
k29 kd29
k28 kd28
k29 kd29
k18 kd18
k19 kd19
k18 kd18
k19 kd19
k18 kd18
k19 kd19
k18 kd18
k19 kd19
k8 kd8
k20 kd20
k21 kd21
k20 kd20
k21 kd21
k20 kd20
k21 kd21
k20 kd20
k21 kd21
k1 kd1
k2 kd2
k3 kd3
k10b kd10
k2 kd2
k3 kd3
k13 kd13
k8 kd8
k16 kd63
k17 kd17
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Reactant 1 Reactant 2 Product kforward kreverse
(EGF-EGFR*)2-GAP
(EGF-EGFR*)2-GAP-SHC
(EGF-EGFR*)2-GAP-SHC*
(EGF-EGFR*)2-GAP-SHC*-Grb2
(EGF-EGFR*)2-GAP
Grb2-Sos
(EGF-EGFR*)2-GAP
Grb2
Shc*
(EGF-EGFR*)2-GAP
Grb2
(EGF-EGFR*)2-GAP
Shc*-Grb2
(EGF-EGFR*)2-GAP-SHC*
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP-Grb2
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP-SHC
(EGF-EGFRi*)2-GAP-SHC*
(EGF-EGFRi*)2-GAP-SHC*-Grb2
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP-SHC*
Ras-GTP
Ras-GDP
Ras-GTPi
Ras-GDP
Ras-GTP*
Ras-GDP
Ras-GTPi*
Ras-GDP
Sosi
phosphatase3mRNA
phosphatase3mRNA
0
phosphatase3mRNA-cyt
phosphatase3mRNA
phosphatase3mRNA
phosphatase3mRNA-cyt
Shc
0
Grb2
Sos
Shc*-Grb2-Sos
Shc*
Grb2-Sos
Sos
0
Shc*
Shc*
Shc*-Grb2
Sos
Grb2-Sos
Grb2
Sos
Shc
0
Grb2
Sos
Shc*-Grb2-Sos
Grb2-Sos
Shc*
Shc*-Grb2
Grb2-Sos
GAP
GAP
GAP
GAP
GAP
GAP
GAP
GAP
0
ERK-PP
ERKi-PP
0
phosphatase3
0
0
0
(EGF-EGFR*)2-GAP-SHC
(EGF-EGFR*)2-GAP-SHC*
(EGF-EGFR*)2-GAP-SHC*-Grb2
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
Shc*-Grb2-Sos
(EGF-EGFR*)2-GAP-Grb2-Sos
Grb2-Sos
She
(EGF-EGFR*)2-GAP-SHC*
Shc*-Grb2
(EGF-EGFR*)2-GAP-SHC*-Grb2
Shc*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC
(EGF-EGFRi*)2-GAP-SHC*
(EGF-EGFRi*)2-GAP-SHC*-Grb2
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*
(EGF-EGFRi*)2-GAP-SHC*-Grb2
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
GAP-Ras-GTP
GAP-Ras-GTP
GAP-Ras-GTPi
GAP-Ras-GTPi
GAP-Ras-GTP*
GAP-Ras-GTP*
GAP-Ras-GTPi*
GAP-Ras-GTPi*
Sos
ERK-PP
ERKi-PP
phosphatase3
phosphatase3mRNAcyt
phosphatase3mRNA-cyt
0
0
Table A.8: Expanded EGFR model Parameters.
Parameter Value
kO 0.00 X 10+00
kd0 0.00 x 10+00
k1 3.00 X 10+
0 7
kdI 3.84 x 10-03
k0b 5.43 x 10-02
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k22
k23
k16
k25
k32
k33
k34
k35
k36
k37
k16
k37
k40
k41
k16
k17
k22
k23
k16
k25
k32
k34
k37
k37
k41
k300
0
k300
0
k300
0
k300
0
k300
0
0
k1001
0
k1004
k1005
k1005
kd22
kd23
kd24
kd25
kd32
kd33
kd34
kd35
kd36
kd37
kd24
kd37
kd40
hd41
kd63
kd17
kd22
kd23
kd24
kd25
kd32
kd34
kd37
kd37
kd41
kd20
kd21
kd20
kd21
kd20
kd21
kd20
kd21
0
k1000
k1000
k1002
k1003
0
0
0
Table A.8 continued from previous page
Parameter Value
kd1O 1.10 X 10-02
k2 1.66 x 10-05
kd2 1.00 X 10-01
k3 1.00 x 10+00
kd3 1.00 X 10-02
k4 1.73 x 10-07
kd4 1.66 x 10-03
kd5 1.48 x 10-02
k5 0.00 X 10+00
k6 5.00 x 10-04
kd6 5.00 x 10-03
k8 1.66 x 10-06
kd8 2.00 x 10-01
k13 2.17 x 10+00
kd13 0.00 x 10+00
ki5 1.00 X 10+04
kd15 0.00 X 10+00
k16 1.66 x 10-05
kd16 0.00 x 10+00
k17 1.66 x 10-05
kd17 6.00 x 10-02
k18 2.50 x 10-05
kd18 1.30 x 10+00
k19 1.66 x 10-07
kd19 5.00 x 10-01
k20 3.50 x 10-06
kd20 4.00 x 10-01
k21 3.66 x 10-07
kd2l 2.30 x 10-02
k22 3.50 x 10-05
kd22 1.00 X 10-01
k23 6.00 X 10+00
kd23 6.00 x 10-02
kd24 5.50 x 10-01
k25 1.66 X 10-05
kd25 2.14 x 10-02
k28 1.66 x 10-06
kd28 5.30 x 10-03
k29 1.17 x 10-06
kd29 1.00 X 10+00
kd32 1.00 X 10-01
k32 4.00 x 10-07
kd33 2.00 x 10-01
k33 3.50 x 10-05
kd34 3.00 x 10-02
k34 7.50 x 10-06
kd35 1.50 x 10-03
k35 7.50 x 10-06
k36 5.00 x 10-03
kd36 0.00 X 10+00
kd37 3.00 x 10-01
k37 1.50 X 10-06
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Parameter Value
k40 5.00 x 10-05
kd40 6.40 x 10-02
k41 5.00 x 10-05
kd41 4.29 x 10-02
k42 1.18 X 10-04
kd42 2.00 x 10-01
kd43 1.00 X 10+00
k43 0.00 X 10+00
kd44 1.83 x 10-02
kd45 3.50 X 10+00
k45 0.00 X 10+00
kd47 2.90 X 10+00
k47 0.00 X 10+00
k48 2.38 x 10-05
kd48 8.00 X 10-01
kd49 5.80 x 10-02
k49 0.00 X 10+00
k50 4.50 x 10 -07
kd50 5.00 x 10-01
kd52 3.30 x 10-02
kd53 1.60 x 10+01
k53 0.00 X 10+00
kd55 5.70 X 10+00
k55 0.00 X 10+00
kd56 6.00 x 10-01
k56 2.35 x 10-05
kd57 2.46 x 10~01
k57 0.00 X 10+00
k58 8.33 x 10-06
kd58 5.00 x 10-01
k52 8.91 X 10-05
k44 1.96 x 10-05
k60 5.50 x 10-03
kd60 0.00 X 10+00
k61 6.70 X 10-04
kd61 0.00 X 10+00
kd63 2.75 x 10-01
k63 0.00 x 10+00
k126 1.66 x 10-07
kd126 2.00 x 10+00
kd127 1.00 x 10-04
k127 0.00 X 10+00
k200 2.17 x 10+00
kd214 1.81 X 10-04
kd222 1.97 x 10-04
kd224 8.25 x 10-05
kd226 3.01 x 10-05
kd231 3.00 X 10-05
kd230 5.43 X 10-05
k300 1.00 X 10-06
k1000 1.00 X 10+00
k1001 1.00 X 10+02
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Parameter Value
k1002 1.00 X 10-05
k1003 1.00 x 10-06
k1004 1.39 x 10-04
k1005 4.17 x 10-04
Table A.9: Expanded EGFR model Species.
Species
EGF
EGFR
EGF-EGFR
(EGF-EGFR)2
(EGF-EGFR*)2
EGFRi
(EGF-EGFR*)2-GAP-Grb2-Prot
(EGF-EGFRi*)2
Proti
EGF-EGFRi
(EGF-EGFRi)2
Prot
GAP
(EGF-EGFR*)2-GAP
EGFi
(EGF-EGFRi*)2-GAP
(EGF-EGFRi*)2-GAP-Grb2
(EGF-EGFRi*)2-GAP-Grb2-Sos
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-Grb2-Sos-Ras-GTP
Grb2
(EGF-EGFR*)2-GAP-Grb2
Sos
(EGF-EGFR*)2-GAP-Grb2-Sos
Ras-GDP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP
Ras-GTP
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP
Grb2-Sos
Shc
(EGF-EGFR*)2-GAP-SHC
(EGF-EGFR*)2-GAP-SHC*
(EGF-EGFR*)2-GAP-SHC*-Grb2
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
Shc*-Grb2-Sos
Shc*-Grb2
Shc*
Raf
Ra-f-Ras-GTP
Ras-GTP*
Initial Concentration Is Input
8.00 x 10-09 yes
5.00 X 10+04 no
0.00 x 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 x 10+00 no
0.00 x 10+00
0.00 X 10+00 no
0.00 X 10+00 no
0.00 x 10+00 no
8.10 X 10+04 no
1.20 X 10+04 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 x 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 X 10+110  no
0.00 X 10+00 n1o
1.10 X 10+04
0.00 X 10+00 no
2.63 X 10+04 no
0.00 X 10+00 no
7.20 x 10+04 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
4.00 x 10+04
1.01 X 10+05 no
0.00 x 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 X 10+00 no
0.00 X 10+00
0.00 X 10+00 no
0.00 X 10+00 no
4.00 X 10+04 no
0.00 X 10+00 no
0.00 X 10+00 ro
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Species
Phosphatase1
Raf*
Raf*-phosphatasel
MEK
MEK-Raf*
MEK-P
MEK-P-Raf*
MEK-PP
MEK-PP-phosphatase2
phosphatase2
MEK-P-phosphatase2
ERK
ERK-MEK-PP
ERK-P
ERK-P-MEK-PP
ERK-PP
phosphatase3
ERK-PP-phosphatase3
ERK-P-phosphatase3
(EGF-EGFRi*)2-GAP-SHC
(EGF-EGFRi*)2-GAP-SHC*
(EGF-EGFRi*)2-GAP-SHC*-Grb2
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GDP
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-Ras-GTP
Ras-GTPi
Raf-Ras-GTPi
Ras-GTPi*
Rafi*
Rafi*-phosphatasel
MEK-Raf i*
MEKi-P
MEK-P-Rafi*
MEKi-PP
MEKi-PP-phosphatase2
MEKi-P-phosphatase2
ERKi-MEKi-PP
ERKi-P
ERKi-P-MEKi-PP
ERKi-PP
ERKi-PP-phosphatase3
ERKi-P-phosphatase3
(EGF-EGFR*)2-GAP-Grb2-Sos-Prot
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GDP-Prot
(EGF-EGFR*)2-GAP-Grb2-Sos-Ras-GTP-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GDP-Prot
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-Ras-GTP-Prot
(EGF-EGFR*)2-GAP-Grb2-Sos-ERK-PP
(EGF-EGFRi*)2-GAP-Grb2-Sos-ERKi-PP
(EGF-EGFR*)2-GAP-SHC*-Grb2-Sos-ERK-PP
Initial Concentration
4.00 x 10+04
0.00 X 10+00
0.00 x 10+00
2.10 x 10+07
0.00 x 10+00
0.00 x 10+00
0.00 X 10+00
0.00 x 10+00
0.00 x 10+00
4.00 x 10+04
0.00 x 10+00
2.21 x 10+07
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
1.00 x 10+07
0.00 x 10+00
0.00 x 10+00
0.00 X 10+00
0.00 x 10+00
0.00 X 10+00
0.00 x 10+00
0.00 x 1 0 +00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 X 10+00
0.00 x 10+00
0.00 x 10+00
0.00 X 10+00
0.00 X 10+00
0.00 X 10+00
0.00 x 10+00
0.00 X 10+00
0.00 x 10+00
0.00 X 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
0.00 x 10+00
Continued o
Is Input
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
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Species Initial Concentration Is Input
(EGF-EGFRi*)2-GAP-SHC*-Grb2-Sos-ERKi-PP 0.00 x 10+00 no
Sos-ERK-PP 0.00 x 10+00 nio
Sos-ERKi-PP 0.00 x 10+00 no
Sosi 0.00 x 10+00 no
GAP-Ras-GTP 0.00 x 10+00 no
GAP-Ras-GTPi 0.00 x 10+00 no
GAP-Ras-GTP* 0.00 x 10+00 no
GAP-Ras-GTPi* 0.00 x 10+00 no
phosphatase3mRNA 0.00 x 10+00 no
phosphatase3mRNA-cyt 0.00 x 10+00 no
A.3 Four Models of a Mitogen Activated Protein Kinase Reac-
tion
Table A.10: MAPK Distributive-Kinase Distributive-Phosphatase Model Reactions.
Reactant 1 Reactant 2 Product kforward kreverse
E S E:S kion kioff
E M E:S 0 kicat
E M E:M k2on k2off
E D E:M 0 k2cat
P D P:D k3on k3off
P M P:D 0 k2cat
P M P:M k4on k4off
P S P:M 0 k4cat
Table A.11: MAPK Distributive-Kinase Distributive-Phosphatase Model Parameters
Parameter Value
kion 2.00 x 10-02
kioff 1.00 x 10+00
kicat 1.00 x 10-02
k2on 3.20 x 10-02
k2off 1.00 x 10+00
k2cat 1.50 x 10+01
k3on 4.50 x 10-02
k3off 1.00 x 10+00
k3cat 9.20 x 10-02
k4on 1.00 X 10-02
k4off 1.00 x 10+00
k4cat 5.00 x 10-01
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Table A.12: MAPK (All) Model Species
Species Initial Concentration Is Input
E 1.00 X 10+00 yes
S 2.00 x 10+00 no
E:S 0.00 X 10+00 no
M 0.00 X 1 0 +00 no
E:M 0.00 X 10+00 no
D 0.00 X 10+00 no
P 1.00 X 10+00 no
P:D 0.00 X 10+00 no
P:M 0.00 X 10+00 no
A.4 Mass Action Model of E. coli Central Central
Carbon Metabolism
Table A. 13: E coli Model Reactions.
Reactant 1 Reactant 2 Product kforward kreverse
F6P Mur Mur:F6P Mur-kO 0
F6P Mur Mur:F6P 0 Mur-ki
murine Mur Mur:F6P 0 Mur-k2
0 0 GAP Tryp-ksynth 0
0 0 PYR Tryp-ksynth 0
0 0 PYR Met ksynth 0
RIBU5P RuSP Ru5P:RIBU5P Ru5P-k0 0
RIBU5P Ru5P Ru5P:RIBU5P 0 Ru5P-kl
Ru5P:RIBUSP 0 Ru5P:XYL5P Ru5P-k2 0
Ru5P:XYL5P 0 Ru5P:RIBU5P Ru5P-k3 0
XYL5P Ru5P Ru5P:XYL5P 0 Ru5P-k4
XYL5P Ru5P Ru5P:XYL5P Ru5P-k5 0
RIBU5P R5PI R5P1:RIBUSP RSP1_k0 0
RIBU5P RSP1 R5P1:RIBU5P 0 R5P1.k1
RSP1:RIBU5P 0 R5P1:RIB5P R5P1_k2 0
R5P1:RIB5P 0 R5P1:RIBU5P R5P1_k3 0
RIB5P R5P1 R5P1:RIBSP 0 R5P1_k4
RIBSP R5P1 R5P1:RIB5P R5P1_k5 0
RIB5P TKa TKa:RIBSP TKa-kO 0
RIB5P TKa TKa:RIB5P 0 TKa-ki
TKa:RIB5P XYL5P TKa:RIB5P:XYL5P TKa-k2 0
TKa:RIB5P XYL5P TKa:RIB5P:XYL5P 0 TKa-k3
TKa:RIBSP:XYL5P 0 TKa:SED7P:GAP TKa-k4 0
TKa:SED7P:GAP 0 TKa:RIB5P:XYL5P TKa-k5 0
TKa:GAP SED7P TKa:SED7P:GAP TKa-k6 0
TKa:GAP SED7P TKa:SED7P:GAP 0 TKa-k7
GAP TKa TKa:GAP TKa-k8 0
GAP TKa TKa:GAP 0 TKa-k9
XYL5P TKb TKb:XYLSP TKb-kO 0
XYL5P TKb TKb:XYL5P 0 TKb-ki
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Reactant 1 Reactant 2 Product kforward kreverse
TKb:XYL5P E4P TKb:XYL5P:E4P TKbk2 0
TKb:XYL5P E4P TKb:XYL5P:E4P 0 TKb_k3
TKb:XYL5P:E4P 0 TKb:F6P:GAP TKb_k4 0
TKb:F6P:GAP 0 TKb:XYLSP:E4P TKb-k5 0
TKb:GAP F6P TKb:F6P:GAP TKb_k6 0
TKb:GAP F6P TKb:F6P:GAP 0 TKbk7
GAP TKb TKb:GAP TKb_k8 0
GAP TKb TKb:GAP 0 TKbk9
GAP TA TA:GAP TA_kO 0
GAP TA TA:GAP 0 TAk1
TA:GAP SED7P TA:GAP:SED7P TAk2 0
TA:GAP SED7P TA:GAP:SED7P 0 TA_k3
TA:GAP:SED7P 0 TA:E4P:F6P TA-k4 0
TA:E4P:F6P 0 TA:GAP:SED7P TA-k5 0
TA:F6P E4P TA:E4P:F6P TAk6 0
TA:F6P E4P TA:E4P:F6P 0 TA-k7
F6P TA TA:F6P TA_k8 0
F6P TA TA:F6P 0 TA.k9
RIB5P RPPK RPPK:RIB5P RPPK-kO 0
RIB5P RPPK RPPK:RIB5P 0 RPPK-ki
nucleotide RPPK RPPK:RIB5P 0 RPPK-k2
G3PDH DHAP G3PDH:DHAP G3PDH-k0 0
G3PDH DHAP G3PDH:DHAP 0 G3PDHk1
glycerol G3PDH G3PDH:DHAP 0 G3PDH-k2
SerSynth PG3 SerSynth:PG3 SerSynth-k0 0
SerSynth PG3 SerSynth:PG3 0 SerSynth-kl
SerSynth serine SerSynth:PG3 0 SerSynth-k2
Synth1 PEP Synthl:PEP Synth1.k0 0
Synthi PEP Synthl:PEP 0 Synthlk1
cho-mur Synth1 Synthl:PEP 0 Synthlk2
Synth2 PYR Synth2:PYR Synth2_k0 0
Synth2 PYR Synth2:PYR 0 Synth2_kl
Synth2 ile Synth2:PYR 0 Synth2.k2
G6PDH G6P G6PDH:G6P G6PDHk0 0
G6PDH G6P G6PDH:G6P 0 G6PDHRk1
G6PDH PG G6PDH:G6P 0 G6PDH-k2
PDGH PG PDGH:PG PDGHJkO 0
PDGH PG PDGH:PG 0 PDGH-k1
RIBU5P PDGH PDGH:PG 0 PDGH-k2
DHAP TIS TIS:DHAP TIS-k0 0
DHAP TIS TIS:DHAP 0 TIS-ki
TIS:DHAP 0 TIS:GAP TIS-k2 0
TIS:GAP 0 TIS:DHAP TIS-k3 0
GAP TIS TIS:GAP 0 TIS-k4
GAP TIS TIS:GAP TISk5 0
PGluMu PG3 PGiuMu:PG3 PGluMu-k0 0
PGluMu PG3 PGluMu:PG3 0 PGluMu-ki
PGluMu:PG3 0 PGluMu:PG2 PGluMu-k2 0
PGluMu:PG2 0 PGluMu:PG3 PGluMu-k3 0
PGluMu PG2 PGluMu:PG2 0 PGluMu-k4
PGluMu PG2 PGluMu:PG2 PGluMu-k5 0
PG2 Eno Eno:PG2 Eno-k0 0
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Reactant 1
PG2
Eno:PG2
Eno:PEP
PEP
PEP
G6P
G6P
PGM:G6P
PGM:G1P
G1P
G1P
GAPDH
GAPDH
GAPDH:GAP
GAPDH:PGP
GAPDH
GAPDH
PGPD
PGP
PGK:PGP
PGK:PG3
PG3
PG3
Aldolase
Aldolase
Aldolase:FDP
Aldolase:DHAP:GAP
Aldolase:DHAP P
Aldolase:DHAP
Aldolase:
Aldolase
PYR
PYR
PDH:PYR_1
PDH:PYR_1
PDH:PYR_2
PDH:PYR_2
PDH:PYR_3
PDH:PYR_3
accoa
PDH:PYR_1
PDH:PYR_2
PDH:PYR_3
DHAPSOO
DHAPSOO
DHAPSOO
DHAPSOO
DRAPS01
DHAPSO1
DHAPSO1
DHAPSO1
DHAPSO2
Reactant 2
Eno
0
0
Eno
Eno
PGM
PGM
0
0
PGM
PGM
GAP
GAP
0
0
PGP
PGP
PGK
PGK
0
0
PGK
PGK
FDP
FDP
0
0
GAP
GAP
DRAP
DHAP
PDH
PDH
PYR
PYR
PYR
PYR
PYR
PYR
PDH
accoa
accoa
accoa
E4P
E4P
PEP
PEP
E4P
E4P
PEP
PEP
E4P
Product
Eno:PG2
Eno:PEP
Eno:PG2
Eno:PEP
Eno:PEP
PGM: G6P
PGM: G6P
PGM:G1P
PGM:G6P
PGM: G1P
PGM: G1P
GAPDH:GAP
GAPDH:GAP
GAPDH:PGP
GAPDH:GAP
GAPDH:PGP
GAPDH:PGP
PGK:PGP
PGK:PGP
PGK:PG3
PGK:PGP
PGK:PG3
PGK:PG3
Aldolase:FDP
Aldolase:FDP
Aldolase:DHAP:GAP
Aldolase:FDP
Aldolase:DHAP:GAP
Aldolase:DHAP:GAP
Aldolase:DHAP
Aldolase:DHAP
PDH:PYR_1
PDH:PYR_1l
PDH:PYR_2
PDH:PYR_2
PDH:PYR_3
PDH:PYR_3
PDH:PYR_4
PDH:PYR_4
PDH:PYR_1
PDH:PYR_2
PDH:PYR_3
PDH:PYR_4
DHAPSO
DRAPS10
DXAPSO1
DHAPS01
DHAPS11
DHAPS11
DHAPSO2
DHAPSO2
DHAPS12
kforward kreverse
0 Eno-kI
Eno-k2 0
Eno-k3 0
0 Eno-k4
Eno-k5 0
PGMkO 0
0 PGM-k1
PGM-k2 0
PGM-k3 0
0 PGM-k4
PGM-k5 0
GAPDHkO 0
0 GAPDH-k1
GAPDH-k2 0
GAPDH-k3 0
0 GAPDHLk4
GAPDH-k5 0
PGK-kO 0
0 PGKki
PGKk2 0
PGK-k3 0
0 PGKk4
PGKk5 0
AldolasejkO 0
0 Aldolase-kl
Aldolasejk2 0
Aldolasek3 0
0 Aldolase-k4
Aldolase-k5 0
0 Aldolasejk6
Aldolase-k7 0
PDH-kO 0
0 PDHkI
PDH-k2 0
0 PDHk3
PDHk4 0
0 PDHk5
PDH-k6 0
0 PDH-k7
0 PDHJk8
0 PDHk9
0 PDH-k1O
0 PDH-kI1
DHAPS-kO 0
0 DAPS-ki
DRAPS-k2 0
0 DAPS-k3
DAPS-k4 0
0 DAPS-k5
DRAPSk6 0
0 DRAPS-k7
DAPS-k8 0
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DEAPSO2 E4P DRAPS12 0 DRAPS-k9
DHAPS1O E4P DRAPS20 DRAPS-k10 0
DHAPS10 E4P DHAPS20 0 DHAPS-k11
DHAPS10 PEP DRAPS11 DHAPS_k12 0
DHAPS10 PEP DHAPS11 0 DHAPSk13
DHAPS11 E4P DRAPS21 DHAPSk14 0
DHAPS11 E4P DHAPS21 0 DHAPSk15
DHAPS11 PEP DHAPS12 DHAPS-k16 0
DHAPS11 PEP DHAPS12 0 DHAPSk17
DHAPS12 E4P DHAPS22 DHAPS-k18 0
DHAPS12 E4P DHAPS22 0 DHAPS-k19
DHAPS20 PEP DRAPS21 DHAPSk20 0
DHAPS20 PEP DHAPS21 0 DHAPS-k21
DRAPS21 PEP DRAPS22 DHAPSk22 0
DHAPS21 PEP DHAPS22 0 DHAPSk23
DHAPS11 aaa DRAPS22 0 DHAPS-k24
PEPCxylase0 FDP PEPCxylasel PEPCxylase-kO 0
PEPCxylaseO FDP PEPCxylasei 0 PEPCxylase-kl
PEPCxylaseO PEP PEPCxylase0A PEPCxylase-k2 0
PEPCxylaseO PEP PEPCxylaseOA 0 PEPCxylase-k3
PEPCxylaseO oaa PEPCxylaseOA 0 PEPCxylase-k4
PEPCxylasel FDP PEPCxylase2 PEPCxylase-kS 0
PEPCxylasel FDP PEPCxylase2 0 PEPCxylase-k6
PEPCxylasel PEP PEPCxylaselA PEPCxylasejk7 0
PEPCxylasel PEP PEPCxylaselA 0 PEPCxylasejk8
PEPCxylasei oaa PEPCxylaselA 0 PEPCxylasejk9
PEPCxylase2 FDP PEPCxylase3 PEPCxylasejk1O 0
PEPCxylase2 FDP PEPCxylase3 0 PEPCxylase-kll
PEPCxylase2 PEP PEPCxylase2A PEPCxylase-k12 0
PEPCxylase2 PEP PEPCxylase2A 0 PEPCxylase-k13
PEPCxylase2 oaa PEPCxylase2A 0 PEPCxylase-k14
PEPCxylase3 FDP PEPCxylase4 PEPCxylase-klS 0
PEPCxylase3 FDP PEPCxylase4 0 PEPCxylase-k16
PEPCxylase3 PEP PEPCxylase3A PEPCxylasejkl7 0
PEPCxylase3 PEP PEPCxylase3A 0 PEPCxylase-k18
PEPCxylase3 oaa PEPCxylase3A 0 PEPCxylase-k19
PEPCxylase4 PEP PEPCxylase4A PEPCxylase-k20 0
PEPCxylase4 PEP PEPCxylase4A 0 PEPCxylasek2l
PEPCxylase4 oaa PEPCxylase4A 0 PEPCxylasek22
GIPATO FDP G1PAT1 G1PAT-kO 0
G1PATO FDP G1PATI 0 G1PAT-ki
GIPATI FDP G1PAT2 G1PAT-k2 0
G1PATI FDP G1PAT2 0 G1PATk3
G1PATO G1P G1PATOA G1PAT-k4 0
G1PATO G1P GiPATOA 0 G1PAT-k5
G1PAT1 GP GIPAT1A G1PAT-k6 0
G1PAT1 GP G1PAT1A 0 G1PAT-k7
G1PAT2 GP G1PAT2A G1PAT-k8 0
G1PAT2 GIP G1PAT2A 0 G1PAT-k9
PolySac GIPATO G1PATOA 0 G1PATk1O
PolySac GIPATI GIPAT1A 0 G1PAT-k11
PolySac G1PAT2 G1PAT2A 0 G1PATk12
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G6P PGI PGI:G6P PGIk0 0
G6P PGI PGI:G6P 0 PGI_ki
F6P PGI PGI:G6P 0 PGI_k2
F6P PGI PGI:F6P PGI-k3 0
F6P PGI PGI:F6P 0 PGI-k4
G6P PGI PGI:F6P 0 PGI-k5
PGI PG PGI:PG PGI~k6 0
PGI PG PGI:PG 0 PGI~k7
PGI:PG PG PGI:PG:PG PGI-k8 0
PGI:PG PG PGI:PG:PG 0 PGI-k9
PGI:PG F6P PGI:PG:F6P PGI-k1O 0
PGI:PG F6P PGI:PG:F6P 0 PGI-k11
PGI:PG G6P PGI:PG:F6P 0 PGI_ki2
PGI:PG G6P PGI:PG:G6P PGI_k13 0
PGI:PG G6P PGI:PG:G6P 0 PGI-k14
PGI:PG F6P PGI:PG:G6P 0 PGI_k15
PFK_0_0 F6P PFK.1.0 PFK_k0 0
PFK_I_0 F6P PFK_2_0 PFK_kI 0
PFK_2_0 F6P PFK_3.0 PFK_k2 0
PFK-3.0 F6P PFK_4_0 PFKJk3 0
PFK.4.0 F6P PFK_5_0 PFKk4 0
PFK_5_0 F6P PFK6.-0 PFK_k5 0
PFK_6.0 F6P PFKJ7_0 PFKk6 0
PFK_7_0 F6P PFK.8.0 PFK-k7 0
PFK_8.0 F6P PFK_9.0 PFK-k8 0
PFK-9.0 F6P PFK_10_0 PFKk9 0
PFK.10.0 P6P PFK_11_0 PFKk1O 0
PFK_0_0 F6P PFK_1.0 0 PFK_k11
PFK_1.0 F6P PFK_2_0 0 PFK_k12
PFK_2_0 F6P PFK_3_0 0 PFK-k13
PFK.3_0 F6P PFK_4_0 0 PFK-k14
PFK_4_0 F6P PFK-5.0 0 PFKk15
PFK_5_0 F6P PFK_6.0 0 PFKk16
PFK_6_0 F6P PFK_7.0 0 PFKk17
PFK_7.0 F6P PFK_8_0 0 PFKk18
PFK_8_0 F6P PFK_9.0 0 PFKk19
PFK_9_0 F6P PFK_10_0 0 PFK_k20
PFK_10_0 F6P PFK_1I_ 0 PFK-k21
PFK_0_0 FDP PFK_1_0 0 PFKk22
PFK_1_0 FDP PFK.2_0 0 PFKk23
PFK_2_0 FDP PFK_3_0 0 PFKk24
PFK_3_0 FDP PFK.4.0 0 PFKk25
PFK.4.0 FDP PFK_5_0 0 PFKk26
PFK_5_0 FDP PFK.60. 0 PFK-k27
PFK_6_0 FDP PFK_7.0 0 PFKk28
PFK.7.0 FDP PFK_8_0 0 PFK_k29
PFK.8.0 FDP PFK_9_0 0 PFK_k30
PFK_9_0 FDP PFK.10_0 0 PFKk31
PFK_10.0 FDP PFK_11.0 0 PFKk32
PFK_0_0 PEP PFK_0_1 PFK-k33 0
PFKI_ PEP PFK..2 PFK_k34 0
PFK_0_2 PEP PFK_0_3 PFK_k35 0
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PFK.0.3 PEP PFK.0.4 PFKk36 0
PFK_0_0 PEP PFK0.1 0 PFK_k37
PFK_0.1 PEP PFK_0_2 0 PFKk38
PFK.0.2 PEP PFK_0_3 0 PFKk39
PFK_0_3 PEP PFK_0.4 0 PFK-k40
PK00 PEP PK10 PK-k0 0
PK10 PEP PK20 PKkI 0
PK20 PEP PK30 PK-k2 0
PK30 PEP PK40 PK-k3 0
PK01 PEP PK11 PK_k4 0
PK11 PEP PK21 PK-k5 0
PK21 PEP PK31 PK_k6 0
PK31 PEP PK41 PK_k7 0
PK00 PEP PK10 0 PK_k8
PK10 PEP PK20 0 PK_k9
PK20 PEP PK30 0 PK_k1O
PK30 PEP PK40 0 PK-k1i
PK01 PEP PK11 0 PK_k12
PK11 PEP PK21 0 PK-k13
PK21 PEP PK31 0 PK_k14
PK31 PEP PK41 0 PK-kI5
PK00 PYR PK10 0 PK_k16
PK10 PYR PK20 0 PK-k17
PK20 PYR PK30 0 PK_k18
PK30 PYR PK40 0 PK_k19
PK01 PYR PK11 0 PK_k20
PK11 PYR PK21 0 PK_k21
PK21 PYR PK31 0 PKk22
PK31 PYR PK41 0 PK_k23
PK00 FDP PK01 PK_k24 0
PK00 FDP PK01 0 PK_k25
PEP PTS PTS:PEP PTS_kO 0
PEP PTS PTS:PEP 0 PTS_ki
PTS:PEP GlcEx PTS:GlcEx:PEP PTSk2 0
PTS:PEP GlcEx PTS:GlcEx:PEP 0 PTS_k3
PTS:G6P PYR PTS:GlcEx:PEP 0 PTS-k4
G6P PTS PTS:G6P 0 PTSk5
PYR PTS PTS:PYR PTSk6 0
PYR PTS PTS:PYR 0 PTSk7
G6P PTS PTS:I1 PTSk8 0
G6P PTS PTS:I1 0 PTS_k9
PTS:I1 G6P PTS:I2 PTS_kO 0
PTS:I1 G6P PTS:I2 0 PTS_k1
PTS:12 G6P PTS:I3 PTSk12 0
PTS:I2 G6P PTS:I3 0 PTS_k13
PTS:I3 G6P PTS:I4 PTS-k14 0
PTS:I3 G6P PTS:I4 0 PTS115
PTS:PEP G6P PTS:PEP:I1 PTS-k16 0
PTS:PEP G6P PTS:PEP:I1 0 PTSk17
PTS:PEP:I1 G6P PTS:PEP:I2 PTSk18 0
PTS:PEP:I1 G6P PTS:PEP:I2 0 PTS-k19
PTS:PEP:I2 G6P PTS:PEP:I3 PTS-k20 0
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Parameter Value
1.0000000000000000 X 10e+06
2.1432425069066049 X 10e+1
1.3523049253249044 x 1 0 e+10
3.7515064123159544 x 1oe+04
1.3272251897466273 X 10e+04
5.2480865482485516 X 10e+05
5.5142136973924341 X 1 0 e+05
1.5931625876649143 X 1 0 e+05
1.0000000000000000 X 1 0 e+06
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Aldolasejk0
Aldolaseki
Aldolase-k2
Aldolase-k3
Aldolase-k4
Aldolasek5
Aldolasek6
Aldolasejk7
DHAPS-k0
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Reactant 1
PTS:PEP:12
PTS:PEP:13
PTS:PEP:13
PTS:PYR
PTS:PYR
PTS: PYR: I I
PTS:PYR:11
PTS:PYR:12
PTS:PYR:12
PTS:PYR:13
PTS:PYR:13
PTS:GlcEx:PEP
PTS:GlcEx:PEP
PTS:GlcEx:PEP:1
PTS:GlcEx:PEP:1
PTS:GlcEx:PEP:12
PTS:GlcEx:PEP:12
PTS:GlcEx:PEP:13
PTS:GlcEx:PEP:13
PEP
G6P
PYR
F6P
GaP
PG
FDP
SED7P
GAP
E4P
XYL5P
RIB5P
DHAP
PGP
PG3
PG2
RIBU5P
Reactant 2
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
G6P
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Product
PTS:PEP:I3
PTS:PEP:14
PTS:PEP:14
PTS: PYR: I I
PTS: PYR: I I
PTS:PYR:12
PTS: PYR: 12
PTS: PYR: 1
PTS:PYR:13
PTS:PYR:14
PTS:PYR:I4
PTS:GlcEx:PEP:I1
PTS:GlcEx:PEP:I1
PTS:GlcEx:PEP:12
PTS:GlcEx:PEP:12
PTS:GlcEx:PEP:13
PTS:GlcEx:PEP:13
PTS:GlcEx:PEP:14
PTS:GlcEx:PEP:14
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
kforward
0
PTSk22
0
PTS-k24
0
PTSk26
0
PTS-k28
0
PTS-k30
0
PTS-k32
0
PTS-k34
0
PTS-k36
0
PTS-k38
0
mu
MU
MU
mu
MU
MU
mu
mu
mu
mu
mu
mu
mu
MU
MU
MU
mu
kreverse
PTS-k21
0
PTSk23
0
PTS-k25
0
PTS-k27
0
PTSk29
0
PTS-k31
0
PTS-k33
0
PTS-k35
0
PTS-k37
0
PTS-k39
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
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DHAPS_kl 9.9817107844498411 X 10e+07
DHAPS-k1O 1.0000000000000000 X 10e+06
DHAPS_kl1 6.6502850754803978 X 10e+02
DHAPS-k12 1.0000000000000000 x 10e+06
DHAPSk13 2.4520481110314261 x 10e+07
DHAPS-k14 1.0000000000000000 x 1 0 e+06
DHAPS-k15 6.6502850754803978 X 10e+02
DHAPS-k16 1.0000000000000000 X 10e+06
DHAPS-k17 2.3599185370351299 x 10+02
DHAPS-k18 1.0000000000000000 X 10e+06
DHAPS-k19 6.6502850754803978 X 10e+02
DHAPSk2 1.0000000000000000 X 10et06
DHAPS-k20 1.0000000000000000 x 10e+06
DHAPS-k21 2.4520481110314261 x 10e+07
DHAPS-k22 1.0000000000000000 X 10e+06
DHAPS-k23 2.3599185370351299 x 10e+02
DHAPS-k24 1.0795300000000000 X 10e+02
DHAPS-k3 2.4520481110314261 x 10e+07
DHAPS-k4 1.0000000000000000 X 10e+06
DHAPS-k5 9.9817107844498411 x 1 0 e+07
DHAPS-k6 1.0000000000000000 X 10e+06
DHAPS-k7 2.3599185370351299 X 10e+02
DHAPSk8 1.0000000000000000 X 10e+06
DHAPS-k9 9.9817107844498411 x 1 0 e+07
Eno-kO 5.0000000101437066 X 10e+06
Eno-ki 2.9218301435726549 x 10e+05
Eno.k2 8.0157979662077827 X 1 0 e+05
Enok3 3.2094787250456912 x 10e+05
Enok4 7.8733175414130231 x 10e+05
Eno-k5 5.0000000093835955 x 1 0 e+06
G1PAT_kO 1.0000000000000000 X 1 0 e+06
G1PAT-k1 2.4304657998068865 x 10e+0
7
G1PAT-k1O 4.9648818237709991 X 1 0 e+00
G1PAT-kI1 5.8436405292493612 X 10e+02
G1PAT_k12 5.8436405292493612 X 1 0 e+02
G1PATk2 1.0000000000000000 X 1 0 e+06
G1PAT-k3 8.2375643149453239 x 10e+05
G1PAT-k4 1.0000000000000000 X 10e+06
G1PAT-k5 3.2424563390401872 X 10e+06
G1PAT-k6 1.0000000000000000 X 10e+06
G1PAT-k7 3.2424563390401872 x 10e+06
G1PAT-k8 1.0000000000000000 X 10e+06
G1PAT-k9 3.2424563390401872 x 10e+06
G3PDH-kO 1.0000000000000000 X 10e+06
G3PDH-kl 9.9998837960008031 X 10e+05
G3PDH-k2 1.1620400014434582 x 10e+01
G6PDH-kO 1.0000000000000000 x 10e+06
G6PDH-kl 1.4399283648649601 x 10e+07
G6PDH-k2 7.1635135039816817 x 1 0 e+02
GAPDH-kO 1.0000000000006935 X 10 e+08
GAPDH-ki 1.4255280428825211 X 10 e+1O
GAPDH-k2 1.6388988054630449 x 10e+08
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GAPDH-k3
GAPDH-k4
GAPDHk5
Met-ksynth
Mur-kO
Mur-k1
Mur-k2
PDGH_kO
PDGH.k1
PDGH-k2
PDH-kO
PDH_kI
PDHk1O0
PDH_k11
PDH-k2
PDHk3
PDH-k4
PDHk5
PDHk6
PDH_k7
PDH-k8
PDH-k9
PEPCxylase-kO
PEPCxylase-kl
PEPCxylase-klO
PEPCxylasekll
PEPCxylase-k12
PEPCxylasek13
PEPCxylasek14
PEPCxylase-k15
PEPCxylase-k16
PEPCxylasek17
PEPCxylase-k18
PEPCxylasek19
PEPCxylase-k2
PEPCxylase-k20
PEPCxylase-k21
PEPCxylase-k22
PEPCxylase-k3
PEPCxylase-k4
PEPCxylase-k5
PEPCxylase66
PEPCxylase-k7
PEPCxylasek8
PEPCxylase-k9
PFKkO
PFK-kl
PFK-klO
PFK-k11
PFKk12
PFK-k13
PFK-k14
179
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1.2911085406985128 x 1 0 e+00
7.7999872389368911 x 1 0e+05
7.5000000000000000 x 10e+10
2.2626999999999999 x 106e03
1.0000000000000000 X 1 0 e+06
9.1257800000000007 x 10e+00
8.7422000000000000 x 106-01
1.0000000000000000 X 10e+06
3.7493441681434162 x 10e+07
6.6131700196873326 x 10e+03
1.00000000000oooo x 10+e06
3.2796807369650561 x 10e+07
6.1083901753922198 X 10e03
6.0591000000000004 X 10e+03
1.0000000000000000 X 10e+06
1.3342595718633172 x 10+08
1.0000000000000000 X 10e+06
5.7301676644809306 x loe+07
1.0000000000000000 x 10e+06
1.1604907565945291 x 10e+03
5.3909705176307341 x 10e+02
1.3070034036390993 x 10e-01
1.0000000000000000 x 10e+06
8.0389506995677967 x 10e+09
1.0000000000000000 X 10et06
3.7438683203464447 X 10e+04
1.0000000000000000 X 10e+06
4.2269846243484896 x 10e+06
1.5672073331787424 x 10e+04
1.0000000000000000 X 10e+06
6.1748854911452996 x 10e+04
1.0000000000000000 x 10e+06
4.2269846243484896 X 10e+06
1.5672073331787424 x 10e+04
1.0000000000000000 x 10et06
1.0000000000000000 x 10e+06
4.2269846243484896 x 10e+06
1.5672073331787424 x 10e+04
4.2269846243484896 x 10e+06
1.0409077486997710 x 10e+02
1.0000000000000000 x 10e+06
1.8475454057381491 X 10e+06
1.0000000000000000 X 10e+06
4.2269846243484896 x 10e+06
1.5672073331787424 x 1 0 Oe+04
1.0000000000000000 x 10e+07
1.0000000000000000 x 10e+07
1.0000000000000000 x 10e+07
2.6712452857997687 x 10e+11
5.0595719542775881 X 10e+06
8.7380380875207596 x 10e+06
1.5472046597139845 X 10e+06
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PFK_k15 1.0734927311884861 X 1 e+06
PFK-k16 1.2802574296156896 X 10e+05
PFK_k17 2.6036228513296116 X 10e+06
PFK_k18 1.2214080272582300 X 10e+07
PFK_k19 7.0377567750365064 x 10e+07
PFK_k2 1.0000000000000000 x 1Oe+07
PFK_k20 9.9999549409321338 x 10e+11
PFK_k21 9.9999309857040869 x 10e+1
PFKk22 1.9587802413186693 X 10e+05
PFK_k23 3.9175604826373386 x 10e+05
PFK_k24 5.8763407239560073 X 1 0e+05
PFK_k25 7.8351209652746771 x 10e+05
PFK_k26 9.7939012065933459 X 10e+05
PFKk27 1.1752681447912015 x 1 0 e+06
PFKk28 1.3711461689230686 X 1 0e+06
PFK_k29 1.5670241930549354 x 1 0e+06
PFK_k3 1.0000000000000000 x 10e+07
PFK_k30 1.7629022171868025 X 10e+06
PFK-k31 1.9587802413186692 x 10e+06
PFKk32 2.1546582654505363 X 10e+06
PFK-k33 1.0000000000000000 x 10e+07
PFK_k34 1.0000000000000000 X 10e+07
PFKk35 1.0000000000000000 x 10e+07
PFK_k36 1.0000000000000000 X 10e+07
PFK_k37 5.9635382316240445 X 10e+06
PFK_k38 1.6965801757957079 X 10e+07
PFK-k39 1.1067662775874595 x 10e+08
PFK-k4 1.0000000000000000 x 10e+07
PFK-k40 3.6151580682876729 x 10e+06
PFK_k5 1.0000000000000000 x 1 0 e+07
PFKk6 1.0000000000000000 X 10e+07
PFK-k7 1.0000000000000000 x 10e+07
PFKk8 1.0000000000000000 x 10e+07
PFK-k9 1.0000000000000000 x 10e+07
PGI-kO 1.0000000000000000 X 1 0 e+07
PGI-ki 2.8349012000000000 x 10e+07
PGI_k1O 1.0000000000000000 x 10e+07
PGI_kll 9.8243774409480381 x 10e+09
PGIjk12 5.8103971870257437 x 10c+08
PGI-k13 1.0000000000000000 x 10e+07
PGI-k14 5.2308735245413914 x 10e+09
PGI_ki5 5.0487078613706931 x 1 0 e+07
PGIk2 6.5098800000000000 x 10e+05
PGI_k3 1.0000000000000000 X 10e+07
PGI-k4 2.3138474602698651 X 10e+06
PGI-k5 3.4615253973013500 x 1 0 e+05
PGI~k6 1.0000000000000000 X 10e+07
PGI-k7 9.4894223244003777 X 1 0 e+05
PGI-k8 1.0000000000000000 X 1 0 e+07
PGI-k9 4.5388900358918821 x ioe+06
PGK_kO 4.0000000002418436 x 10e+07
PGK_kI 1.1910390732145230 x 10e+06
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PGKk2 1.1269927270629425 x 10e+06
PGKk3 6.7872263734852197 X 10e+04
PGK-k4 4.8336212363022659 x 10e+06
PGKk5 1.0000000006215300 x 1 0 e+07
PGM-kO 1.0000000000657211 X 10e+06
PGM_ki 1.1057198740453522 X 10e+06
PGM-k2 8.9905333325119841 x 1 0 e+02
PGM-k3 5.6188706748316008 x 10e+01
PGMk4 1.3544552052271876 x 10e+04
PGM-k5 1.0000000000267429 x 10e+06
PGluMu.kO 5.0000000090073664 x 10 e+
0 6
PGluMu-ki 9.1468901122812752 x 10 e+05
PGluMu-k2 1.8627073889027213 X 10e+05
PGluMu-k3 2.3599201792045962 x 1 0 e+07
PGluMu-k4 2.1786325514186662 x 10e+07
PGluMu-k5 5.0000000097447606 X 1 0e+06
PK-kO 1.0000000000000000 x 10e+06
PK-ki 1.0000000000000000 X 1 0 e+06
PK.k10 1.0000000002271533 x 10e+09
PKk11 1.0225518958698046 x 10e+05
PK-k12 2.9876784545354487 x 10e+05
PK-k13 1.0000000002269371 x 10e+09
PKk14 1.0000000001866658 X 10e+09
PK-k15 1.0185295983817041 x 10e+05
PK-k16 4.3397280988943159 X 10e+01
PK-k17 4.3397280988943159 X 10e+01
PK-k18 4.3397280988943159 x 1 0 e+01
PK_k19 4.3397280988943159 X 10e+01
PK-k2 1.0000000000000000 x 10e+06
PKk20 4.3397280988943159 X 10e+01
PK-k21 4.3397280988943159 X 10e+01
PKk22 4.3397280988943159 x 1 0e+01
PKk23 4.3397280988943159 x 10e+01
PK-k24 1.0000000000000000 X 1 0 e+06
PKk25 9.5936588789919496 X 10e+05
PK-k3 1.0000000000000000 X 1 0 e+06
PK-k4 1.0000000000000000 X 10e+06
PK-kS 1.0000000000000000 x 1 0 e+06
PK-k6 1.0000000000000000 X 10e+06
PK-k7 1.0000000000000000 X 10e+06
PKk8 7.2423405259541015 X 10e+05
PK-k9 1.0000000001940010 x 10e+09
PTS-kO 1.0000000000000000 X 10e+07
PTS-kl 9.7994562714464098 X 10e+07
PTS-k10 1.0000000000000000 X 10e+07
PTS-k11 4.4431084048532810 x 10e+09
PTS-ki2 1.0000000000000000 X 10e+07
PTS-k13 3.5048308261415991 X 10e+06
PTS-k14 1.0000000000000000 X 1 0 e+07
PTS-k15 3.4544908924983547 x 10e+03
PTS-k16 1.0000000000000000 X 10e+07
PTS-k17 7.3663401327365232 X 10e+08
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PTSk18 1.0000000000000000 X 10 e+07
PTSk19 4.4431084048532810 x 1 0 e+09
PTSk2 1.0000000000000000 X 1 0 e+07
PTSk2O 1.0000000000000000 X 1 0 e+07
PTSk21 3.5048308261415991 x 1 0 e+06
PTS-k22 1.0000000000000000 x 10e+07
PTS-k23 3.4544908924983547 x 1 0 e+03
PTSk24 1.0000000000000000 x 10e+07
PTSk25 7.3663401327365232 X 10e+08
PTSk26 1.0000000000000000 X 10e+07
PTS-k27 4.4431084048532810 x 10e+09
PTS-k28 1.0000000000000000 X 10e+07
PTSk29 3.5048308261415991 X 10e+06
PTS-k3 9.8206114610983102 x 10e+04
PTS_k30 1.0000000000000000 X 10e+07
PTS-k31 3.4544908924983547 x 10e+03
PTSk32 1.0000000000000000 x 10e+07
PTS-k33 7.3663401327365232 X 10e+08
PTS-k34 1.0000000000000000 X 10e+07
PTSk35 4.4431084048532810 x 10e+09
PTSk36 1.0000000000000000 x 10e+07
PTS-k37 3.5048308261415991 x 10e+06
PTS-k38 1.0000000000000000 x 1 0 e+07
PTS-k39 3.4544908924983547 x 1 0 e+03
PTS-k4 3.8431720438436768 X 10e+17
PTSk5 1.9216353838636899 x 10e+17
PTS-k6 1.0000000000000000 X 10e+07
PTS-k7 1.8217268567845707 X 1 0e+06
PTSk8 1.0000000000000000 X 10e+07
PTS-k9 7.3663401327365232 x 1 0e+08
R5P1.k0 1.0000000000000000 X 10e+06
RSPlkl 1.0000000000000000 X 10e+08
R5P1_k2 4.8678508226233616 x 1 0 e+05
RSPIk3 1.2169627056558404 x 10e+05
R5P1_k4 1.0000000000000000 X 10e+08
R5P1.k5 1.0000000000000000 X 10e+06
RPPK-k0 1.0000000000000000 X 10e+06
RPPK-k1 9.9987099500719385 X 10e+04
RPPKk2 1.2900500010069370 X 1 0 e+01
Ru5P-k0 1.0000000000000000 x 10e+06
Ru5P-kl 1.0000000000000000 X 10e+08
Ru5P-k2 6.8177933958198258 X 10e+05
Ru5P-k3 4.8698524255855900 X 10e+05
Ru5P-k4 1.0000000000000000 x 10e+08
Ru5Pk5 1.0000000000000000 X 10e+06
SerSynth-kO 1.0000000000000000 x 10e+06
SerSynth-k1 9.9997428790023155 x 10e+05
SerSynth-k2 2.5712100031931431 x 1 0 e+01
SynthlkO 1.0000000000000000 X 10e+06
Synth1.k1 9.9998046100016276 X 1 0 e+05
Synthlk2 1.9539000024280771 x 1 0 e+01
Synth2.kO 1.0000000000000000 x 1 0 e+06
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Synth2_kl 9.9992638140082860 X 10e+05
Synth2.k2 7.3618600090699971 x 10e+01
TA-kO 1.0000000000000000 X 10e+06
TA-k1 3.4778381567798972 X 1 0 e+08
TA_k2 8.9883651167260800 x 10e+06
TA-k3 4.7635749118695432 X 10e+08
TAk4 3.4703800526606350 x 10e+09
TAk5 3.7609461023649335 x 10e+09
TAk6 8.9851047801328618 x 10e+06
TAk7 4.4990066821897930 x 10e+08
TA_k8 1.0000000000000000 X 10e+06
TA-k9 4.1921580168042737 x 10e+08
TIS-kO 1.0000000041046800 x 10e+06
TIS-kl 3.5595691019993504 X 10e+06
TISk2 9.1148290773014291 X 1 0 e+04
TIS-k3 5.4371626067903580 X 10e+03
TISk4 2.9514540109794273 X 10e+05
TIS-k5 1.0000000039979001 X 10e+06
TKa-kO 1.0000000000000000 x 10e+06
TKa-ki 2.6036940805652425 x 10e+08
TKa-k2 8.9967360636448544 X 10e+06
TKa-k3 2.8001449621866381 x 10e+08
TKa-k4 1.7756398926550952 x 10e+08
TKa-k5 2.0250717720637748 x 10e+08
TKa-k6 9.1054817665767353 x 10e+06
TKa-k7 3.4125932570363659 X 10e+08
TKa-k8 1.0000000000000000 x 10e+06
TKa-k9 2.9609630557678908 X 10e+08
TKbkO 1.0000000000000000 X 1 0 e+06
TKb_kl 4.2299426220451057 X 1 0 e+07
TKb-k2 6.1249203330969810 x 10e+06
TKbk3 1.9782231094656538 X 10e+07
TKbk4 7.3182174368234470 X 1 0 e+07
TKb-k5 4.7686047850095838 x 10e+07
TKbk6 6.5235836531243715 X 10e+06
TKbk7 6.2673145318268642 X 10e+07
TKb-k8 1.0000000000000000 x 10et06
TKb-k9 9.4166383622396722 x 10E+07
Tryp-ksynth 1.0369999999999999 x 10e-03
mu 2.780000000000000 x 10 -05
Table A.15: E. coli Model Species
Species Initial Concentration Is Input
Aldolase 0.0000000000000000 X 10e+00 no
Aldolase:DHAP 0.0000000000000000 X 10e+00 no
Aldolase:DHAP:GAP 0.0000000000000000 x 10e+00 no
Aldolase:FDP 0.0000000000000000 x 10e+00 no
DHAP 0.0000000000000000 X 10e+00 no
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DHAPSOO 0.0000000000000000 X 1 0 e+00 no
DHAPSO1 0.0000000000000000 X 10e+00 no
DHAPSO2 0.0000000000000000 X 1 0 e+00 no
DHAPS10 0.0000000000000000 X 10e+00 no
DHAPS11 0.0000000000000000 X 10 e+00 no
DHAPS12 0.0000000000000000 X 10e+00 no
DHAPS20 0.0000000000000000 x 10C+00 no
DHAPS21 0.0000000000000000 X 10 e+00 no
DHAPS22 0.0000000000000000 X 10 e+00 no
E4P 0.0000000000000000 X 10+00 no
Eno 0.0000000000000000 X 10e+00 no
Eno:PEP 0.0000000000000000 X 10e+00 no
Eno:PG2 0.0000000000000000 X no+00
F6P 0.0000000000000000 X 1 0 e+00 no
FDP 0.0000000000000000 X 10e+00 no
G1P 0.0000000000000000 X 10e+00 no
G1PATO 0.0000000000000000 X 1 0 e+00 no
GiPATOA 0.0000000000000000 X 1 0 e+00 no
GIPAT1 0.0000000000000000 X 1 0 e+00 no
G1PAT1A 0.0000000000000000 X 10e+00 no
G1PAT2 0.0000000000000000 X 1 0 e+00 no
GIPAT2A 0.0000000000000000 X 10e+00 no
G3PDH 0.0000000000000000 X 1 0 e+00 no
G3PDH:DHAP 0.0000000000000000 X 10e+00 no
G6P 0.0000000000000000 X 10e+00 no
G6PDH 0.0000000000000000 X 1 0 e+00 no
G6PDH:G6P 0.0000000000000000 x 10e+00 no
GAP 0.0000000000000000 X 10e+00 no
GAPDH 0.0000000000000000 X 1 0 e+00 no
GAPDH:GAP 0.0000000000000000 X I0e+00 no
GAPDH:PGP 0.0000000000000000 X 1 06e0 rno
GlcEx 0.0000000000000000 X 10C+00 yes
Met 0 no
Mur 0.0000000000000000 < 10+00 no
Mur:F6P 0.0000000000000000 X 10e+00 no
PDGH 0.0000000000000000 X 1 0 e+00 no
PDGH:PG 0.0000000000000000 X 10e+00 no
PDH 0.0000000000000000 X 1 0 e+00 no
PDH:PYR_1 0.0000000000000000 X e+00 no
PDH:PYR.2 0.0000000000000000 x 10e+00 no
PDH:PYR_3 0.0000000000000000 X 10e+00 no
PDH:PYR.4 0.0000000000000000 X 10e+00 no
PEP 0.0000000000000000 X 10e+00 no
PEPCxylaseO 0.0000000000000000 X i0e+00 no
PEPCxylaseOA 0.0000000000000000 X 1O+00 no
PEPCxylasel 0.0000000000000000 X 10e+00 no
PEPCxylaselA 0.0000000000000000 X 10+00 no
PEPCxylase2 0.0000000000000000 X 10e+00 no
PEPCxylase2A 0.0000000000000000 X 10e+00 no
PEPCxylase3 0.0000000000000000 X 1Oe+00 no
PEPCxylase3A 0.0000000000000000 X lOe+00 no
PEPCxylase4 0.0000000000000000 X 10e+00 no
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PEPCxylase4A
PFK_0.0
PFK_0_1
PPK_0_2
PFK_0_3
PFK.0.4
PFK_10_0
PFK_11.0
PFK_1_0
PFK_2_0
PFK_3.0
PFK_4_0
PFK_5_0
PFK_6-0
PFK_7_0
PFK.8-0
PFK_9_0
PG
PG2
PG3
PGI
PGI:F6P
PGI:G6P
PGI:PG
PGI:PG:F6P
PGI:PG:G6P
PGI:PG:PG
PGK
PGK:PG3
PGK:PGP
PGM
PGM:G1P
PGM:G6P
PGP
PGluMu
PGluMu:PG2
PGluMu:PG3
PK00
PK01
PK10
PK11
PK20
PK21
PK30
PK31
PK40
PK41
PTS
PTS:G6P
PTS:GicEx:PEP
PTS:GlcEx:PEP:I1
PTS:GlcEx:PEP:12
Initial Concentration
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 1 0 e+00
0.0000000000000000 x 10e+00
0.0000000000000000 X 106+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e-+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 x 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
0.0000000000000000 X 10e+00
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no
no
no
no
no0
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no0
no
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Species Initial Concentration Is Input
PTS:GlcEx:PEP:13 0.0000000000000000 X 10e+00 no
PTS:GlcEx:PEP:14 0.0000000000000000 X 10e+00 no
PTS:I1 0.0000000000000000 x 10e+00 no
PTS:2 0.0000000000000000 X 1e+00 no
PTS:13 0.0000000000000000 X 10e+00 no
PTS:14 0.0000000000000000 X 1 0 e+00 no
PTS:PEP 0.0000000000000000 X 1 0 e+00 no
PTS:PEP:I1 0.0000000000000000 X 10c+00 no
PTS:PEP:12 0.0000000000000000 X 1 0 e+00 no
PTS:PEP:13 0.0000000000000000 X 10e+00 no
PTS:PEP:14 0.0000000000000000 X 10e+00 no
PTS:PYR 0.0000000000000000 x i0e+00 no
PTS:PYR:I1 0.0000000000000000 X 10e+00 no
PTS:PYR:12 0.0000000000000000 x 10e+00 no
PTS:PYR:13 0.0000000000000000 X 10e+00 no
PTS:PYR:14 0.0000000000000000 X 10e+00 no
PYR 0.0000000000000000 X 1 0 e+00 no
PolySac 0.0000000000000000 X 10e+00 no
R5P1 0.0000000000000000 x 1 0 e+00 no
R5Pl:RIB5P 0.0000000000000000 X 10 e+00 no
R5P1:RIBU5P 0.0000000000000000 x 10e+00 no
RIB5P 0.0000000000000000 X 10 e+00 no
RIBU5P 0.0000000000000000 x 10e+00 no
RPPK 0.0000000000000000 X 10e+00 no
RPPK:RIB5P 0.0000000000000000 X 10e+00 no
Ru5P 0.0000000000000000 X 10e+00 no
Ru5P:RIBU5P 0.0000000000000000 x 10e+00 no
Ru5P:XYL5P 0.0000000000000000 X 10e+00 o
SED7P 0.0000000000000000 x 10e+00 no
SerSynth 0.0000000000000000 X 10 e+00 no
SerSynth:PG3 0.0000000000000000 x 10e+00 no
Synth1 0.0000000000000000 X i0e+00 no
Synthl:PEP 0.0000000000000000 X 10e+00 no
Synth2 0.0000000000000000 X 10e+00 no
Synth2:PYR 0.0000000000000000 X 10e+00 no
TA 0.0000000000000000 X 1 0e+00 no
TA:E4P:F6P 0.0000000000000000 x 0e+00 no
TA:F6P 0.0000000000000000 x 10e+00 no
TA:GAP 0.0000000000000000 X 10e+00 no
TA:GAP:SED7P 0.0000000000000000 x 10e+00 no
TIS 0.0000000000000000 X 10e+00 no
TIS:DHAP 0.0000000000000000 X 1 0 e+
0 0  
no
TIS:GAP 0.0000000000000000 x 10e+00 no
TKa 0.0000000000000000 x 105±00 +0
TKa:GAP 0.0000000000000000 X 10e+00 no
TKa:RIB5P 0.0000000000000000 x 10e+00 no
TKa:RIB5P:XYL5P 0.0000000000000000 X 1 oe+00 no
TKa:SED7P:GAP 0.0000000000000000 X 10e+00 no
TKb 0.0000000000000000 X 10e+00 no
TKb:F6P:GAP 0.0000000000000000 X 10e+00 no
TKb:GAP 0.0000000000000000 x 1 0 e+00 no
TKb:XYL5P 0.0000000000000000 X 10e+00 no
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TKb:XYL5P:E4P 0.0000000000000000 x 10je+00 no
Tryp 0 no
XYLSP 0.0000000000000000 x 1 0e+00 no
aaa 0.0000000000000000 x 10e+00 no
accoa 0.0000000000000000 x 10e+00 no
cho-mur 0.0000000000000000 X 1oe+00 no
glycerol 0.0000000000000000 x 1 0 s+00 no
ile 0.0000000000000000 x lOe+oo no
murine 0.0000000000000000 x 10e+lO no
nucleotide 0.0000000000000000 x 10e+00 no
oaa 0.0000000000000000 x 10e+oo no
serine 0.0000000000000000 x 1Oe+00 no
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Figure B-1: Fit of Aldolase Mass Action Mechanism to Aggregated Rate Law Mechanism. Rate
vs substrate plot (a), and simulation from initial conditions (b)
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Figure B-4: Fit of G1PAT Mass Action Mechanism to Aggregated Rate Law Mechanism. Rate
vs substrate plot (a), and simulation from initial conditions (b)
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Figure B-5: Fit of G3PDH Mass Action Mechanism to Aggregated Rate Law Mechanism. Rate
vs substrate plot (a), and simulation from initial conditions (b)
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Figure B-6: Fit of G6PDH Mass Action Mechanism to Aggregated Rate Law Mechanism. Rate
vs substrate plot (a), and simulation from initial conditions (b)
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Figure B-7: Fit of GADPH Mass Action Mechanism to Aggregated Rate Law Mechanism. Rate
vs substrate plot (a), and simulation from initial conditions (b)
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